

PETITORIO

AS: 104.858



SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO



No. 07-090213- -00000-0000

Fecha: 2007-09-03 16:09:59 Dep. 2020 NUECREACIONE
Tra. 11 PATENTEIYII Eve: 378 FASENACIONALI
Act. 411 PRESENTACION Folios: 328

FORMULARIO ÚNICO DE SOLICITUD DE PATENTE PCT ENTRADA EN FASE NACIONAL

4/sep/2007


1 SOLICITUD DE:			
☒ Patente de Invención.		☐ Patente de Modelo de Utilidad.	
☒ Capítulo I.		☐ Capítulo II.	
2 SOLICITANTE (71)	Nombre: ASTRAZENECA AB Dirección: S-1-51 85 Södertälje, Suecia Nacionalidad o Domicilio: Suecia Lugar de Constitución: Suecia Teléfono: Fax: E-mail:		IDENTIFICACIÓN C.C. ☐ NIT ☐ C.E. ☐ Otro ☐ Cual _____ Número _____
3 REPRESENTANTE O APODERADO	Nombre: JUAN PABLO CADENA SARMIENTO Dirección: Cra. 7 No. 71-21 Torre B – Piso 4, Bogotá, Colombia. Teléfono: 744-2200 Fax: 742-2200 E-mail:		IDENTIFICACIÓN C.C. ☒ NIT ☐ C.E. ☐ Otro ☐ Cual _____ Número <u>80.410.337</u> TP <u>57492</u>
4 INVENTOR (ES) (72)	Nombre: Audrey DAVIES, Michelle LAMB, Paul LYNE, Peter MOHR, Bin WANG, Tao WANG, Dingwei YU. Dirección: AstraZeneca R & D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, US; AstraZeneca R & D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, US; AstraZeneca R & D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, US; Array BioPharma Inc, 3200 Walnut Street, Boulder, Colorado 80301, US; Array BioPharma Inc, 3200 Walnut Street, Boulder, Colorado 80301, US; AstraZeneca R & D Boston, 35 Gatehouse Drive, Walham, Massachusetts 02451, US; AstraZeneca R & D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, US (Respectivamente). Nacionalidad o Domicilio: Estados Unidos de América (Respectivamente).		
5 PCT (86)			
Solicitud Internacional No. <u>PCT/GB2006/000334</u>		Fecha <u>01-02-2006</u>	
Publicación Internacional No. <u>WO 2006/082392 A1</u>		Fecha <u>10-08-2006</u>	
6 Título (54): <u>DERIVADOS DE PIRAZOLILAMINOPIRIDINA ÚTILES COMO INHIBIDORES DE CINASA</u>			
7 Clasificación Internacional (51): _____			
8 Prioridad SI ☒ NO ☐	(33) País de Origen	(32) Fecha	(31) Número de Solicitud
	US	04-02-2005	60/650,053
	US	16-02-2005	60/653,329
	US	29-09-2005	60/721,633
9 Comprobante de pago No. <u>07—54,102</u> Fecha <u>03-09-2007</u>			
Instrucciones para el diligenciamiento del presente formulario, ver reverso de esta página.			

10

ANEXOS


- ☒ Comprobante de pago de la tasa de presentación de la solicitud. \$482.000
- ☒ Documento que acredite la existencia y representación legal cuando el solicitante sea persona jurídica.
- ☒ Poderes, si fuere el caso. **Fotocopia Autenticada**
- ☒ Documento de cesión del inventor al solicitante o a su causante.
- ☐ Declaraciones
- ☒ Copia de la solicitud internacional. (Resumen, descripción, reivindicaciones, dibujos)
- ☒ Traducción de la solicitud internacional al castellano. (Resumen, descripción, reivindicaciones, dibujos)
- ☐ Copia del examen preliminar efectuado por la IPEA.
- ☐ Traducción del examen preliminar efectuado por la IPEA.
- ☐ De ser el caso, copia del contrato de acceso.
- ☐ De ser el caso, documento que acredite la licencia o autorización de uso de conocimientos tradicionales de las comunidades indígenas.
- ☐ De ser el caso, certificado de depósito del material biológico.
- ☐ Arte final 12x12.
- ☐ De ser el caso, información sobre otras solicitudes de patente o títulos obtenidos en el extranjero por el mismo titular o su causante, relacionadas parcial o totalmente con la invención de esta solicitud.
- ☒ Otros: Extracto para Publicación y Tarjeta de Archivo Temático
Tarjeta de Propietarios
Documentos PCT

11 FIGURA CARACTERÍSTICA:



12 Solicito la concesión de la patente,

NOMBRE: JUAN PABLO CADENA SARMIENTO

FIRMA: 

C.C. 80.410.337 de Usaquén T.P. 57492 del C.S.J.

Instrucciones para la presentación de los anexos, ver reverso de esta página.

Ab 104.203
3 3

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

NIT : 800176089-2

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO



No. 07-090213- -00000-0000

Fecha: 2007-09-03 16:09:59 Dep. 2020 NUECREACIONE
Tra. 11 PATENTEIYII Eve: 378 FASENACIONALI
Act. 411 PRESENTACION Folios: 328

RECIBO OFICIAL DE CAJA : 07 - 54,102
FECHA : JULIO 4 DE 2007

***** CONSIGNACION *****

DEBITANTE	TIPO PAGO	BANCO	CUENTA	No. PAGO	FECHA PGO	Vr. PAGO
BRIGAND & CASTRO LTDA	CONSIGNACION	BANCO POPULAR	050-00110-6	36865819	04/07/2007	48,540,000.00

***** CONCEPTO *****

CANT.	RENTISTICO	CONCEPTO	TOTAL CONCEPTO
1	50003-01401	SOLICITUDES	
		1 TRAMITES DE SOL. DE PATENTE DE IN	482,000.00
		TOTAL :	\$ 482,000.00

SON: CUATROCIENTOS OCHENTA Y DOS MIL PESOS

RESPONSABLE :

RECIBO DE CANCELACION AL EXPEDIENTE No. _____

(1) No. de solicitud:					(51) Int Cl:	
(22) Fecha de solicitud: 12-03-2007					(71) Solicitante (s): ASTRAZENECA AB	
(30) Prioridad	(31)	No. Prioridad	(32)	Fecha	(33)	País
		60/650,053		04-02-2005		US
		60/653,329		16-02-2005		US
		60/721,633		29-09-2005		US
(85) Fecha inicio fase nacional: 04-09-2007					(87) Publicación internacional	
(86) Datos relativos a la presentación de la solíc. PCT					Fecha: 10-08-2006	
Fecha de presentación de la solicitud: 01-02-2006					Nº publicación: WO 2006/082392 A1	
No. de solicitud: PCT/GB2006/000334						
(54) Título: DERIVADOS DE PIRAZOLILAMINOPIRIDINA ÚTILES COMO INHIBIDORES DE CINASA						

(55) Resumen:

La presente invención se refiere a novedosos compuestos de pirazol, o sus sales farmacéuticamente aceptables, que poseen actividad inhibidora de cinasas Trk y, en consecuencia, son útiles por su actividad anti-proliferación y/o pro-apoptótica (tal como anti-neoplásica) y en métodos de tratamiento del cuerpo humano o animal. La invención se refiere igualmente a procesos para la fabricación de dichos compuestos de pirazol, o sus sales farmacéuticamente aceptables, a composiciones farmacéuticas que los contienen y a su empleo en la fabricación de medicamentos para utilizarlos en la producción de un efecto anti-proliferación y/o pro-apoptótico en animales de sangre caliente.

Retiro folios 4 y 5
"Tazetas"



(57) Abstract: This invention relates to novel compounds having the Formula (I) to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer.

PYRAZOLYLAMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS

Field of the invention

The present invention relates to novel pyrazole derivatives, their pharmaceutical compositions and methods of use. In addition, the present invention relates to therapeutic methods for the treatment and prevention of cancers and to the use of these pyrazole derivatives in the manufacture of medicaments for use in the treatment and prevention of cancers.

Background of the invention

Receptor tyrosine kinases (RTK's) are a sub-family of protein kinases that play a critical role in cell signalling and are involved in a variety of cancer related processes including cell proliferation, survival, angiogenesis and metastasis. Currently up to 100 different RTK's including tropomyosin-related kinases (Trk's) have been identified.

Trk's are the high affinity receptors activated by a group of soluble growth factors called neurotrophins (NT). The Trk receptor family has three members - TrkA, TrkB and TrkC. Among the NTs there are (i) nerve growth factor (NGF) which activates TrkA, (ii) brain-derived growth factor (BDNF) and NT-4/5 which activate TrkB and (iii) NT3 which activates TrkC. Each Trk receptor contains an extra-cellular domain (ligand binding), a trans-membrane region and an intra-cellular domain (including kinase domain). Upon binding of the ligand, the kinase catalyzes auto-phosphorylation and triggers downstream signal transduction pathways.

Trk's are widely expressed in neuronal tissue during its development where Trk's are critical for the maintenance and survival of these cells. A post-embryonic role for the Trk/neurotrophin axis (or pathway), however, remains in question. There are reports showing that Trk's play important role in both development and function of the nervous system (Patapoutian, A. et al *Current Opinion in Neurobiology*, 2001, 11, 272-280).

In the past decade, a considerable number of literature documentations linking Trk signalling with cancer have published. For example, while Trk's are expressed at low levels outside the nervous system in the adult, Trk expression is increased in late stage prostate cancers. Both normal prostate tissue and androgen- dependent prostate tumours express low levels of Trk A and undetectable levels of Trk B and C. However, all isoforms of Trk receptors as well as their cognate ligands are up-regulated in late stage, androgen-independent prostate cancer. There is additional evidence that these late stage prostate cancer

cells become dependent on the Trk/neurotrophin axis for their survival. Therefore, Trk inhibitors may yield a class of apoptosis-inducing agents specific for androgen- independent prostate cancer (Weeraratna, A. T. et al *The Prostate*, 2000, 45, I40-I48).

Furthermore, very recent literature also shows that over-expression, activation, amplification and/or mutation of Trk's are associated with secretory breast carcinoma (*Cancer Cell*, 2002, 2, 367-376), colorectal cancer (Bardelli et al *Science*, 2003, 300, 949-949) and ovarian cancer (Davidson, B. et al *Clinical Cancer Research*, 2003, 9, 2248-2259).

There are a few reports of selective Trk tyrosine kinase inhibitors. Cephalon described CEP-751, CEP-701 (George, D. et al *Cancer Research*, 1999, 59, 2395-2341) and other indolocarbazole analogues (WO0114380) as Trk inhibitors. It was shown that CEP-701 and/or CEP751, when combined with surgically or chemically induced androgen ablation, offered better efficacy compared with mono-therapy alone. GlaxoSmithKline disclosed certain oxindole compounds as Trk A inhibitors in WO0220479 and WO0220513. Recently, Japan Tobacco reported pyrazolyl condensed cyclic compounds as Trk inhibitors (JP2003231687A).

In addition to the above, Vertex Pharmaceuticals have described pyrazole compounds as inhibitors of GSK3, Aurora, etc. in WO0250065, WO0262789, WO03027111 and WO200437814; and AstraZeneca have reported pyrazole compounds as inhibitors against IGF-1 receptor kinase (WO0348133).

Summary of the invention

In accordance with the present invention, the applicants have hereby discovered novel pyrazole compounds, or pharmaceutically acceptable salts thereof, which possess Trk kinase inhibitory activity and are accordingly useful for their anti-proliferation and/or proapoptotic (such as anti-cancer) activity and in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said pyrazole compounds, or pharmaceutically acceptable salts thereof, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments for use in the production of an anti-proliferation and/or proapoptotic effect in warm-blooded animals such as man.

Also in accordance with the present invention the applicants provide methods of using such pyrazole compounds, or pharmaceutically acceptable salts thereof, in the treatment of cancer.


The properties of the compounds claimed in this invention are expected to be of value in the treatment of disease states associated with cell proliferation such as cancers (solid

tumors and leukemia), fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation.

- 5 Furthermore, the compounds, or pharmaceutically acceptable salts thereof, of the invention are expected to be of value in the treatment or prophylaxis of cancers selected from congenital fibrosarcoma, mesoblastic nephroma, mesothelioma, acute myeloblastic leukemia, acute lymphocytic leukemia, multiple myeloma, melanoma, oesophageal cancer, myeloma, hepatocellular, pancreatic, cervical cancer, Ewings sarcoma, neuroblastoma, Kaposi sarcoma, 10 ovarian cancer, breast cancer including secretory breast cancer, colorectal cancer, prostate cancer including hormone refractory prostate cancer, bladder cancer, melanoma, lung cancer - non small cell lung cancer (NSCLC), and small cell lung cancer (SCLC), gastric cancer, head and neck cancer, renal cancer, lymphoma, thyroid cancer including papillary thyroid cancer, mesothelioma and leukaemia; particularly ovarian cancer, breast cancer, colorectal cancer, 15 prostate cancer and lung cancer - NSCLC and SCLC; more particularly prostate cancer; and more particularly hormone refractory prostate cancer.

Detailed description of the invention

Accordingly, the present invention provides a compound of formula (I):



wherein:

- R^1 and R^2 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, C_{1-6} alkanoyl, C_{1-6} alkanoyloxy, N -(C_{1-6} alkyl)amino, 25 N,N -(C_{1-6} alkyl) $_2$ amino, C_{1-6} alkanoylamino, N -(C_{1-6} alkyl)carbamoyl, N,N -(C_{1-6} alkyl) $_2$ carbamoyl, C_{1-6} alkylS(O) $_a$ wherein a is 0 to 2, C_{1-6} alkoxycarbonyl,

N-(C₁₋₆alkyl)sulphamoyl, *N,N*-(C₁₋₆alkyl)₂sulphamoyl, C₁₋₆alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R¹ and R² independently of each other may be optionally substituted on carbon by one or more R⁶; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R⁷;

5 one of X¹, X², X³ and X⁴ is =N-, the other three are independently selected from =CR⁸-, =CR⁹- and =CR¹⁰-;

R³ is hydrogen or optionally substituted C₁₋₆alkyl; wherein said optional substituents are selected from one or more R¹¹;

10 R⁴ and R³⁴ are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, *N*-(C₁₋₆alkyl)amino, *N,N*-(C₁₋₆alkyl)₂amino, C₁₋₆alkanoylamino, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)₂carbamoyl, C₁₋₆alkylS(O)_a wherein a is 0 to 2, C₁₋₆alkoxycarbonyl, *N*-(C₁₋₆alkyl)sulphamoyl, *N,N*-(C₁₋₆alkyl)₂sulphamoyl, C₁₋₆alkylsulphonylamino, carbocyclyl
15 or heterocyclyl; wherein R⁴ and R³⁴ may be independently optionally substituted on carbon by one or more R¹²; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R¹³;

A is a direct bond or C₁₋₂alkylene; wherein said C₁₋₂alkylene may be optionally substituted by one or more R¹⁴;

20 Ring C is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R¹⁵;

R⁵ is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, *N*-(C₁₋₆alkyl)amino, *N,N*-(C₁₋₆alkyl)₂amino, C₁₋₆alkanoylamino, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)₂carbamoyl, C₁₋₆alkylS(O)_a
25 wherein a is 0 to 2, C₁₋₆alkoxycarbonyl, *N*-(C₁₋₆alkyl)sulphamoyl, *N,N*-(C₁₋₆alkyl)₂sulphamoyl, C₁₋₆alkylsulphonylamino, carbocyclyl-R³⁷- or heterocyclyl-R³⁸-; wherein R⁵ may be optionally substituted on carbon by one or more R¹⁶; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group
30 selected from R¹⁷;

n is 0, 1, 2 or 3; wherein the values of R⁵ may be the same or different;

R⁸, R⁹ and R¹⁰ are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C₁₋₆alkyl, C₂₋₆alkenyl,

C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, *N*-(C₁₋₆alkyl)amino, *N,N*-(C₁₋₆alkyl)₂amino, C₁₋₆alkanoylamino, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)₂carbamoyl, C₁₋₆alkylS(O)_a wherein a is 0 to 2, C₁₋₆alkoxycarbonyl, *N*-(C₁₋₆alkyl)sulphamoyl, *N,N*-(C₁₋₆alkyl)₂sulphamoyl, C₁₋₆alkylsulphonylamino, carbocyclyl-R²⁵- or heterocyclyl-R²⁶-; wherein R⁸, R⁹ and R¹⁰ independently of each other may be optionally substituted on carbon by one or more R¹⁸; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R¹⁹;

R⁶, R¹¹, R¹², R¹⁴, R¹⁶ and R¹⁸ are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, *N*-(C₁₋₆alkyl)amino, *N,N*-(C₁₋₆alkyl)₂amino, C₁₋₆alkanoylamino, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)₂carbamoyl, C₁₋₆alkylS(O)_a wherein a is 0 to 2, C₁₋₆alkoxycarbonyl, *N*-(C₁₋₆alkyl)sulphamoyl, *N,N*-(C₁₋₆alkyl)₂sulphamoyl, C₁₋₆alkylsulphonylamino, carbocyclyl-R²⁷- or heterocyclyl-R²⁸-; wherein R⁶, R¹¹, R¹², R¹⁴, R¹⁶ and R¹⁸ independently of each other may be optionally substituted on carbon by one or more R²⁰; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R²¹;

R⁷, R¹³, R¹⁵, R¹⁷, R¹⁹ and R²¹ are independently selected from C₁₋₆alkyl, C₁₋₆alkanoyl, C₁₋₆alkylsulphonyl, C₁₋₆alkoxycarbonyl, carbamoyl, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; wherein R⁷, R¹³, R¹⁵, R¹⁷, R¹⁹ and R²¹ independently of each other may be optionally substituted on carbon by one or more R²²;


R²⁰ and R²² are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, *N*-(C₁₋₆alkyl)amino, *N,N*-(C₁₋₆alkyl)₂amino, C₁₋₆alkanoylamino, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)₂carbamoyl, C₁₋₆alkylS(O)_a wherein a is 0 to 2, C₁₋₆alkoxycarbonyl, *N*-(C₁₋₆alkyl)sulphamoyl, *N,N*-(C₁₋₆alkyl)₂sulphamoyl, C₁₋₆alkylsulphonylamino, C₁₋₆alkylsulphonyl-*N*-(C₁₋₆alkyl)amino, carbocyclyl-R³⁵- or heterocyclyl-R³⁶-; wherein R²⁰ and R²² independently of each other may be optionally substituted on carbon by one or more R²³; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R²⁴;

$R^{25}, R^{26}, R^{27}, R^{28}, R^{35}, R^{36}, R^{37}$ and R^{38} are independently selected from a direct bond, $-O-$, $-N(R^{29})-$, $-C(O)-$, $-N(R^{30})C(O)-$, $-C(O)N(R^{31})-$, $-S(O)_s-$, $-NH=CH-$, $-SO_2N(R^{32})-$ or $-N(R^{33})SO_2-$; wherein $R^{29}, R^{30}, R^{31}, R^{32}$ and R^{33} are independently selected from hydrogen or C_{1-6} alkyl and s is 0-2;

5 R^{23} is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxymethyl, methylamino, ethylamino, dimethylamino, diethylamino, *N*-methyl-*N*-ethylamino, acetylamino, *N*-methylcarbamoyl, *N*-ethylcarbamoyl, *N,N*-dimethylcarbamoyl, *N,N*-diethylcarbamoyl, *N*-methyl-*N*-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, *N*-methylsulphamoyl, *N*-ethylsulphamoyl, *N,N*-dimethylsulphamoyl, *N,N*-diethylsulphamoyl, *N*-methyl-*N*-ethylsulphamoyl or phenyl; and

10 R^{24} is selected from C_{1-6} alkyl, C_{1-6} alkanoyl, C_{1-6} alkylsulphonyl, C_{1-6} alkoxycarbonyl, carbamoyl, *N*-(C_{1-6} alkyl)carbamoyl, *N,N*-(C_{1-6} alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;
15 or a pharmaceutically acceptable salt thereof.

According to a further feature of the present invention there is provided a compound of formula (I) which is a compound of formula (Ia):



wherein:

R^1 and R^2 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, C_{1-6} alkanoyl, C_{1-6} alkanoyloxy, *N*-(C_{1-6} alkyl)amino, *N,N*-(C_{1-6} alkyl)₂amino, C_{1-6} alkanoylamino, *N*-(C_{1-6} alkyl)carbamoyl, *N,N*-(C_{1-6} alkyl)₂carbamoyl, C_{1-6} alkylS(O)_a wherein a is 0 to 2, C_{1-6} alkoxycarbonyl,

N-(C₁₋₆alkyl)sulphamoyl, *N,N*-(C₁₋₆alkyl)₂sulphamoyl, C₁₋₆alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R¹ and R² independently of each other may be optionally substituted on carbon by one or more R⁶; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R⁷;

5 one of X¹, X², X³ and X⁴ is =N-, the other three are independently selected from =CR⁸-, =CR⁹- and =CR¹⁰-;

R³ is hydrogen or optionally substituted C₁₋₆alkyl; wherein said optional substituents are selected from one or more R¹¹;

10 R⁴ is selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, *N*-(C₁₋₆alkyl)amino, *N,N*-(C₁₋₆alkyl)₂amino, C₁₋₆alkanoylamino, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)₂carbamoyl, C₁₋₆alkylS(O)_a wherein a is 0 to 2, C₁₋₆alkoxycarbonyl, *N*-(C₁₋₆alkyl)sulphamoyl, *N,N*-(C₁₋₆alkyl)₂sulphamoyl, C₁₋₆alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein
15 R⁴ may be optionally substituted on carbon by one or more R¹²; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R¹³;

A is a direct bond or C₁₋₂alkylene; wherein said C₁₋₂alkylene may be optionally substituted by one or more R¹⁴;

20 Ring C is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R¹⁵;

R⁵ is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, *N*-(C₁₋₆alkyl)amino, *N,N*-(C₁₋₆alkyl)₂amino, C₁₋₆alkanoylamino, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)₂carbamoyl, C₁₋₆alkylS(O)_a wherein a is 0 to 2, C₁₋₆alkoxycarbonyl, *N*-(C₁₋₆alkyl)sulphamoyl, *N,N*-(C₁₋₆alkyl)₂sulphamoyl, C₁₋₆alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein
25 R⁵ may be optionally substituted on carbon by one or more R¹⁶; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group
30 selected from R¹⁷;

n is 0, 1, 2 or 3; wherein the values of R⁵ may be the same or different;

R⁸, R⁹ and R¹⁰ are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C₁₋₆alkyl, C₂₋₆alkenyl,

17 13

C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, *N*-(C₁₋₆alkyl)amino, *N,N*-(C₁₋₆alkyl)₂amino, C₁₋₆alkanoylamino, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)₂carbamoyl, C₁₋₆alkylS(O)_a wherein a is 0 to 2, C₁₋₆alkoxycarbonyl, *N*-(C₁₋₆alkyl)sulphamoyl, *N,N*-(C₁₋₆alkyl)₂sulphamoyl, C₁₋₆alkylsulphonylamino, carbocyclyl-R²⁵- or heterocyclyl-R²⁶-; wherein R⁸, R⁹ and R¹⁰ independently of each other may be optionally substituted on carbon by one or more R¹⁸; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R¹⁹;

R⁶, R¹¹, R¹², R¹⁴, R¹⁶ and R¹⁸ are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, *N*-(C₁₋₆alkyl)amino, *N,N*-(C₁₋₆alkyl)₂amino, C₁₋₆alkanoylamino, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)₂carbamoyl, C₁₋₆alkylS(O)_a wherein a is 0 to 2, C₁₋₆alkoxycarbonyl, *N*-(C₁₋₆alkyl)sulphamoyl, *N,N*-(C₁₋₆alkyl)₂sulphamoyl, C₁₋₆alkylsulphonylamino, carbocyclyl-R²⁷- or heterocyclyl-R²⁸-; wherein R⁶, R¹¹, R¹², R¹⁴, R¹⁶ and R¹⁸ independently of each other may be optionally substituted on carbon by one or more R²⁰; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R²¹;

R⁷, R¹³, R¹⁵, R¹⁷, R¹⁹ and R²¹ are independently selected from C₁₋₆alkyl, C₁₋₆alkanoyl, C₁₋₆alkylsulphonyl, C₁₋₆alkoxycarbonyl, carbamoyl, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; wherein R⁷, R¹³, R¹⁵, R¹⁷, R¹⁹ and R²¹ independently of each other may be optionally substituted on carbon by one or more R²²;

R²⁰ and R²² are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, *N*-(C₁₋₆alkyl)amino, *N,N*-(C₁₋₆alkyl)₂amino, C₁₋₆alkanoylamino, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)₂carbamoyl, C₁₋₆alkylS(O)_a wherein a is 0 to 2, C₁₋₆alkoxycarbonyl, *N*-(C₁₋₆alkyl)sulphamoyl, *N,N*-(C₁₋₆alkyl)₂sulphamoyl, C₁₋₆alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R²⁰ and R²² independently of each other may be optionally substituted on carbon by one or more R²³; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R²⁴;

16
14

R^{25} , R^{26} , R^{27} and R^{28} are independently selected from a direct bond, -O-, -N(R^{29})-, -C(O)-, -N(R^{30})C(O)-, -C(O)N(R^{31})-, -S(O)_s-, -SO₂N(R^{32})- or -N(R^{33})SO₂-; wherein R^{29} , R^{30} , R^{31} , R^{32} and R^{33} are independently selected from hydrogen or C₁₋₆alkyl and s is 0-2;

R^{23} is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxymethyl, methylamino, ethylamino, dimethylamino, diethylamino, *N*-methyl-*N*-ethylamino, acetylamino, *N*-methylcarbamoyl, *N*-ethylcarbamoyl, *N,N*-dimethylcarbamoyl, *N,N*-diethylcarbamoyl, *N*-methyl-*N*-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, *N*-methylsulphamoyl, *N*-ethylsulphamoyl, *N,N*-dimethylsulphamoyl, *N,N*-diethylsulphamoyl or *N*-methyl-*N*-ethylsulphamoyl; and

R^{24} is selected from C₁₋₆alkyl, C₁₋₆alkanoyl, C₁₋₆alkylsulphonyl, C₁₋₆alkoxycarbonyl, carbamoyl, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;

or a pharmaceutically acceptable salt thereof.

Accordingly to a further feature of the present invention there is provided a compound of formula (I) wherein:

R^1 and R^2 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, *N*-(C₁₋₆alkyl)amino, *N,N*-(C₁₋₆alkyl)₂amino, C₁₋₆alkanoylamino, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)₂carbamoyl, C₁₋₆alkylS(O)_a wherein a is 0 to 2, C₁₋₆alkoxycarbonyl, *N*-(C₁₋₆alkyl)sulphamoyl, *N,N*-(C₁₋₆alkyl)₂sulphamoyl, C₁₋₆alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R^1 and R^2 independently of each other may be optionally substituted on carbon by one or more R^6 ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^7 ;

one of X^1 , X^2 , X^3 and X^4 is =N-, the other three are independently selected from =CR⁸-, =CR⁹- and =CR¹⁰-;

R^3 is hydrogen or optionally substituted C₁₋₆alkyl; wherein said optional substituents are selected from one or more R^{11} ;

R^4 and R^{34} are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, *N*-(C₁₋₆alkyl)amino,

15

N,N-(C₁₋₆alkyl)₂amino, C₁₋₆alkanoylamino, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)₂carbamoyl, C₁₋₆alkylS(O)_a wherein a is 0 to 2, C₁₋₆alkoxycarbonyl, *N*-(C₁₋₆alkyl)sulphamoyl, *N,N*-(C₁₋₆alkyl)₂sulphamoyl, C₁₋₆alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R⁴ and R³⁴ may be independently optionally substituted on carbon by one or more R¹²; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R¹³;

A is a direct bond or C₁₋₂alkylene; wherein said C₁₋₂alkylene may be optionally substituted by one or more R¹⁴;

Ring C is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R¹⁵;

R⁵ is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, *N*-(C₁₋₆alkyl)amino, *N,N*-(C₁₋₆alkyl)₂amino, C₁₋₆alkanoylamino, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)₂carbamoyl, C₁₋₆alkylS(O)_a wherein a is 0 to 2, C₁₋₆alkoxycarbonyl, *N*-(C₁₋₆alkyl)sulphamoyl, *N,N*-(C₁₋₆alkyl)₂sulphamoyl, C₁₋₆alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R⁵ may be optionally substituted on carbon by one or more R¹⁶; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R¹⁷;

n is 0, 1, 2 or 3; wherein the values of R⁵ may be the same or different;

R⁸, R⁹ and R¹⁰ are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, *N*-(C₁₋₆alkyl)amino, *N,N*-(C₁₋₆alkyl)₂amino, C₁₋₆alkanoylamino, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)₂carbamoyl, C₁₋₆alkylS(O)_a wherein a is 0 to 2, C₁₋₆alkoxycarbonyl, *N*-(C₁₋₆alkyl)sulphamoyl, *N,N*-(C₁₋₆alkyl)₂sulphamoyl, C₁₋₆alkylsulphonylamino, carbocyclyl-R²⁵- or heterocyclyl-R²⁶-; wherein R⁸, R⁹ and R¹⁰ independently of each other may be optionally substituted on carbon by one or more R¹⁸; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R¹⁹;

R⁶, R¹¹, R¹², R¹⁴, R¹⁶ and R¹⁸ are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, *N*-(C₁₋₆alkyl)amino,

4
16

N,N-(C₁₋₆alkyl)₂amino, C₁₋₆alkanoylamino, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)₂carbamoyl, C₁₋₆alkylS(O)_a wherein a is 0 to 2, C₁₋₆alkoxycarbonyl, *N*-(C₁₋₆alkyl)sulphamoyl, *N,N*-(C₁₋₆alkyl)₂sulphamoyl, C₁₋₆alkylsulphonylamino, carbocyclyl-R²⁷- or heterocyclyl-R²⁸-; wherein R⁶, R¹¹, R¹², R¹⁴, R¹⁶ and R¹⁸ independently of each other may be optionally substituted on carbon by one or more R²⁰; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R²¹;

R⁷, R¹³, R¹⁵, R¹⁷, R¹⁹ and R²¹ are independently selected from C₁₋₆alkyl, C₁₋₆alkanoyl, C₁₋₆alkylsulphonyl, C₁₋₆alkoxycarbonyl, carbamoyl, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)₂carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; wherein R⁷, R¹³, R¹⁵, R¹⁷, R¹⁹ and R²¹ independently of each other may be optionally substituted on carbon by one or more R²²;

R²⁰ and R²² are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, *N*-(C₁₋₆alkyl)amino, *N,N*-(C₁₋₆alkyl)₂amino, C₁₋₆alkanoylamino, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)₂carbamoyl, C₁₋₆alkylS(O)_a wherein a is 0 to 2, C₁₋₆alkoxycarbonyl, *N*-(C₁₋₆alkyl)sulphamoyl, *N,N*-(C₁₋₆alkyl)₂sulphamoyl, C₁₋₆alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R²⁰ and R²² independently of each other may be optionally substituted on carbon by one or more R²³; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R²⁴;

R²⁵, R²⁶, R²⁷ and R²⁸ are independently selected from a direct bond, -O-, -N(R²⁹)-, -C(O)-, -N(R³⁰)C(O)-, -C(O)N(R³¹)-, -S(O)_s-, -SO₂N(R³²)- or -N(R³³)SO₂-; wherein R²⁹, R³⁰, R³¹, R³² and R³³ are independently selected from hydrogen or C₁₋₆alkyl and s is 0-2;

R²³ is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxymethyl, methylamino, ethylamino, dimethylamino, diethylamino, *N*-methyl-*N*-ethylamino, acetylamino, *N*-methylcarbamoyl, *N*-ethylcarbamoyl, *N,N*-dimethylcarbamoyl, *N,N*-diethylcarbamoyl, *N*-methyl-*N*-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, *N*-methylsulphamoyl, *N*-ethylsulphamoyl, *N,N*-dimethylsulphamoyl, *N,N*-diethylsulphamoyl or *N*-methyl-*N*-ethylsulphamoyl; and

R^{24} is selected from C_{1-6} alkyl, C_{1-6} alkanoyl, C_{1-6} alkylsulphonyl, C_{1-6} alkoxycarbonyl, carbamoyl, N -(C_{1-6} alkyl)carbamoyl, N,N -(C_{1-6} alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;

or a pharmaceutically acceptable salt thereof.

- 5 According to a further feature of the invention there is provided a compound of formula (I) wherein:

R^1 and R^2 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, C_{1-6} alkanoyl, C_{1-6} alkanoyloxy, N -(C_{1-6} alkyl)amino, N,N -(C_{1-6} alkyl)₂amino, C_{1-6} alkanoylamino, N -(C_{1-6} alkyl)carbamoyl, N,N -(C_{1-6} alkyl)₂carbamoyl, C_{1-6} alkylS(O)_a wherein a is 0 to 2, C_{1-6} alkoxycarbonyl, N -(C_{1-6} alkyl)sulphamoyl, N,N -(C_{1-6} alkyl)₂sulphamoyl, C_{1-6} alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R^1 and R^2 independently of each other may be optionally substituted on carbon by one or more R^6 ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^7 ;

one of X^1 , X^2 , X^3 and X^4 is =N-, the other three are independently selected from =CR⁸-, =CR⁹- and =CR¹⁰-;

R^3 is hydrogen or optionally substituted C_{1-6} alkyl; wherein said optional substituents are selected from one or more R^{11} ;

- 20 R^4 and R^{34} are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, C_{1-6} alkanoyl, C_{1-6} alkanoyloxy, N -(C_{1-6} alkyl)amino, N,N -(C_{1-6} alkyl)₂amino, C_{1-6} alkanoylamino, N -(C_{1-6} alkyl)carbamoyl, N,N -(C_{1-6} alkyl)₂carbamoyl, C_{1-6} alkylS(O)_a wherein a is 0 to 2, C_{1-6} alkoxycarbonyl, N -(C_{1-6} alkyl)sulphamoyl, N,N -(C_{1-6} alkyl)₂sulphamoyl, C_{1-6} alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R^4 and R^{34} may be independently optionally substituted on carbon by one or more R^{12} ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^{13} ;

- 30 A is a direct bond or C_{1-2} alkylene; wherein said C_{1-2} alkylene may be optionally substituted by one or more R^{14} ;

Ring C is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^{15} ;

18

R^5 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, C_{1-6} alkanoyl, C_{1-6} alkanoyloxy, N -(C_{1-6} alkyl)amino, N,N -(C_{1-6} alkyl)₂amino, C_{1-6} alkanoylamino, N -(C_{1-6} alkyl)carbamoyl, N,N -(C_{1-6} alkyl)₂carbamoyl, C_{1-6} alkylS(O)_a wherein a is 0 to 2, C_{1-6} alkoxycarbonyl, N -(C_{1-6} alkyl)sulphamoyl, N,N -(C_{1-6} alkyl)₂sulphamoyl, C_{1-6} alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R^5 may be optionally substituted on carbon by one or more R^{16} ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^{17} ;

10 n is 0, 1, 2 or 3; wherein the values of R^5 may be the same or different;

R^8 , R^9 and R^{10} are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, C_{1-6} alkanoyl, C_{1-6} alkanoyloxy, N -(C_{1-6} alkyl)amino, N,N -(C_{1-6} alkyl)₂amino, C_{1-6} alkanoylamino, N -(C_{1-6} alkyl)carbamoyl, N,N -(C_{1-6} alkyl)₂carbamoyl, C_{1-6} alkylS(O)_a wherein a is 0 to 2, C_{1-6} alkoxycarbonyl, N -(C_{1-6} alkyl)sulphamoyl, N,N -(C_{1-6} alkyl)₂sulphamoyl, C_{1-6} alkylsulphonylamino, carbocyclyl- R^{25} - or heterocyclyl- R^{26} -; wherein R^8 , R^9 and R^{10} independently of each other may be optionally substituted on carbon by one or more R^{18} ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^{19} ;

20 R^6 , R^{11} , R^{12} , R^{14} , R^{16} and R^{18} are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, C_{1-6} alkanoyl, C_{1-6} alkanoyloxy, N -(C_{1-6} alkyl)amino, N,N -(C_{1-6} alkyl)₂amino, C_{1-6} alkanoylamino, N -(C_{1-6} alkyl)carbamoyl, N,N -(C_{1-6} alkyl)₂carbamoyl, C_{1-6} alkylS(O)_a wherein a is 0 to 2, C_{1-6} alkoxycarbonyl, N -(C_{1-6} alkyl)sulphamoyl, N,N -(C_{1-6} alkyl)₂sulphamoyl, C_{1-6} alkylsulphonylamino, carbocyclyl- R^{27} - or heterocyclyl- R^{28} -; wherein R^6 , R^{11} , R^{12} , R^{14} , R^{16} and R^{18} independently of each other may be optionally substituted on carbon by one or more R^{20} ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^{21} ;

30 R^7 , R^{13} , R^{15} , R^{17} , R^{19} and R^{21} are independently selected from C_{1-6} alkyl, C_{1-6} alkanoyl, C_{1-6} alkylsulphonyl, C_{1-6} alkoxycarbonyl, carbamoyl, N -(C_{1-6} alkyl)carbamoyl, N,N -(C_{1-6} alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; wherein

R⁷, R¹³, R¹⁵, R¹⁷, R¹⁹ and R²¹ independently of each other may be optionally substituted on carbon by on or more R²²;

R²⁰ and R²² are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, *N*-(C₁₋₆alkyl)amino, *N,N*-(C₁₋₆alkyl)₂amino, C₁₋₆alkanoylamino, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)₂carbamoyl, C₁₋₆alkylS(O)_a wherein a is 0 to 2, C₁₋₆alkoxycarbonyl, *N*-(C₁₋₆alkyl)sulphamoyl, *N,N*-(C₁₋₆alkyl)₂sulphamoyl, C₁₋₆alkylsulphonylamino, C₁₋₆alkylsulphonyl-*N*-(C₁₋₆alkyl)amino, carbocyclyl-R³⁵- or heterocyclyl-R³⁶-; wherein R²⁰ and R²² independently of each other may be optionally substituted on carbon by one or more R²³; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R²⁴;

R²⁵, R²⁶, R²⁷, R²⁸, R³⁵ and R³⁶ are independently selected from a direct bond, -O-, -N(R²⁹)-, -C(O)-, -N(R³⁰)C(O)-, -C(O)N(R³¹)-, -S(O)_s-, -NH=CH-, -SO₂N(R³²)- or -N(R³³)SO₂-; wherein R²⁹, R³⁰, R³¹, R³² and R³³ are independently selected from hydrogen or C₁₋₆alkyl and s is 0-2;

R²³ is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxymethyl, methylamino, ethylamino, dimethylamino, diethylamino, *N*-methyl-*N*-ethylamino, acetylamino, *N*-methylcarbamoyl, *N*-ethylcarbamoyl, *N,N*-dimethylcarbamoyl, *N,N*-diethylcarbamoyl, *N*-methyl-*N*-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, *N*-methylsulphamoyl, *N*-ethylsulphamoyl, *N,N*-dimethylsulphamoyl, *N,N*-diethylsulphamoyl, *N*-methyl-*N*-ethylsulphamoyl or phenyl; and

R²⁴ is selected from C₁₋₆alkyl, C₁₋₆alkanoyl, C₁₋₆alkylsulphonyl, C₁₋₆alkoxycarbonyl, carbamoyl, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)₂carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; or a pharmaceutically acceptable salt thereof.

Particular values of the variable groups contained in formula (I) are as follows. Such values may be used, where appropriate, with any of the definitions, claims or embodiments defined hereinbefore or hereinafter.

R¹ is C₁₋₆alkoxy or carbocyclyl.

R¹ is C₁₋₆alkyl, C₁₋₆alkoxy and cyclopropyl.

20

R¹ is isopropoxy or cyclopropyl.

R¹ is C₁₋₆alkoxy.

R¹ is cyclopropyl.

R¹ is isopropoxy.

5 R¹ is methyl, *t*-butyl, isopropoxy or cyclopropyl.

R² is hydrogen.

R¹ and R² are independently selected from hydrogen, C₁₋₆alkoxy and carbocyclyl.

R¹ and R² are independently selected from hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy and carbocyclyl.

10 R¹ and R² are independently selected from hydrogen, C₁₋₆alkoxy and cyclopropyl.

R¹ and R² are independently selected from hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy and cyclopropyl.

R¹ and R² are independently selected from hydrogen, isopropoxy and cyclopropyl.

R¹ and R² are independently selected from hydrogen, methyl, *t*-butyl, isopropoxy and

15 cyclopropyl.

R¹ is C₁₋₆alkoxy or carbocyclyl and R² is hydrogen.

R¹ is C₁₋₆alkyl, C₁₋₆alkoxy or carbocyclyl and R² is hydrogen.

R¹ is C₁₋₆alkoxy and cyclopropyl and R² is hydrogen.

R¹ is C₁₋₆alkyl, C₁₋₆alkoxy and cyclopropyl and R² is hydrogen.

20 R¹ is C₁₋₆alkoxy and R² is hydrogen.

R¹ is isopropoxy and R² is hydrogen.

R¹ is cyclopropyl and R² is hydrogen.

R¹ is isopropoxy or cyclopropyl and R² is hydrogen.

R¹ is methyl, *t*-butyl, isopropoxy or cyclopropyl and R² is hydrogen.

25 X¹ is =N-, X² is =CR⁸-, X³ is =CR⁹- and X⁴ is =CR¹⁰-.

X² is =N-, X¹ is =CR⁸-, X³ is =CR⁹- and X⁴ is =CR¹⁰-.

X³ is =N-, X² is =CR⁸-, X¹ is =CR⁹- and X⁴ is =CR¹⁰-.

X⁴ is =N-, X² is =CR⁸-, X³ is =CR⁹- and X¹ is =CR¹⁰-.

30 X³ or X⁴ is =N-, X¹ and X² and the other of X³ and X⁴ are independently selected from =CR⁸-, =CR⁹- and =CR¹⁰-.

R³ is hydrogen.

R³ is optionally substituted C₁₋₆alkyl; wherein said optional substituents are selected from one or more R¹¹.

R⁴ is not hydrogen.

R⁴ is selected from hydrogen or C₁₋₆alkyl; wherein R⁴ may be optionally substituted on carbon by one or more R¹²; wherein R¹² is selected from hydroxy.

5 R⁴ is selected from hydrogen or C₁₋₆alkyl; wherein R⁴ may be optionally substituted on carbon by one or more R¹²; wherein R¹² is selected from hydroxy and R³⁴ is hydrogen.

R⁴ and R³⁴ are independently selected from hydrogen or C₁₋₆alkyl; wherein R⁴ and R³⁴ may be independently optionally substituted on carbon by one or more R¹²; wherein R¹² is selected from hydroxy.

10 R⁴ is selected from hydrogen or methyl; wherein R⁴ may be optionally substituted on carbon by one or more R¹²; wherein R¹² is selected from hydroxy.

R⁴ is selected from hydrogen or methyl; wherein R⁴ may be optionally substituted on carbon by one or more R¹²; wherein R¹² is selected from hydroxy and R³⁴ is hydrogen.

15 R⁴ and R³⁴ are independently selected from hydrogen or methyl; wherein R⁴ and R³⁴ may be independently optionally substituted on carbon by one or more R¹²; wherein R¹² is selected from hydroxy.

R⁴ is selected from hydrogen, methyl or hydroxymethyl.

R⁴ is selected from hydrogen, methyl or hydroxymethyl and R³⁴ is hydrogen.

R⁴ and R³⁴ are independently selected from hydrogen, methyl or hydroxymethyl.

R³⁴ is selected from hydrogen.

20 R³⁴ is selected from hydrogen or hydroxymethyl.

R⁴ is selected from methyl or hydroxymethyl.

R⁴ is selected from methyl or hydroxymethyl and R³⁴ is hydrogen.

R⁴ is selected from methyl and R³⁴ is hydrogen.

R⁴ is selected from hydroxymethyl and R³⁴ is hydrogen.

25 A is a direct bond.

A is C₁₋₂alkylene; wherein said C₁₋₂alkylene may be optionally substituted by one or more R¹⁴.

Ring C is carbocyclyl.

30 Ring C is or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R¹⁵;

Ring C is carbocyclyl or heterocyclyl.

Ring C is phenyl, pyridyl or pyrimidinyl.

Ring C is phenyl, pyrid-2-yl, pyrid-3-yl or pyrimidin-2-yl.

Ring C is phenyl.

Ring C is pyridyl.

Ring C is pyrid-2-yl.

R^5 is selected from halo, C_{1-6} alkanoylamino, C_{1-6} alkylsulphonylamino or

5 carbocyclyl- R^{37} -; wherein

R^{37} is $-C(O)N(R^{31})-$; wherein R^{31} is hydrogen.

R^5 is halo.

R^5 is selected from fluoro, acetylamino, mesylamino or cyclopropyl- R^{37} -; wherein R^{37} is $-C(O)N(R^{31})-$; wherein R^{31} is hydrogen.

10 R^5 is fluoro.

R^5 is selected from fluoro, acetylamino, mesylamino or cyclopropylcarbonylamino.

n is 0.

n is 1.

n is 1 or 2; wherein the values of R^5 may be the same or different.

15 n is 2; wherein the values of R^5 may be the same or different.

n is 3; wherein the values of R^5 may be the same or different.

Ring C and $(R^5)_n$ together form 4-fluorophenyl; wherein the fluoro group is para to the A group of formula (I).

Ring C and $(R^5)_n$ together form 4-fluorophenyl, 5-fluoropyrid-2-yl,

20 3,5-difluoropyrid-2-yl, 5-fluoropyrimidin-2-yl, 4-fluoro-3-mesylaminophenyl,

6-fluoropyrid-3-yl, 4-fluoro-3-acetylamino-phenyl and 4-fluoro-3-cyclopropylcarbonylamino.

Ring C and $(R^5)_n$ together form 5-fluoropyrid-2-yl; wherein the fluoro group is para to the A group of formula (I).

R^8 , R^9 and R^{10} are independently selected from hydrogen, halo, nitro, cyano, amino,

25 carboxy, carbamoyl, C_{1-6} alkyl, C_{1-6} alkanoyl, $N-(C_{1-6}alkyl)amino$ or carbocyclyl- R^{25} -; wherein R^8 , R^9 and R^{10} independently of each other may be optionally substituted on carbon by one or more R^{18} ;

R^{18} is selected from hydroxy, amino, $N-(C_{1-6}alkyl)amino$, C_{1-6} alkanoylamino,

C_{1-6} alkylsulphonylamino, carbocyclyl- R^{27} - or heterocyclyl- R^{28} -; wherein R^{18} may be

30 optionally substituted on carbon by one or more R^{20} ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^{21} ;

R^{20} is selected from halo, amino, C_{1-6} alkyl, N,N -(C_{1-6} alkyl)₂amino, C_{1-6} alkylsulphonyl- N -(C_{1-6} alkyl)amino, carbocyclyl- R^{35} - or heterocyclyl- R^{36} -; wherein R^{20} may be optionally substituted on carbon by one or more R^{23} ;

R^{21} is selected from C_{1-6} alkylsulphonyl;

5 R^{23} is dimethylamino or phenyl; and

R^{27} , R^{28} , R^{35} and R^{36} are independently selected from a direct bond, -C(O)N(R^{31})-, -NH=CH- or -SO₂N(R^{32})-; wherein R^{31} and R^{32} are independently selected from hydrogen or C_{1-6} alkyl.

10 R^8 , R^9 and R^{10} are independently selected from hydrogen, halo, nitro, cyano, amino, carbamoyl and C_{1-6} alkyl; wherein R^8 , R^9 and R^{10} independently of each other may be optionally substituted on carbon by one or more R^{18} ; wherein

R^{18} is selected from amino, C_{1-6} alkanoylamino, C_{1-6} alkylsulphonylamino or heterocyclyl- R^{28} -; wherein R^{18} may be optionally substituted on carbon by one or more R^{20} ;

R^{20} is amino; and

15 R^{28} is -C(O)N(R^{31})-; wherein R^{31} is hydrogen.

R^8 , R^9 and R^{10} are independently selected from hydrogen, fluoro, chloro, iodo, nitro, cyano, amino, carboxy, carbamoyl, methyl, isopropyl, formyl, methylamino, isopropylamino or cyclopropyl- R^{25} -; wherein R^8 , R^9 and R^{10} independently of each other may be optionally substituted on carbon by one or more R^{18} ;

20 R^{18} is selected from hydroxy, amino, methylamino, acetylamino, propionylamino, 3-methylbutanoylamino, mesylamino, cyclopropyl- R^{27} -, phenyl- R^{27} -, tetrahydrofuran-2-yl- R^{28} -, furan-2-yl- R^{28} -, pyrrol-2-yl- R^{28} -, isoxazol-5-yl- R^{28} -, isoxazol-4-yl- R^{28} -, piperidin-4-yl- R^{28} -, thien-2-yl- R^{28} -, pyrid-3-yl- R^{28} -, pyrid-4-yl- R^{28} -, tetrahydro-2H-thiopyran-4-yl- R^{28} -, morpholino- R^{28} - or 2-oxopyrrolidin-5-yl- R^{28} -; wherein
25 R^{18} may be optionally substituted on carbon by one or more R^{20} ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^{21} ;

R^{20} is selected from fluoro, amino, methyl, dimethylamino, N -(isopropyl)- N -(mesyl)amino, N -(ethyl)- N -(mesyl)amino, phenyl- R^{35} -, thien-2-yl- R^{36} -,
30 thien-3-yl- R^{36} -, pyrid-3-yl- R^{36} - or morpholino- R^{36} -; wherein R^{20} may be optionally substituted on carbon by one or more R^{23} ;

R^{21} is selected from mesyl;

R^{23} is dimethylamino or phenyl; and

24

R^{27} , R^{28} , R^{35} and R^{36} are independently selected from a direct bond, $-C(O)N(R^{31})-$, $-NH=CH-$ or $-SO_2N(R^{32})-$; wherein R^{31} and R^{32} are independently selected from hydrogen or methyl.

R^8 , R^9 and R^{10} are independently selected from hydrogen, fluoro, chloro, nitro, cyano, amino, carboxy, carbamoyl, methyl, isopropyl, formyl, methylamino, isopropylamino or cyclopropyl- R^{25} -; wherein R^8 , R^9 and R^{10} independently of each other may be optionally substituted on carbon by one or more R^{18} ;

R^{18} is selected from hydroxy, amino, methylamino, acetylamino, propionylamino, 3-methylbutanoylamino, mesylamino, cyclopropyl- R^{27} -, phenyl- R^{27} -, tetrahydrofuran-2-yl- R^{28} -, furan-2-yl- R^{28} -, pyrrol-2-yl- R^{28} -, isoxazol-5-yl- R^{28} -, isoxazol-4-yl- R^{28} -, piperidin-4-yl- R^{28} -, thien-2-yl- R^{28} -, pyrid-3-yl- R^{28} -, pyrid-4-yl- R^{28} -, tetrahydro-2H-thiopyran-4-yl- R^{28} -, morpholino- R^{28} - or 2-oxopyrrolidin-5-yl- R^{28} -; wherein R^{18} may be optionally substituted on carbon by one or more R^{20} ; and wherein if said heterocyclyl contains an $-NH-$ moiety that nitrogen may be optionally substituted by a group selected from R^{21} ;

R^{20} is selected from fluoro, amino, methyl, dimethylamino, *N*-(isopropyl)-*N*-(mesyl)amino, *N*-(ethyl)-*N*-(mesyl)amino, phenyl- R^{35} -, thien-2-yl- R^{36} -, thien-3-yl- R^{36} -, pyrid-3-yl- R^{36} - or morpholino- R^{36} -; wherein R^{20} may be optionally substituted on carbon by one or more R^{23} ;

R^{21} is selected from mesyl;

R^{23} is dimethylamino or phenyl; and

R^{27} , R^{28} , R^{35} and R^{36} are independently selected from a direct bond, $-C(O)N(R^{31})-$, $-NH=CH-$ or $-SO_2N(R^{32})-$; wherein R^{31} and R^{32} are independently selected from hydrogen or methyl.

R^8 , R^9 and R^{10} are independently selected from hydrogen, fluoro, chloro, nitro, cyano, amino, carbamoyl and methyl; wherein R^8 , R^9 and R^{10} independently of each other may be optionally substituted on carbon by one or more R^{18} ; wherein

R^{18} is selected from amino, acetylamino, mesylamino or 2-oxopyrrolidin-5-yl- R^{28} -; wherein R^{18} may be optionally substituted on carbon by one or more R^{20} ;

R^{20} is amino; and

R^{28} is $-C(O)N(R^{31})-$; wherein R^{31} is hydrogen.

R^8 , R^9 and R^{10} are independently selected from hydrogen, fluoro, chloro, iodo, nitro, cyano, amino, carboxy, carbamoyl, formyl, methylamino, hydroxymethyl,

25

- acetylaminomethyl, (2-aminoacetyl)aminomethyl, (2-morpholinoacetyl)aminomethyl,
(R)-2-oxopyrrolidin-5-yl-carbonylaminomethyl,
(S)-2-oxopyrrolidin-5-yl-carbonylaminomethyl,
(R,S)-2-oxopyrrolidin-5-yl-carbonylaminomethyl, isoxaxol-5-yl-carbonylaminomethyl,
5 mesylaminomethyl, morpholinomethyl, benzoylaminomethyl,
pyrid-3-yl-carbonylaminomethyl, 6-dimethylaminopyrid-3-yl-carbonylaminomethyl,
6-morpholinopyrid-3-yl-carbonylaminomethyl, pyrid-4-yl-carbonylaminomethyl,
5-methylisoxaxol-4-yl-carbonylaminomethyl, thien-2-yl-carbonylaminomethyl,
4-dimethylaminobenzylcarbonylaminomethyl,
10 2-(*N*-(isopropyl)-*N*-(mesyl)amino)acetylaminomethyl,
2-(*N*-(phenethyl)-*N*-(mesyl)amino)acetylaminomethyl,
1-mesylpiperidin-1-ylcarbonylaminomethyl, 2-(pyrid-3-yl)acetylaminomethyl,
tetrahydro-2*H*-thiopyran-4-yl-carbonylaminomethyl,
2-(thien-2-yl)acetylcarbonylaminomethyl, 2-(thien-3-yl)acetylcarbonylaminomethyl,
15 3-phenylpropionylaminomethyl, 2-(*N*-benzoyl-*N*-methylamino)acetylaminomethyl,
4-dimethylaminobenzoylaminomethyl, phenylsulphonylaminomethyl,
2-amino-3-methylbutanoylaminomethyl, cyclopropylcarbonylaminomethyl,
pyrrol-2-yl-carbonylaminomethyl, tetrahydrofuran-2-yl-carbonylaminomethyl,
furan-2-yl-carbonylaminomethyl, cyclopropylsulphonylaminomethyl,
20 (cyclopropylimino)methyl, methylaminomethyl, trifluoromesylaminomethyl, isopropyl,
isopropylamino or methylamino.

- R^8 , R^9 and R^{10} are independently selected from hydrogen, fluoro, chloro, nitro, cyano,
amino, carboxy, carbamoyl, formyl, methylamino, hydroxymethyl, acetylaminomethyl,
(2-aminoacetyl)aminomethyl, (2-morpholinoacetyl)aminomethyl,
25 (R)-2-oxopyrrolidin-5-yl-carbonylaminomethyl,
(S)-2-oxopyrrolidin-5-yl-carbonylaminomethyl,
(R,S)-2-oxopyrrolidin-5-yl-carbonylaminomethyl, isoxaxol-5-yl-carbonylaminomethyl,
mesylaminomethyl, morpholinomethyl, benzoylaminomethyl,
pyrid-3-yl-carbonylaminomethyl, 6-dimethylaminopyrid-3-yl-carbonylaminomethyl,
30 6-morpholinopyrid-3-yl-carbonylaminomethyl, pyrid-4-yl-carbonylaminomethyl,
5-methylisoxaxol-4-yl-carbonylaminomethyl, thien-2-yl-carbonylaminomethyl,
4-dimethylaminobenzylcarbonylaminomethyl,
2-(*N*-(isopropyl)-*N*-(mesyl)amino)acetylaminomethyl,

2-(*N*-(phenethyl)-*N*-(mesyl)amino)acetylaminomethyl,
1-mesylpiperidin-1-ylcarbonylaminomethyl, 2-(pyrid-3-yl)acetylaminomethyl,
tetrahydro-2*H*-thiopyran-4-yl-carbonylaminomethyl,
2-(thien-2-yl)acetylcarbonylaminomethyl, 2-(thien-3-yl)acetylcarbonylaminomethyl,
5 3-phenylpropionylaminomethyl, 2-(*N*-benzoyl-*N*-methylamino)acetylaminomethyl,
4-dimethylaminobenzoylaminomethyl, phenylsulphonylaminomethyl,
2-amino-3-methylbutanoylaminomethyl, cyclopropylcarbonylaminomethyl,
pyrrol-2-yl-carbonylaminomethyl, tetrahydrofuran-2-yl-carbonylaminomethyl,
furan-2-yl-carbonylaminomethyl, cyclopropylsulphonylaminomethyl,
10 (cyclopropylimino)methyl, methylaminomethyl, trifluoromesylaminomethyl, isopropyl,
isopropylamino or methylamino.

R^8 , R^9 and R^{10} are independently selected from hydrogen, fluoro, chloro, nitro, cyano,
amino, carbamoyl, aminomethyl, acetylaminomethyl, mesylaminomethyl,
2-oxopyrrolidin-5-ylcarbonylaminomethyl and (2-aminoacetyl)aminomethyl.

15 R^8 , R^9 and R^{10} are independently selected from hydrogen, fluoro and cyano.

Therefore in a further aspect of the invention there is provided a compound of formula
(I) (as depicted herein above) wherein:

R^1 and R^2 are independently selected from hydrogen, C_{1-6} alkoxy and carbocyclyl;

X^3 or X^4 is =N-, X^1 and X^2 and the other of X^3 and X^4 are independently selected from
20 =CR⁸-, =CR⁹- and =CR¹⁰-;

R^3 is hydrogen;

R^4 is selected from hydrogen or C_{1-6} alkyl; wherein R^4 may be optionally substituted on
carbon by one or more R^{12} ;

R^{34} is hydrogen;

25 A is a direct bond;

Ring C is carbocyclyl;

R^5 is halo;

n is 1;

R^8 , R^9 and R^{10} are independently selected from hydrogen, halo, nitro, cyano, amino,
30 carbamoyl and C_{1-6} alkyl; wherein R^8 , R^9 and R^{10} independently of each other may be
optionally substituted on carbon by one or more R^{18} ;

R^{12} is selected from hydroxy;

25
27

R^{18} is selected from amino, C_{1-6} alkanoylamino, C_{1-6} alkylsulphonylamino or heterocyclyl- R^{28} -; wherein R^{18} may be optionally substituted on carbon by one or more R^{20} ;

R^{20} is amino; and

R^{28} is $-C(O)N(R^{31})-$; wherein R^{31} is hydrogen;

5 or a pharmaceutically acceptable salt thereof.

Therefore in a further aspect of the invention there is provided a compound of formula (I) (as depicted herein above) wherein:

R^1 and R^2 are independently selected from hydrogen, C_{1-6} alkyl, C_{1-6} alkoxy and carbocyclyl;

10 X^3 or X^4 is $=N-$, X^1 and X^2 and the other of X^3 and X^4 are independently selected from $=CR^8-$, $=CR^9-$ and $=CR^{10}-$;

R^3 is hydrogen;

R^4 and R^{34} are independently selected from hydrogen or C_{1-6} alkyl; wherein R^4 and R^{34} may be independently optionally substituted on carbon by one or more R^{12} ;

15 A is a direct bond;

Ring C is carbocyclyl;

R^5 is halo;

n is 1;

20 R^8 , R^9 and R^{10} are independently selected from hydrogen, halo, nitro, cyano, amino, carbamoyl and C_{1-6} alkyl; wherein R^8 , R^9 and R^{10} independently of each other may be optionally substituted on carbon by one or more R^{18} ;

R^{12} is selected from hydroxy;

R^{18} is selected from amino, C_{1-6} alkanoylamino, C_{1-6} alkylsulphonylamino or heterocyclyl- R^{28} -; wherein R^{18} may be optionally substituted on carbon by one or more R^{20} ;

25 R^{20} is amino; and

R^{28} is $-C(O)N(R^{31})-$; wherein R^{31} is hydrogen;

or a pharmaceutically acceptable salt thereof.

Therefore in a further aspect of the invention there is provided a compound of formula (I) (as depicted herein above) wherein:

30 R^1 is C_{1-6} alkyl, C_{1-6} alkoxy or carbocyclyl;

R^2 is hydrogen;

X^3 or X^4 is $=N-$, X^1 and X^2 and the other of X^3 and X^4 are independently selected from $=CR^8-$, $=CR^9-$ and $=CR^{10}-$;

28

R^3 is hydrogen;

R^4 and R^{34} are independently selected from hydrogen or C_{1-6} alkyl; wherein R^4 and R^{34} may be independently optionally substituted on carbon by one or more R^{12} ; wherein R^{12} is selected from hydroxy;

5 A is a direct bond;

Ring C is carbocyclyl;

R^5 is halo;

n is 1;

10 R^8 , R^9 and R^{10} are independently selected from hydrogen, halo, nitro, cyano, amino, carboxy, carbamoyl, C_{1-6} alkyl, C_{1-6} alkanoyl, N -(C_{1-6} alkyl)amino or carbocyclyl- R^{25} -; wherein R^8 , R^9 and R^{10} independently of each other may be optionally substituted on carbon by one or more R^{18} ;

15 R^{18} is selected from hydroxy, amino, N -(C_{1-6} alkyl)amino, C_{1-6} alkanoylamino, C_{1-6} alkylsulphonylamino, carbocyclyl- R^{27} - or heterocyclyl- R^{28} -; wherein R^{18} may be optionally substituted on carbon by one or more R^{20} ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^{21} ;

R^{20} is selected from halo, amino, C_{1-6} alkyl, N,N -(C_{1-6} alkyl)₂amino, C_{1-6} alkylsulphonyl- N -(C_{1-6} alkyl)amino, carbocyclyl- R^{35} - or heterocyclyl- R^{36} -; wherein R^{20} may be optionally substituted on carbon by one or more R^{23} ;

20 R^{21} is selected from C_{1-6} alkylsulphonyl;

R^{23} is dimethylamino or phenyl; and

R^{27} , R^{28} , R^{35} and R^{36} are independently selected from a direct bond, -C(O)N(R^{31})-, -NH=CH- or -SO₂N(R^{32})-; wherein R^{31} and R^{32} are independently selected from hydrogen or C_{1-6} alkyl;

25 or a pharmaceutically acceptable salt thereof.

Therefore in a further aspect of the invention there is provided a compound of formula (I) (as depicted herein above) wherein:

R^1 is C_{1-6} alkyl, C_{1-6} alkoxy or carbocyclyl;

R^2 is hydrogen;

30 X^3 or X^4 is =N-, X^1 and X^2 and the other of X^3 and X^4 are independently selected from =CR⁸-, =CR⁹- and =CR¹⁰-;

R^3 is hydrogen;

R^4 and R^{34} are independently selected from hydrogen or C_{1-6} alkyl; wherein R^4 and R^{34} may be independently optionally substituted on carbon by one or more R^{12} ; wherein R^{12} is selected from hydroxy;

A is a direct bond;

5 Ring C is carbocyclyl or heterocyclyl;

R^5 is selected from fluoro, acetyl amino, mesyl amino or cyclopropyl- R^{37} -; wherein R^{37} is -C(O)N(R^{31})-; wherein R^{31} is hydrogen;

n is 1 or 2; wherein the values of R^5 may be the same or different;

10 R^8 , R^9 and R^{10} are independently selected from hydrogen, halo, nitro, cyano, amino, carboxy, carbamoyl, C_{1-6} alkyl, C_{1-6} alkanoyl, *N*-(C_{1-6} alkyl)amino or carbocyclyl- R^{25} -; wherein R^8 , R^9 and R^{10} independently of each other may be optionally substituted on carbon by one or more R^{18} ;

15 R^{18} is selected from hydroxy, amino, *N*-(C_{1-6} alkyl)amino, C_{1-6} alkanoylamino, C_{1-6} alkylsulphonylamino, carbocyclyl- R^{27} - or heterocyclyl- R^{28} -; wherein R^{18} may be optionally substituted on carbon by one or more R^{20} ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^{21} ;

R^{20} is selected from halo, amino, C_{1-6} alkyl, *N,N*-(C_{1-6} alkyl)₂amino, C_{1-6} alkylsulphonyl-*N*-(C_{1-6} alkyl)amino, carbocyclyl- R^{35} - or heterocyclyl- R^{36} -; wherein R^{20} may be optionally substituted on carbon by one or more R^{23} ;

20 R^{21} is selected from C_{1-6} alkylsulphonyl;

R^{23} is dimethylamino or phenyl; and

R^{27} , R^{28} , R^{35} and R^{36} are independently selected from a direct bond, -C(O)N(R^{31})-, -NH=CH- or -SO₂N(R^{32})-; wherein R^{31} and R^{32} are independently selected from hydrogen or C_{1-6} alkyl;

25 or a pharmaceutically acceptable salt thereof.

Therefore in a further aspect of the invention there is provided a compound of formula (I) (as depicted herein above) wherein:

R^1 is isopropoxy or cyclopropyl;

R^2 is hydrogen;

30 X^3 or X^4 is =N-, X^1 and X^2 and the other of X^3 and X^4 are independently selected from =CR⁸-, =CR⁹- and =CR¹⁰-;

R^3 is hydrogen;

R^4 is selected from hydrogen, methyl or hydroxymethyl;

R³⁴ is hydrogen;

A is a direct bond;

Ring C is phenyl;

R⁵ is fluoro;

5 n is 1; and

R⁸, R⁹ and R¹⁰ are independently selected from hydrogen, fluoro, chloro, nitro, cyano, amino, carbamoyl, aminomethyl, acetylaminomethyl, mesylaminomethyl, 2-oxopyrrolidin-5-ylcarbonylaminomethyl and (2-aminoacetyl)aminomethyl; or a pharmaceutically acceptable salt thereof.

10 Therefore in a further aspect of the invention there is provided a compound of formula (I) (as depicted herein above) wherein:

R¹ is methyl, *t*-butyl, isopropoxy or cyclopropyl;

R² is hydrogen;

15 X³ or X⁴ is =N-, X¹ and X² and the other of X³ and X⁴ are independently selected from =CR⁸-, =CR⁹- and =CR¹⁰-;

R³ is hydrogen;

R⁴ is selected from hydrogen, methyl or hydroxymethyl;

R³⁴ is selected from hydrogen or hydroxymethyl;

A is a direct bond;

20 Ring C is phenyl;

R⁵ is fluoro;

n is 1; and

25 R⁸, R⁹ and R¹⁰ are independently selected from hydrogen, fluoro, chloro, nitro, cyano, amino, carbamoyl, aminomethyl, acetylaminomethyl, mesylaminomethyl, 2-oxopyrrolidin-5-ylcarbonylaminomethyl and (2-aminoacetyl)aminomethyl; or a pharmaceutically acceptable salt thereof.

Therefore in a further aspect of the invention there is provided a compound of formula (I) (as depicted herein above) wherein:

R¹ is methyl, *t*-butyl, isopropoxy or cyclopropyl;

30 R² is hydrogen;

X³ or X⁴ is =N-, X¹ and X² and the other of X³ and X⁴ are independently selected from =CR⁸-, =CR⁹- and =CR¹⁰-;

R³ is hydrogen;

R^4 and R^{34} are independently selected from hydrogen, methyl or hydroxymethyl;

A is a direct bond;

Ring C is phenyl;

R^5 is fluoro;

5 n is 1;

R^8 , R^9 and R^{10} are independently selected from hydrogen, fluoro, chloro, nitro, cyano, amino, carboxy, carbamoyl, formyl, methylamino, hydroxymethyl, acetylaminomethyl,

(2-aminoacetyl)aminomethyl, (2-morpholinoacetyl)aminomethyl,

(R)-2-oxopyrrolidin-5-yl-carbonylaminomethyl,

10 (S)-2-oxopyrrolidin-5-yl-carbonylaminomethyl,

(R,S)-2-oxopyrrolidin-5-yl-carbonylaminomethyl, isoxaxol-5-yl-carbonylaminomethyl,

mesylaminomethyl, morpholinomethyl, benzoylaminomethyl,

pyrid-3-yl-carbonylaminomethyl, 6-dimethylaminopyrid-3-yl-carbonylaminomethyl,

6-morpholinopyrid-3-yl-carbonylaminomethyl, pyrid-4-yl-carbonylaminomethyl,

15 5-methylisoxaxol-4-yl-carbonylaminomethyl, thien-2-yl-carbonylaminomethyl,

4-dimethylaminobenzylcarbonylaminomethyl,

2-(N-(isopropyl)-N-(mesyl)amino)acetylaminomethyl,

2-(N-(phenethyl)-N-(mesyl)amino)acetylaminomethyl,

1-mesylpiperidin-1-ylcarbonylaminomethyl, 2-(pyrid-3-yl)acetylaminomethyl,

20 tetrahydro-2H-thiopyran-4-yl-carbonylaminomethyl,

2-(thien-2-yl)acetylcarbonylaminomethyl, 2-(thien-3-yl)acetylcarbonylaminomethyl,

3-phenylpropionylaminomethyl, 2-(N-benzoyl-N-methylamino)acetylaminomethyl,

4-dimethylaminobenzoylaminomethyl, phenylsulphonylaminomethyl,

2-amino-3-methylbutanoylaminomethyl, cyclopropylcarbonylaminomethyl,

25 pyrrol-2-yl-carbonylaminomethyl, tetrahydrofuran-2-yl-carbonylaminomethyl,

furan-2-yl-carbonylaminomethyl, cyclopropylsulphonylaminomethyl,

(cyclopropylimino)methyl, methylaminomethyl, trifluoromesylaminomethyl, isopropyl,

isopropylamino or methylamino;

or a pharmaceutically acceptable salt thereof.

30 Therefore in a further aspect of the invention there is provided a compound of formula (I) (as depicted herein above) wherein:

R^1 is methyl, *t*-butyl, isopropoxy or cyclopropyl;

R^2 is hydrogen;

X^3 or X^4 is =N-, X^1 and X^2 and the other of X^3 and X^4 are independently selected from =CR⁸-, =CR⁹- and =CR¹⁰-;

R^3 is hydrogen;

R^4 and R^{34} are independently selected from hydrogen, methyl or hydroxymethyl;

5 A is a direct bond;


Ring C is phenyl, pyrid-2-yl, pyrid-3-yl or pyrimidin-2-yl;

R^5 is selected from fluoro, acetylamino, mesylamino or cyclopropylcarbonylamino;

n is 1 or 2; wherein the values of R^5 may be the same or different;

R^8 , R^9 and R^{10} are independently selected from hydrogen, fluoro, chloro, iodo, nitro,
 10 cyano, amino, carboxy, carbamoyl, formyl, methylamino, hydroxymethyl,
 acetylaminomethyl, (2-aminoacetyl)aminomethyl, (2-morpholinoacetyl)aminomethyl,
 (R)-2-oxopyrrolidin-5-yl-carbonylaminoethyl,
 (S)-2-oxopyrrolidin-5-yl-carbonylaminoethyl,
 (R,S)-2-oxopyrrolidin-5-yl-carbonylaminoethyl, isoxaxol-5-yl-carbonylaminoethyl,
 15 mesylaminomethyl, morpholinomethyl, benzoylaminoethyl,
 pyrid-3-yl-carbonylaminoethyl, 6-dimethylaminopyrid-3-yl-carbonylaminoethyl,
 6-morpholinopyrid-3-yl-carbonylaminoethyl, pyrid-4-yl-carbonylaminoethyl,
 5-methylisoxaxol-4-yl-carbonylaminoethyl, thien-2-yl-carbonylaminoethyl,
 4-dimethylaminobenzylcarbonylaminoethyl,
 20 2-(N-(isopropyl)-N-(mesyl)amino)acetylaminomethyl,
 2-(N-(phenethyl)-N-(mesyl)amino)acetylaminomethyl,
 1-mesylpiperidin-1-ylcarbonylaminoethyl, 2-(pyrid-3-yl)acetylaminomethyl,
 tetrahydro-2H-thiopyran-4-yl-carbonylaminoethyl,
 2-(thien-2-yl)acetylcarbonylaminoethyl, 2-(thien-3-yl)acetylcarbonylaminoethyl,
 25 3-phenylpropionylaminomethyl, 2-(N-benzoyl-N-methylamino)acetylaminomethyl,
 4-dimethylaminobenzoylaminoethyl, phenylsulphonylaminoethyl,
 2-amino-3-methylbutanoylaminoethyl, cyclopropylcarbonylaminoethyl,
 pyrrol-2-yl-carbonylaminoethyl, tetrahydrofuran-2-yl-carbonylaminoethyl,
 furan-2-yl-carbonylaminoethyl, cyclopropylsulphonylaminoethyl,
 30 (cyclopropylimino)methyl, methylaminomethyl, trifluoromesylaminomethyl, isopropyl,
 isopropylamino or methylamino;
 or a pharmaceutically acceptable salt thereof.


In a further aspect of the invention there is provided a compound of formula (Ia):



(Ia)

wherein R^a is nitro or amino; and other variable groups are as defined herein above.

In a further aspect of the invention there is provided a compound of formula (Ib):



(Ib)

wherein R^b is nitro or amino; and other variable groups are as defined herein above.

In another aspect of the invention, preferred compounds of the invention are any one of the Examples or a pharmaceutically acceptable salt thereof.

10 In another aspect of the invention, preferred compounds of the invention are any one of Examples 1, 6, 11, 16, 64, 110, 112, 113, 119 and 120 or a pharmaceutically acceptable salt thereof.

In an additional embodiment the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use as a medicament.

15 In an additional embodiment the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the manufacture of a medicament for use in the inhibition of Trk activity.

In an additional embodiment the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the manufacture of a medicament for use in the treatment or prophylaxis of cancer.

5 In an additional embodiment the present invention provides a compound of the formula (I), or a pharmaceutically acceptable salt thereof, for use in the manufacture of a medicament for use in the treatment of cancer in a warm-blooded animal such as man.

10 In an additional embodiment the present invention provides a compound of the formula (I), or a pharmaceutically acceptable salt thereof, for use in the manufacture of a medicament for use in the treatment or prophylaxis of cancers (solid tumors and leukemia), fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation in a warm-blooded animal such as man.

15 In an additional embodiment the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the manufacture of a medicament for use in the production of an anti-proliferative effect.

In an additional embodiment the present invention provides a method of inhibiting Trk activity comprising administering to a host in need of such treatment a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof.

20 In an additional embodiment the present invention provides a method for the treatment of cancer comprising administering to a host in need of such treatment a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof.

25 In an additional embodiment the present invention provides a method for the treatment or prophylaxis of cancer comprising administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.

30 In an additional embodiment the present invention provides a method for the treatment or prophylaxis of cancers (solid tumors and leukemia), fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation in a warm-blooded animal such as man comprising administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.

35

In an additional embodiment the present invention provides a method of producing an anti-proliferative effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof.

5 In an additional embodiment the present invention provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, diluent or excipient.

10 In an additional embodiment the present invention provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, diluent or excipient for use in the inhibition of Trk activity.

15 In an additional embodiment the present invention provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, diluent or excipient for use in the treatment of cancer.

In an additional embodiment the present invention provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, diluent or excipient for use in the treatment or prophylaxis of cancer.

20 In an additional embodiment the present invention provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, diluent or excipient for use in the treatment or prophylaxis of cancers (solid tumors and leukemia), fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation.

25 In an additional embodiment the present invention provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, diluent or excipient for use in the production of an anti-proliferative effect in a warm-blooded animal such as man.

30 In an additional embodiment the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the inhibition of Trk activity.

5 In an additional embodiment the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment or prophylaxis of cancer.

10 In an additional embodiment the present invention provides a compound of the formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer in a warm-blooded animal such as man.

15 In an additional embodiment the present invention provides a compound of the formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment or prophylaxis of cancers (solid tumours and leukaemia), fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation in a warm-blooded animal such as man.

20 In an additional embodiment the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the production of an anti-proliferative effect.


In one embodiment where the inhibition of Trk activity is referred to particularly this refers to the inhibition of Trk A activity.

25 In another embodiment where the inhibition of Trk activity is referred to particularly this refers to the inhibition of Trk B activity.

Where the treatment (or prophylaxis) of cancer is referred to, particularly it refers to the treatment (or prophylaxis) of mesoblastic nephroma, mesothelioma, acute myeloblastic leukemia, acute lymphocytic leukemia, multiple myeloma, oesophageal cancer, myeloma, hepatocellular, pancreatic, cervical cancer, Ewings sarcoma, neuroblastoma, Kaposi sarcoma, ovarian cancer, breast cancer including secretory breast cancer, colorectal cancer, prostate cancer including hormone refractory prostate cancer, bladder cancer, melanoma, lung cancer - non small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).


In a further aspect of the present invention provides a process for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof which process (wherein variable groups are, unless otherwise specified, as defined in formula (I)) comprises of:

- 5 *Process a)* reaction of a compound of formula (II):



(II)

wherein Pg is a nitrogen protecting group; with a compound of formula (III):




(III)

10

wherein L is a displaceable group;

Process b) for compounds of formula (I) wherein R^4 is hydroxymethyl and R^{34} is hydrogen; reaction of a compound of formula (II) with an epoxide of formula (IV):




(IV)

15


Process c) reacting a compound of formula (V):

23
38




with hydrazine;


Process d) reacting a compound of formula (VI):



wherein L is a displaceable group; with an amine of formula (VII):




10 Process e) reacting a compound of formula (VIII):




(VIII)

wherein L is a displaceable group; with an amine of formula (IX):




(IX)

Process f) reacting an amine of formula (X):



(X)

with a compound of formula (XI):



(XI)

wherein L is a displaceable group;

and thereafter if necessary:

i) converting a compound of the formula (I) into another compound of the formula (I);

- ii) removing any protecting groups;
- iii) forming a pharmaceutically acceptable salt.


L is a displaceable group, suitable values for L are for example, a halo or sulphonyloxy group, for example a chloro, bromo, methanesulphonyloxy or toluene-4-sulphonyloxy group.

Pg is a nitrogen protecting group. Suitable values for Pg are described herein below.

Specific reaction conditions for the above reactions are as follows.

- Process a)* Compounds of formula (II) and (III) may be reacted together under standard nucleophilic addition reactions for example in the presence of a suitable base such as potassium carbonate and a suitable solvent such as DMF and at a temperature in the range from 25 to 100°C.

Compounds of the formula (II) may be prepared according to *Scheme 1*:



Scheme 1

- wherein Pg is a nitrogen protecting group. Suitable values for Pg are defined below; and wherein L is a displaceable group as defined above.


Compounds of formula (III), (IIa) and (IIb) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art.

- Process b)* Compounds of formula (II) and (IV) may be reacted together under epoxide ring opening reaction conditions for example in the presence of a suitable catalyst such as LiClO₄, NaClO₄, Mg(ClO₄)₂ and a suitable solvent such as CH₃CN and at a temperature in the range from 25 to 80°C.

- Compounds of formula (IV) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art.

Process c) The s reaction may be carried out in a suitable solvent, for example, an alcohol such as ethanol or butanol at a temperature in the range from 50-120°C, in particular in the range from 70-100°C.

Compounds of the formula (V) may be prepared according to *Scheme 2*:




Scheme 2

Compounds of the formula (Va) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art.

- 5 *Process d)* Compounds of formula (VI) and (VII) may be reacted together under the conditions listed in *Process a)*.

Compounds of formula (VI) may be prepared according to *Scheme 3*:




Scheme 3

- 10 wherein L is a displaceable group as defined herein above.

Compounds of the formula (VIa) and (VII) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art.

Process e) Compounds of formula (VIII) and (IX) may be reacted together under the conditions listed in *Process a)*.

- 15 Compounds of formula (VIII) may be prepared according to *Scheme 4*:




Scheme 4

Compounds of the formula (IX) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art.

Process f) Compounds of formula (X) and (XI) may be reacted together under the conditions listed in *Process a)*.

Compounds of formula (X) may be prepared according to *Scheme 5*:



Scheme 5

wherein L is a displaceable group as defined herein above.

Compounds of the formula (Xa) and (XI) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art.

It will be appreciated that certain of the various ring substituents in the compounds of the present invention may be introduced by standard aromatic substitution reactions or generated by conventional functional group modifications either prior to or immediately following the processes mentioned above, and as such are included in the process aspect of the invention. Such reactions and modifications include, for example, introduction of a substituent by means of an aromatic substitution reaction, reduction of substituents, alkylation of substituents and oxidation of substituents. The reagents and reaction conditions for such procedures are well known in the chemical art. Particular examples of aromatic substitution reactions include the introduction of a nitro group using concentrated nitric acid, the introduction of an acyl group using, for example, an acyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; the introduction of an alkyl group using an alkyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; and the introduction of a halogeno group. Particular examples of modifications include the reduction of a nitro group to an amino group by for example, catalytic hydrogenation with a nickel catalyst or treatment with iron in the presence of hydrochloric acid with heating; oxidation of alkylthio to alkylsulphinyl or alkylsulphonyl.

It will also be appreciated that in some of the reactions mentioned herein it may be necessary/desirable to protect any sensitive groups in the compounds. The instances where protection is necessary or desirable and suitable methods for protection are known to those skilled in the art. Conventional protecting groups may be used in accordance with standard practice (for illustration see T.W. Green, *Protective Groups in Organic Synthesis*, John Wiley

C
43

and Sons, 1991). Thus, if reactants include groups such as amino, carboxy or hydroxy it may be desirable to protect the group in some of the reactions mentioned herein.

A suitable protecting group for an amino or alkylamino group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an alkoxycarbonyl group, for example a methoxycarbonyl, ethoxycarbonyl or *t*-butoxycarbonyl group, an arylmethoxycarbonyl group, for example benzyloxycarbonyl, or an aroyl group, for example benzoyl. The deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an acyl group such as a *t*-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon, or by treatment with a Lewis acid for example boron tris(trifluoroacetate). A suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example dimethylaminopropylamine, or with hydrazine.

A suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, or an arylmethyl group, for example benzyl. The deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.

A suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a *t*-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.

The protecting groups may be removed at any convenient stage in the synthesis using conventional techniques well known in the chemical art.

45
44

Definitions

In this specification the term "alkyl" includes both straight and branched chain alkyl groups but references to individual alkyl groups such as "propyl" are specific for the straight chain version only. For example, "C₁₋₆alkyl" and "C₁₋₄alkyl" include methyl, ethyl, propyl, isopropyl and *t*-butyl. However, references to individual alkyl groups such as 'propyl' are specific for the straight-chained version only and references to individual branched chain alkyl groups such as 'isopropyl' are specific for the branched-chain version only. A similar convention applies to other radicals. The term "halo" refers to fluoro, chloro, bromo and iodo.

Where optional substituents are chosen from "one or more" groups it is to be understood that this definition includes all substituents being chosen from one of the specified groups or the substituents being chosen from two or more of the specified groups.

A "heterocyclyl" is a saturated, partially saturated or unsaturated, mono or bicyclic ring containing 4-12 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked, wherein a -CH₂- group can optionally be replaced by a -C(O)-, and a ring sulphur atom may be optionally oxidised to form the S-oxides. Examples and suitable values of the term "heterocyclyl" are morpholino, piperidyl, pyridyl, pyranyl, pyrrolyl, isothiazolyl, indolyl, quinolyl, thienyl, 1,3-benzodioxolyl, thiadiazolyl, piperazinyl, thiazolidinyl, pyrrolidinyl, thiomorpholino, pyrrolinyl, homopiperazinyl, 3,5-dioxapiperidinyl, tetrahydropyranyl, imidazolyl, pyrimidyl, pyrazinyl, pyridazinyl, isoxazolyl, *N*-methylpyrrolyl, 4-pyridone, 1-isoquinolone, 2-pyrrolidone, 4-thiazolidone, pyridine-*N*-oxide and quinoline-*N*-oxide. Further examples and suitable values of the term "heterocyclyl" are morpholino, piperazinyl and pyrrolidinyl. In one aspect of the invention a "heterocyclyl" is a saturated, partially saturated or unsaturated, mono or bicyclic ring containing 5 or 6 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, it may, unless otherwise specified, be carbon or nitrogen linked, a -CH₂- group can optionally be replaced by a -C(O)- and a ring sulphur atom may be optionally oxidised to form the S-oxides. Further examples and suitable values of the term "heterocyclyl" are tetrahydrofuranyl, furanyl, pyrrolyl, isoxaxolyl, piperidinyl, thienyl, pyridyl, tetrahydro-2*H*-thiopyranyl, morpholino and 2-oxopyrrolidinyl.

A "carbocyclyl" is a saturated, partially saturated or unsaturated, mono or bicyclic carbon ring that contains 3-12 atoms; wherein a -CH₂- group can optionally be replaced by a -C(O)-. Particularly "carbocyclyl" is a monocyclic ring containing 5 or 6 atoms or a bicyclic ring containing 9 or 10 atoms. Suitable values for "carbocyclyl" include cyclopropyl,

cyclobutyl, 1-oxocyclopentyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, phenyl, naphthyl, tetralinyl, indanyl or 1-oxoindanyl.

Where "one of X^1 , X^2 , X^3 and X^4 is =N-, the other three are independently selected from =CR⁸-, =CR⁹- and =CR¹⁰-" it is to be understood that this means one of X^1 , X^2 , X^3 and X^4 is =N-, one of the other three is =CR⁸-, one of the remaining two is =CR⁹- and the last is =CR¹⁰-. For example the scenario wherein X^1 is =N-, X^2 is =CR⁸-, X^3 is =CR⁹- and X^4 is =CR¹⁰- is embraced by this definition as is X^3 is =N-, X^1 is =CR⁸-, X^2 is =CR⁹- and X^4 is =CR¹⁰-. The ring containing X^1 , X^2 , X^3 and X^4 is thus a pyridine ring.

The term "C_{m-n}" or "C_{m-n} group" used alone or as a prefix, refers to any group having m to n carbon atoms.

The term "optionally substituted" refers to either groups, structures, or molecules that are substituted and those that are not substituted.

An example of "C₁₋₆alkanoyloxy" is acetoxy. Examples of "C₁₋₆alkoxycarbonyl" include C₁₋₄alkoxycarbonyl, methoxycarbonyl, ethoxycarbonyl, *n*- and *t*-butoxycarbonyl. Examples of "C₁₋₆alkoxy" include C₁₋₄alkoxy, C₁₋₃alkoxy, methoxy, ethoxy and propoxy. Examples of "C₁₋₆alkoxyimino" include C₁₋₄alkoxyimino, C₁₋₃alkoxyimino, methoxyimino, ethoxyimino and propoxyimino. Examples of "C₁₋₆alkanoylamino" include formamido, acetamido and propionylamino. Examples of "C₁₋₆alkylS(O)_a wherein a is 0 to 2" include C₁₋₄alkylsulphonyl, methylthio, ethylthio, methylsulphanyl, ethylsulphanyl, mesyl and ethylsulphonyl. Examples of "C₁₋₆alkylthio" include methylthio and ethylthio. Examples of "C₁₋₆alkylsulphonylamino" include methylsulphonylamino and ethylsulphonylamino. Examples of "C₁₋₆alkanoyl" include C₁₋₄alkanoyl, formyl, propionyl and acetyl. Examples of "N-(C₁₋₆alkyl)amino" include methylamino and ethylamino. Examples of "N,N-(C₁₋₆alkyl)₂amino" include di-*N*-methylamino, di-(*N*-ethyl)amino and *N*-ethyl-*N*-methylamino. Examples of "C₂₋₆alkenyl" are vinyl, allyl and 1-propenyl. Examples of "C₂₋₆alkynyl" are ethynyl, 1-propynyl and 2-propynyl. Examples of "N-(C₁₋₆alkyl)sulphamoyl" are *N*-(methyl)sulphamoyl and *N*-(ethyl)sulphamoyl. Examples of "N-(C₁₋₆alkyl)₂sulphamoyl" are *N,N*-(dimethyl)sulphamoyl and *N*-(methyl)-*N*-(ethyl)sulphamoyl. Examples of "N-(C₁₋₆alkyl)carbamoyl" are *N*-(C₁₋₄alkyl)carbamoyl, methylaminocarbonyl and ethylaminocarbonyl. Examples of "N,N-(C₁₋₆alkyl)₂carbamoyl" are *N,N*-(C₁₋₄alkyl)₂carbamoyl, dimethylaminocarbonyl and methylethylaminocarbonyl. Examples of "C₁₋₆alkylsulphonyl-N-(C₁₋₆alkyl)amino" include *N*-mesyl-*N*-methylamino and *N*-mesyl-*N*-isopropylamino.

46

"RT" or "rt" means room temperature.

A suitable pharmaceutically acceptable salt of a compound of the invention is, for example, an acid-addition salt of a compound of the invention which is sufficiently basic, for example, an acid-addition salt with, for example, an inorganic or organic acid, for example hydrochloric, hydrobromic, sulphuric, phosphoric, trifluoroacetic, citric or maleic acid. In addition a suitable pharmaceutically acceptable salt of a compound of the invention which is sufficiently acidic is an alkali metal salt, for example a sodium or potassium salt, an alkaline earth metal salt, for example a calcium or magnesium salt, an ammonium salt or a salt with an organic base which affords a physiologically-acceptable cation, for example a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine.

It should be noted that the pyrazoles claimed in this invention are capable to exist in different resonance structures and thus the pyrazoles claimed herein include all possible resonance structures, for example optical isomers, diastereoisomers and geometric isomers and all tautomeric forms of the compounds of the formula (I).

It is also to be understood that certain compounds of the formula (I) can exist in solvated as well as unsolvated forms such as, for example, hydrated forms. It is to be understood that the invention encompasses all such solvated forms.

Formulations

Compounds of the present invention may be administered orally, parenteral, buccal, vaginal, rectal, inhalation, insufflation, sublingually, intramuscularly, subcutaneously, topically, intranasally, intraperitoneally, intrathoracically, intravenously, epidurally, intrathecally, intracerebroventricularly and by injection into the joints.

The dosage will depend on the route of administration, the severity of the disease, age and weight of the patient and other factors normally considered by the attending physician, when determining the individual regimen and dosage level as the most appropriate for a particular patient.

An effective amount of a compound of the present invention for use in therapy of cancer is an amount sufficient to symptomatically relieve in a warm-blooded animal, particularly a human the symptoms of cancer, to slow the progression of cancer, or to reduce in patients with symptoms of cancer the risk of getting worse.

For preparing pharmaceutical compositions from the compounds of this invention, inert, pharmaceutically acceptable carriers can be either solid or liquid. Solid form

47

preparations include powders, tablets, dispersible granules, capsules, cachets, and suppositories.

A solid carrier can be one or more substance, which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, or tablet disintegrating agents; it
5 can also be an encapsulating material.

In powders, the carrier is a finely divided solid, which is in a mixture with the finely divided active component. In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.

10 For preparing suppository compositions, a low-melting wax such as a mixture of fatty acid glycerides and cocoa butter is first melted and the active ingredient is dispersed therein by, for example, stirring. The molten homogeneous mixture is then poured into convenient sized molds and allowed to cool and solidify.

Suitable carriers include magnesium carbonate, magnesium stearate, talc, lactose,
15 sugar, pectin, dextrin, starch, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, a low-melting wax, cocoa butter, and the like.

Some of the compounds of the present invention are capable of forming salts with various inorganic and organic acids and bases and such salts are also within the scope of this invention. Examples of such acid addition salts include acetate, adipate, ascorbate, benzoate,
20 benzenesulfonate, bicarbonate, bisulfate, butyrate, camphorate, camphorsulfonate, choline, citrate, cyclohexyl sulfamate, diethylenediamine, ethanesulfonate, fumarate, glutamate, glycolate, hemisulfate, 2-hydroxyethylsulfonate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, hydroxymaleate, lactate, malate, maleate, methanesulfonate, meglumine, 2-naphthalenesulfonate, nitrate, oxalate, pamoate, persulfate, phenylacetate,
25 phosphate, diphosphate, picrate, pivalate, propionate, quinate, salicylate, stearate, succinate, sulfamate, sulfanilate, sulfate, tartrate, tosylate (p-toluenesulfonate), trifluoroacetate, and undecanoate. Base salts include ammonium salts, alkali metal salts such as sodium, lithium and potassium salts, alkaline earth metal salts such as aluminum, calcium and magnesium salts, salts with organic bases such as dicyclohexylamine salts, N-methyl-D-glucamine, and
30 salts with amino acids such as arginine, lysine, ornithine, and so forth. Also, basic nitrogen-containing groups may be quaternized with such agents as: lower alkyl halides, such as methyl, ethyl, propyl, and butyl halides; dialkyl sulfates like dimethyl, diethyl, dibutyl; diamyl sulfates; long chain halides such as decyl, lauryl, myristyl and stearyl halides; aralkyl

48

halides like benzyl bromide and others. Non-toxic physiologically-acceptable salts are preferred, although other salts are also useful, such as in isolating or purifying the product.

The salts may be formed by conventional means, such as by reacting the free base form of the product with one or more equivalents of the appropriate acid in a solvent or
5 medium in which the salt is insoluble, or in a solvent such as water, which is removed *in vacuo* or by freeze drying or by exchanging the anions of an existing salt for another anion on a suitable ion-exchange resin.

In order to use a compound of the formula (I) or a pharmaceutically acceptable salt thereof for the therapeutic treatment (including prophylactic treatment) of mammals including
10 humans, it is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.

In addition to the compounds of the present invention, the pharmaceutical composition of this invention may also contain, or be co-administered (simultaneously or sequentially) with, one or more pharmacological agents of value in treating one or more disease conditions
15 referred to herein.

The term composition is intended to include the formulation of the active component or a pharmaceutically acceptable salt with a pharmaceutically acceptable carrier. For example this invention may be formulated by means known in the art into the form of, for example, tablets, capsules, aqueous or oily solutions, suspensions, emulsions, creams, ointments, gels,
20 nasal sprays, suppositories, finely divided powders or aerosols or nebulisers for inhalation, and for parenteral use (including intravenous, intramuscular or infusion) sterile aqueous or oily solutions or suspensions or sterile emulsions.

Liquid form compositions include solutions, suspensions, and emulsions. Sterile water or water-propylene glycol solutions of the active compounds may be mentioned as an
25 example of liquid preparations suitable for parenteral administration. Liquid compositions can also be formulated in solution in aqueous polyethylene glycol solution. Aqueous solutions for oral administration can be prepared by dissolving the active component in water and adding suitable colorants, flavoring agents, stabilizers, and thickening agents as desired. Aqueous suspensions for oral use can be made by dispersing the finely divided active component in
30 water together with a viscous material such as natural synthetic gums, resins, methyl cellulose, sodium carboxymethyl cellulose, and other suspending agents known to the pharmaceutical formulation art.

The pharmaceutical compositions can be in unit dosage form. In such form, the composition is divided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of the preparations, for example, packeted tablets, capsules, and powders in vials or ampoules. The unit dosage form can also be a capsule, cachet, or tablet itself, or it can be the appropriate number of any of these packaged forms.

Combinations

The anti-cancer treatment defined herein may be applied as a sole therapy or may involve, in addition to the compound of the invention, conventional surgery or radiotherapy or chemotherapy. Such chemotherapy may include one or more of the following categories of anti-tumour agents:

- (i) antiproliferative/antineoplastic drugs and combinations thereof, as used in medical oncology, such as alkylating agents (for example cis-platin, carboplatin, cyclophosphamide, nitrogen mustard, melphalan, chlorambucil, busulphan and nitrosoureas); antimetabolites (for example antifolates such as fluoropyrimidines like 5-fluorouracil and tegafur, raltitrexed, methotrexate, cytosine arabinoside and hydroxyurea); antitumour antibiotics (for example anthracyclines like adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dactinomycin and mithramycin); antimitotic agents (for example vinca alkaloids like vincristine, vinblastine, vindesine and vinorelbine and taxoids like taxol and taxotere); and topoisomerase inhibitors (for example epipodophyllotoxins like etoposide and teniposide, amsacrine, topotecan and camptothecin);
- (ii) cytostatic agents such as antioestrogens (for example tamoxifen, toremifene, raloxifene, droloxifene and idoxifene), oestrogen receptor down regulators (for example fulvestrant), antiandrogens (for example bicalutamide, flutamide, nilutamide and cyproterone acetate), LHRH antagonists or LHRH agonists (for example goserelin, leuporelin and buserelin), progestogens (for example megestrol acetate), aromatase inhibitors (for example as anastrozole, letrozole, vorazole and exemestane) and inhibitors of 5 α -reductase such as finasteride;
- (iii) agents which inhibit cancer cell invasion (for example metalloproteinase inhibitors like marimastat and inhibitors of urokinase plasminogen activator receptor function);
- (iv) inhibitors of growth factor function, for example such inhibitors include growth factor antibodies, growth factor receptor antibodies (for example the anti-erbB2 antibody trastuzumab [HerceptinTM] and the anti-erbB1 antibody cetuximab [C225]), farnesyl

transferase inhibitors, tyrosine kinase inhibitors and serine/threonine kinase inhibitors, for example inhibitors of the epidermal growth factor family (for example EGFR family tyrosine kinase inhibitors such as

N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine

- 5 (gefitinib, AZD1839), N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine (erlotinib, OSI-774) and

6-acrylamido-N-(3-chloro-4-fluorophenyl)-7-(3-morpholinopropoxy)quinazolin-4-amine (CI 1033)), for example inhibitors of the platelet-derived growth factor family and for example inhibitors of the hepatocyte growth factor family;

- 10 (v) antiangiogenic agents such as those which inhibit the effects of vascular endothelial growth factor, (for example the anti-vascular endothelial cell growth factor antibody bevacizumab [Avastin™], compounds such as those disclosed in International Patent Applications WO 97/22596, WO 97/30035, WO 97/32856 and WO 98/13354) and compounds that work by other mechanisms (for example linomide, inhibitors of integrin
15 $\alpha v \beta 3$ function and angiostatin);

(vi) vascular damaging agents such as Combretastatin A4 and compounds disclosed in International Patent Applications WO 99/02166, WO 00/40529, WO 00/41669, WO 01/92224, WO 02/04434 and WO 02/08213;

- (vii) antisense therapies, for example those which are directed to the targets listed above,
20 such as ISIS 2503, an anti-ras antisense;

(viii) gene therapy approaches, including for example approaches to replace aberrant genes such as aberrant p53 or aberrant BRCA1 or BRCA2, GDEPT (gene-directed enzyme pro-drug therapy) approaches such as those using cytosine deaminase, thymidine kinase or a bacterial nitroreductase enzyme and approaches to increase patient tolerance to chemotherapy or

- 25 radiotherapy such as multi-drug resistance gene therapy; and

(ix) immunotherapy approaches, including for example ex-vivo and in-vivo approaches to increase the immunogenicity of patient tumour cells, such as transfection with cytokines such as interleukin 2, interleukin 4 or granulocyte-macrophage colony stimulating factor, approaches to decrease T-cell anergy, approaches using transfected immune cells such as
30 cytokine-transfected dendritic cells, approaches using cytokine-transfected tumour cell lines and approaches using anti-idiotypic antibodies.

(x) other treatment regimes including: dexamethasone, proteasome inhibitors (including bortezomib), isotretinoin (13-cis retinoic acid), thalidomide, revemid, Rituxamab, ALIMTA,

Cephalon's kinase inhibitors CEP-701 and CEP-2563, anti-Trk or anti-NGF monoclonal antibodies, targeted radiation therapy with ¹³¹I-metaiodobenzylguanidine (¹³¹I-MIBG), anti-G(D2) monoclonal antibody therapy with or without granulocyte-macrophage colony-stimulating factor (GM-CSF) following chemotherapy.

5 Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate dosing of the individual components of the treatment. Such combination products employ the compounds of this invention, or pharmaceutically acceptable salts thereof, within the dosage range described hereinbefore and the other pharmaceutically-active agent within its approved dosage range.

10 Synthesis

The compounds, or pharmaceutically acceptable salts thereof, of the present invention can be prepared in a number of ways well known to one skilled in the art of organic synthesis. The compounds, or pharmaceutically acceptable salts thereof, of the present invention can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or variations thereon as appreciated by those skilled in the art. Such methods include, but are not limited to, those described below. All references cited herein are hereby incorporated in their entirety by reference.

15 The novel compounds, or pharmaceutically acceptable salts thereof, of this invention may be prepared using the reactions and techniques described herein. The reactions are performed in solvents appropriate to the reagents and materials employed and are suitable for the transformations being effected. Also, in the description of the synthetic methods described below, it is to be understood that all proposed reaction conditions, including choice of solvent, reaction atmosphere, reaction temperature, duration of the experiment and workup procedures, are chosen to be the conditions standard for that reaction, which should be readily recognized by one skilled in the art. It is understood by one skilled in the art of organic synthesis that the functionality present on various portions of the molecule must be compatible with the reagents and reactions proposed. Such restrictions to the substituents, which are compatible with the reaction conditions, will be readily apparent to one skilled in the art and alternate methods must then be used.

30 Examples

The invention will now be further described with reference to the following illustrative examples in which, unless stated otherwise:

52

- (i) temperatures are given in degrees Celsius (°C); operations are carried out at room temperature or ambient temperature, that is, in a range of 18-25 °C;
- (ii) organic solutions were dried over anhydrous magnesium sulfate; evaporation of organic solvent was carried out using a rotary evaporator under reduced pressure (4.5 – 30 mmHg) with a bath temperature of up to 60 °C;
- (iii) chromatography means flash chromatography on silica gel; thin layer chromatography (TLC) was carried out on silica gel plates;
- (iv) in general, the course of reactions was followed by TLC or liquid chromatography/mass spectroscopy (LC/MS) and reaction times are given for illustration only;
- (v) final products have satisfactory proton nuclear magnetic resonance (NMR) spectra and/or mass spectra data;
- (vi) yields are given for illustration only and are not necessarily those which can be obtained by diligent process development; preparations were repeated if more material was required;
- (vii) when given, NMR data is in the form of delta values for major diagnostic protons, given in part per million (ppm) relative to tetramethylsilane (TMS) as an internal standard, determined at 300 MHz in DMSO-d₆ unless otherwise stated;
- (viii) chemical symbols have their usual meanings;
- (ix) solvent ratio was given in volume:volume (v/v) terms.
- (x) the following abbreviations have been used:
- | | |
|-------|---|
| EtOAc | ethyl acetate; |
| ether | diethyl ether; |
| EtOH | ethanol; |
| THF | tetrahydrofuran; |
| TFP | tetrafluorophenyl; |
| DIEA | diisopropylethylamine; |
| DMAP | 4-dimethylaminopyridine; |
| NMP | N-methylpyridinone; |
| MTBE | methyl tert-butyl ether; |
| DMF | <i>N,N</i> -dimethylformamide; |
| HBTU | 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate; |

22
53

DCE	dichloroethane;
TFP resin	tetrafluorophenol resin;
MeOH	methanol; and
DCM	dichloromethane.

5

Example 1

(S)-6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino)nicotinonitrile

A portion of 2-chloro-6-(5-cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoronicotinonitrile (Method 1; 0.8g, 2.8 mmol) and (S)-1-(4-fluorophenyl)ethanamine (0.8g, 5.6 mmol) were added to a solution of *n*-BuOH (4 ml) and DIEA (0.5g, 3.7 mmol) in a sealed tube. The reaction was heated to 140 °C for 48 hrs, then cooled to 25 °C and concentrated. The resulting residue was purified by column chromatography (DCM - MeOH = 50 : 1) to give the title compound (0.55g, 50%). ¹H NMR (400 MHz, CDCl₃) δ 8.44 (br s, 1H), 7.37-7.33 (m, 2H), 7.27 (d, *J* = 9.6 Hz, 1H), 7.07-7.03 (m, 2H), 6.11 (s, 1H), 5.24-5.20 (m, 2H), 1.87-1.83 (m, 1H), 1.60 (d, *J* = 6.2 Hz, 3H), 1.01-0.98 (m, 2H), 0.79-0.65 (m, 2H). MS: Calcd.: 380; Found: [M+H]⁺ 381.

Example 2

(S)-6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino)nicotinamide

To a solution of (S)-6-(5-cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino)nicotinonitrile (Example 1; 0.5g, 1.3 mmol) in MeOH (50 ml), was added a 25% aqueous solution (2 ml) of KOH (400 mg) at 25 °C, followed by the addition of 0.1 ml of 30% H₂O₂. The resulting dark red solution was heated to 65 °C for 1h, cooled to 25 °C, and concentrated. The resulting residue was dissolved in EtOAc (50 ml), washed with water (30 ml), dried, filtered and concentrated. The resulting solid was purified by column chromatography (DCM - MeOH = 30 : 1) to give the title compound (0.30g, 60%). ¹H NMR (400 MHz, CDCl₃) δ 9.06 (d, *J* = 7.0 Hz, 1H), 7.90 (br s, 1H), 7.35-7.32 (m, 2H), 7.25 (d, *J* = 7.2 Hz, 1H), 7.00-6.95 (m, 2H), 6.00 (br s, 1H), 5.66 (br s, 2H), 5.21-5.17 (m, 1H), 1.86-1.82 (m, 1H), 1.54 (d, *J* = 6.8 Hz, 3H), 0.96-0.92 (m, 2H), 0.69-0.67 (m, 2H). MS: Calcd.: 398; Found: [M+H]⁺ 399.

57
54

Example 3

(S)-3-(Aminomethyl)-N⁶-(5-cyclopropyl-1H-pyrazol-3-yl)-5-fluoro-N²-(1-(4-fluorophenyl)ethyl)pyridine-2,6-diamine

To a MeOH solution (5 ml) was added (S)-6-(5-cyclopropyl-1H-pyrazol-3-ylamino)-
5 5-fluoro-2-(1-(4-fluorophenyl)ethylamino)nicotinonitrile (Example 1; 0.15g, 0.4 mmol), conc.
HCl (0.1 ml), and Pd (10 wt. %, dry basis, on activated carbon, 0.12g). The mixture was then
flushed with N₂, evacuated, and then placed under 40 psi of H₂ for 6 hrs. The reaction was
then evacuated, flushed with N₂, filtered, washed with MeOH (3 x 30 ml), and concentrated.
The resulting solid was dissolved in the mixture of DCM - MeOH (50 : 1, 100 ml), and a
10 saturated aqueous solution of Na₂CO₃ (100 ml) was added, and the mixture was shaken
vigorously for 30 min. The layers were then allowed to separate, and the aqueous layer was
extracted with DCM (3 x 100 ml). The combined organic layers were dried, filtered and
concentrated. The resulting solid was purified by column chromatography (DCM - MeOH =
9: 1) to give the title compound (0.09g, 58%). ¹H NMR (400 MHz, CD₃OD) δ 7.42-7.38 (m,
15 2H), 7.15 (d, J = 11. Hz, 1H), 7.02-6.97 (m, 2H), 5.15-5.08 (m, 1H), 3.74 (s, 2H), 1.88-1.81
(m, 1H), 1.54 (d, J = 7.0 Hz, 3H), 0.93-0.92 (m, 2H), 0.67-0.63 (m, 2H). MS: Calcd.: 384;
Found: [M+H]⁺ 385.

Example 4

20 (S)-N-(((6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino)
pyridin-3-yl)methyl)acetamide

A round bottom flask was charged with (S)-3-(aminomethyl)-N⁶-(5-cyclopropyl-1H-
pyrazol-3-yl)-5-fluoro-N²-(1-(4-fluorophenyl)ethyl)pyridine-2,6-diamine (Example 3; 0.08g,
0.2 mmol) and acetic acid loaded TFP resin (1.4 mmol/g loading, 0.2 mmol) in mixture of
25 THF - DCM (1 : 1, 3 ml) at 0 °C. The resulting solution was shaken vigorously at 0 °C for 45
min and filtered. The resulting resin was washed with a THF - DCM solution (1 : 1, 3 x 5 ml
for 30 min. each). The resulting organic layers were combined and concentrated. The
resulting solid was purified by reverse-phase column chromatography (5-50% CH₃CN in H₂O
over 400 ml) to give the title compound (0.045g, 50%). ¹H NMR (400 MHz, CD₃OD) δ 7.34-
30 7.33 (m, 2H), 7.11 (d, J = 10.7 Hz, 1H), 7.01-6.97 (m, 2H), 5.14-5.04 (m, 1H), 4.30-4.17 (m,
2H), 1.99 (s, 3H), 1.88-1.81 (m, 1H), 1.50 (d, J = 6.8 Hz, 3H), 0.94-0.92 (m, 2H), 0.67-0.63
(m, 2H). MS: Calcd.: 426; Found: [M+H]⁺ 427.

55

Example 5

(S)-N-((6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino)pyridin-3-yl)methyl)methanesulfonamide

A round bottom flask was charged with (S)-3-(aminomethyl)-N⁶-(5-cyclopropyl-1H-pyrazol-3-yl)-5-fluoro-N²-(1-(4-fluorophenyl)ethyl)pyridine-2,6-diamine (Example 3; 0.025g, 0.065 mmol), methanesulfonic acid loaded TFP resin (0.9 mmol/g loading, 0.065 mmol), DIEA (0.017g, 0.13 mmol), DMAP (0.09g, 0.072 mmol), and THF (5 ml). The resulting solution was shaken vigorously at 60 °C for 8 hrs. The reaction was filtered and the resulting resin was washed with a THF - DCM solution (1 : 1, 3 x 5 ml for 30 min. each). The resulting organic layers were combined and concentrated. The resulting solid was purified by reverse-phase column chromatography (5-50% CH₃CN in H₂O over 400 ml) to give the title compound (0.016g, 53%). ¹H NMR (400 MHz, CD₃OD) δ 7.42-7.39 (m, 2H), 7.14 (d, J = 10.7 Hz, 1H), 7.01-6.97 (m, 2H), 5.16-5.09 (m, 1H), 4.15-4.06 (m, 2H), 2.99 (s, 3H), 1.88-1.83 (m, 1H), 1.52 (d, J = 6.8 Hz, 3H), 0.95-0.93 (m, 2H), 0.66-0.64 (m, 2H). MS: Calcd.: 462; Found: [M+H]⁺ 463.

Example 6

(R)-6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)-2-hydroxyethylamino)nicotinonitrile

2-Chloro-6-(5-cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoronicotinonitrile (Method 1; 0.5g, 1.8 mmol) and (R)-2-amino-2-(4-fluorophenyl)ethanol (0.6g, 3.6 mmol) were added to a solution of *n*-BuOH (4 ml) and DIEA (0.3g, 2.3 mmol) in a sealed tube. The reaction was heated to 140 °C for 48 hrs, then cooled to 25 °C and concentrated. The resulting residue was purified by column chromatography (DCM - MeOH = 80 : 1) to give the title compound (0.3g, 40%). ¹H NMR (400 MHz, CD₃OD) δ 7.37-7.35 (m, 3H), 7.05-7.00 (m, 2H), 5.99 (s, 1H), 5.20-5.11 (m, 1H), 3.90-3.77 (m, 2H), 1.90-1.86 (m, 1H), 1.05-0.96 (m, 2H), 0.73-0.66 (m, 2H). MS: Calcd.: 396; Found: [M+H]⁺ 397.

Example 7

(R)-6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)-2-hydroxyethylamino)nicotinamide

(R)-6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)-2-hydroxyethylamino)nicotinonitrile (Example 6; 0.07g, 0.2 mmol), was placed in MeOH (5

ml) at 25 °C. A 25% aqueous solution (0.2 ml) of KOH (50 mg) was then added, followed by the addition of 0.05 ml of 30% H₂O₂. The resulting dark red solution was heated to 65 °C for 1 h, cooled to 25 °C, and concentrated. The resulting residue was dissolved in EtOAc (50 ml), washed with water (30 ml), dried, filtered, and concentrated. The resulting solid was purified
5 by column chromatography (DCM - MeOH = 30 : 1) to give the title compound (0.065g, 90%). ¹H NMR (400 MHz, CD₃OD) δ 7.69 (d, *J* = 12.1 Hz, 1H), 7.39-7.36 (m, 2H), 7.04-7.00 (m, 2H), 5.94 (s, 1H), 5.22-5.16 (m, 1H), 3.87-3.75 (m, 2H), 1.91-1.84 (m, 1H), 0.98-0.96 (m, 2H), 0.74-0.69 (m, 2H). MS: Calcd.: 414; Found: [M+H]⁺ 415.

10 Example 8

(R)-2-(3-(Aminomethyl)-6-(5-cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoropyridin-2-ylamino)-2-(4-fluorophenyl)ethanol

The mixture of (R)-6-(5-cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)-2-hydroxyethylamino)nicotinonitrile (Example 6; 0.13g, 0.33 mmol), conc.
15 HCl (0.1 ml), and Pd (10 wt. %, dry basis, on activated carbon, 0.12g) in MeOH (5 ml) was flushed with N₂, evacuated, and then placed under H₂ (40 psi) for 6 hrs. The reaction was then evacuated, flushed with N₂, filtered, washed with MeOH (3 x 30 ml), and concentrated. The resulting solid was dissolved in the mixture of DCM - MeOH (50 : 1, 100 ml), and a saturated aqueous solution of Na₂CO₃ (100 ml) was added. The mixture was shaken vigorously for 30
20 min and allowed to separate. The aqueous layer was extracted with DCM (3 x 100 ml). The combined organic layer was dried, filtered and concentrated. The resulting solid was purified by reverse-phase column chromatography (5-50% CH₃CN in H₂O over 400 ml) to give the title compound (0.074, 57%). ¹H NMR (400 MHz, CD₃OD) δ 7.45-7.42 (m, 2H), 7.17 (d, *J* = 11.1 Hz, 1H), 7.04-7.00 (m, 2H), 5.72 (br s, 1H), 5.18-5.08 (m, 1H), 3.89-3.72 (m, 4H), 1.87-
25 1.83 (m, 1H), 0.94-0.92 (m, 2H), 0.69-0.65 (m, 2H). MS: Calcd.: 400; Found: [M+H]⁺ 401.

Example 9

(R)-N-((6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)-2-hydroxyethylamino)pyridin-3-yl)methyl)acetamide

30 (R)-2-(3-(Aminomethyl)-6-(5-cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoropyridin-2-ylamino)-2-(4-fluorophenyl)ethanol (Example 8; 0.034g, 0.085 mmol) and acetic acid loaded TFP resin (1.4 mmol/g loading, 0.085 mmol) were placed in a THF - DCM solution (1 : 1, 3 ml) at 0 °C. The resulting suspension was shaken vigorously at 0 °C for 45 min. The reaction

52

was filtered and the resulting resin was washed with a THF - DCM solution (1 : 1, 3 x 5 ml for 30 min. each). The resulting organic layers were combined and concentrated. The resulting solid was purified by reverse-phase column chromatography (5-50% CH₃CN in H₂O over 400 ml) to give the title compound (0.018g, 48%). ¹H NMR (400 MHz, CD₃OD) δ 7.42-7.36 (m, 2H), 7.12 (d, J = 9.6 Hz, 1H), 7.04-6.99 (m, 2H), 6.09 (br s, 1H), 5.19-5.02 (m, 1H), 4.36-4.17 (m, 2H), 3.83-3.71 (m, 2H), 1.99 (s, 3H), 1.88-1.83 (m, 1H), 0.98-0.87 (m, 2H), 0.72-0.66 (m, 2H). MS: Calcd.: 442; Found: [M+H]⁺ 443.

Example 10

10 (R)-N-((6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)-2-hydroxyethylamino)pyridin-3-yl)methyl)methanesulfonamide

A round bottom flask was charged with (R)-2-(3-(aminomethyl)-6-(5-cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoropyridin-2-ylamino)-2-(4-fluorophenyl)ethanol (Example 8; 0.20g, 0.50 mmol), methanesulfonic acid loaded TFP resin (0.9 mmol/g loading, 0.50 mmol), DIEA (0.13g, 1.00 mmol), DMAP (0.067g, 0.067 mmol), and THF (10 ml). The resulting solution was shaken vigorously at 60 °C for 8 hrs. The reaction was filtered and the resulting resin was washed with a THF - DCM solution (1 : 1, 3 x 5 ml for 30 min. each). The resulting organic layers were combined and concentrated. The resulting solid was purified by reverse-phase column chromatography (5-50% CH₃CN in H₂O over 400 ml) to give the title compound (0.075g, 31%). ¹H NMR (400 MHz, CD₃OD) δ 7.50-7.41 (m, 2H), 7.15 (d, J = 9.1 Hz, 1H), 7.04-7.00 (m, 2H), 6.09 (br s, 1H), 5.22-5.03 (m, 1H), 4.20-4.07 (m, 2H), 3.86-3.74 (m, 2H), 2.98 (s, 3H), 1.89-1.85 (m, 1H), 1.04-0.92 (m, 2H), 0.78-0.66 (m, 2H). MS: Calcd.: 478; Found: [M+H]⁺ 479.

25 **Example 11**

(R)-5-Fluoro-2-(1-(4-fluorophenyl)-2-hydroxyethylamino)-6-(5-isopropoxy-1H-pyrazol-3-ylamino)nicotinonitrile

2-Chloro-5-fluoro-6-(5-isopropoxy-1H-pyrazol-3-ylamino)nicotinonitrile (Method 2; 1.6g, 5.0 mmol) and (R)-2-amino-2-(4-fluorophenyl)ethanol (2.0g, 11.0 mmol) were added to a solution of *n*-BuOH (8 ml) and DIEA (0.8g, 6.0 mmol) in a sealed tube. The reaction was heated to 135 °C for 72 hrs, cooled to 25 °C, and concentrated. The resulting residue was purified by column chromatography (DCM - MeOH = 50 : 1) to give the title compound (0.7g, 31%). ¹H NMR (400 MHz, CD₃OD) δ 7.49 (d, J = 9.5 Hz, 1H), 7.41-7.38 (m, 2H),

52
58

7.07-7.02 (m, 2H), 5.40 (s, 1H), 5.10-5.01 (m, 1H), 4.62-4.55 (m, 1H), 3.91-3.79 (m, 2H), 1.33-1.31 (m, 6H). MS: Calcd.: 414; Found: $[M+H]^+$ 415.

Example 12

5 (R)-5-Fluoro-2-(1-(4-fluorophenyl)-2-hydroxyethylamino)-6-(5-isopropoxy-1H-pyrazol-3-ylamino)nicotinamide

(R)-5-Fluoro-2-(1-(4-fluorophenyl)-2-hydroxyethylamino)-6-(5-isopropoxy-1H-pyrazol-3-ylamino)nicotinonitrile (Example 11; 0.06g, 0.1 mmol) was placed in MeOH (5 ml) at 25 °C. A 25% aqueous solution (0.2 ml) of KOH (0.05 g, 0.7 mmol) was then added, followed by the addition of 0.05 ml of 30% H₂O₂. The resulting dark red solution was heated to 65 °C for 1 h, cooled to 25 °C, and concentrated. The resulting residue was dissolved in EtOAc (50 ml), washed with water (30 ml), dried, filtered, and concentrated. The resulting solid was purified by column chromatography (DCM - MeOH = 30 : 1) to give the title compound (0.037g, 60%). ¹H NMR (400 MHz, CD₃OD) δ 7.75 (d, *J* = 11.9 Hz, 1H), 7.43-7.39 (m, 2H), 7.06-7.02 (m, 2H), 5.37 (br s, 1H), 5.10-5.02 (m, 1H), 4.60-4.54 (m, 1H), 3.90-3.86 (m, 1H), 3.79-3.74 (m, 1H), 1.32 (d, *J* = 6.0 Hz, 6H). MS: Calcd.: 432; Found: $[M+H]^+$ 433.

Example 13

20 (R)-2-(3-(Aminomethyl)-5-fluoro-6-(5-isopropoxy-1H-pyrazol-3-ylamino)pyridin-2-ylamino)-2-(4-fluorophenyl)ethanol

A solution of (R)-5-fluoro-2-(1-(4-fluorophenyl)-2-hydroxyethylamino)-6-(5-isopropoxy-1H-pyrazol-3-ylamino)nicotinonitrile (Example 11; 0.60g, 1.44 mmol), conc. HCl (0.3 ml), and Pd (10 wt. %, dry basis, on activated carbon, 0.3g) in MeOH (8 ml) was flushed with N₂, evacuated, and then placed under of H₂ (40 psi) for 6 hrs. The reaction was then evacuated, flushed with N₂, filtered, washed with MeOH (3 x 30 ml), and concentrated. The resulting solid was dissolved in the mixture of DCM - MeOH (50 : 1, 100 ml) and treated with a saturated aqueous Na₂CO₃ solution (100 ml). The resulting mixture was shaken vigorously for 30 min and allowed to separate. The aqueous layer was extracted with DCM (3 x 100 ml). The combined organic layers were dried, filtered and concentrated. The resulting solid was purified by reverse-phase column chromatography (5-50% CH₃CN in H₂O over 400 ml) to give the title compound (0.40g, 66%). ¹H NMR (400 MHz, CD₃OD) δ 7.47-7.44 (m, 2H), 7.37 (d, *J* = 10.7 Hz, 1H), 7.06-7.02 (m, 2H), 5.10-5.06 (m, 1H), 4.57-4.51 (m, 1H), 4.28

59

(d, $J = 14.2$ Hz, 1H), 4.07 (d, $J = 14.2$ Hz, 1H), 3.92-3.80 (m, 2H), 1.32 (d, $J = 3.7$ Hz, 6H).
MS: Calcd.: 418; Found: $[M+H]^+$ 419.

Example 14

5 (R)-N-((5-Fluoro-2-(1-(4-fluorophenyl)-2-hydroxyethylamino)-6-(5-isopropoxy-1H-pyrazol-3-ylamino)pyridin-3-yl)methyl)acetamide

(R)-2-(3-(Aminomethyl)-5-fluoro-6-(5-isopropoxy-1H-pyrazol-3-ylamino)pyridin-2-ylamino)-2-(4-fluorophenyl)ethanol (Example 13; 0.175g, 0.42 mmol) and acetic acid loaded TFP resin (1.4 mmol/g loading, 0.42 mmol) were placed in a THF - DCM solution (1 : 1, 5
10 ml) at 0 °C. The resulting solution was shaken vigorously at 0 °C for 45 min and filtered. The resulting resin was washed with a THF - DCM solution (1 : 1, 3 x 5 ml for 30 min. each). The resulting organic layers were combined and concentrated. The resulting solid was purified by reverse-phase column chromatography (5-50% CH₃CN in H₂O over 400 ml) to give the title
15 compound (0.075g, 39%). ¹H NMR (400 MHz, CD₃OD) δ 7.42-7.39 (m, 2H), 7.17 (d, $J = 10.7$ Hz, 1H), 7.05-7.01 (m, 2H), 5.26 (s, 1H), 5.02-4.95 (m, 1H), 4.55-4.53 (m, 1H), 4.36 (d, $J = 15.0$ Hz, 1H), 4.22 (d, $J = 15.0$ Hz, 1H), 3.84-3.72 (m, 2H), 2.01 (s, 3H), 1.31 (d, $J = 6.0$ Hz, 6H). MS: Calcd.: 460; Found: $[M+H]^+$ 461.

Example 15

20 (R)-N-((5-Fluoro-2-(1-(4-fluorophenyl)-2-hydroxyethylamino)-6-(5-isopropoxy-1H-pyrazol-3-ylamino)pyridin-3-yl)methyl)methanesulfonamide

A round bottom flask was charged with (R)-2-(3-(aminomethyl)-5-fluoro-6-(5-isopropoxy-1H-pyrazol-3-ylamino)pyridin-2-ylamino)-2-(4-fluorophenyl)ethanol (Example 13; 0.10g, 0.24 mmol), methanesulfonic acid loaded TFP resin (0.9 mmol/g loading, 0.24
25 mmol), DIEA (0.062g, 0.48 mmol), DMAP (0.032g, 0.26 mmol), and THF (5 ml). The resulting suspension was shaken vigorously at 60 °C for 8 hrs and filtered. The resulting resin was washed with a THF - DCM solution (1 : 1, 3 x 5 ml for 30 min. each). The resulting organic layers were combined and concentrated. The resulting solid was purified by reverse-phase column chromatography (5-50% CH₃CN in H₂O over 400 ml) to give the title
0 compound (0.075g, 63%). ¹H NMR (400 MHz, CD₃OD) δ 7.48-7.45 (m, 2H), 7.20 (d, $J = 10.9$ Hz, 1H), 7.05-7.01 (m, 2H), 5.30 (s, 1H), 5.04-5.01 (m, 1H), 4.56-4.53 (m, 1H), 4.20 (d, $J = 14.4$ Hz, 1H), 4.12 (d, $J = 14.4$ Hz, 1H), 3.86-3.73 (m, 2H), 3.01 (s, 3H), 1.32 (d, $J = 6.0$ Hz, 3H). MS: Calcd.: 496; Found: $[M+H]^+$ 497.

Example 16

(S)-5-Fluoro-2-(1-(4-fluorophenyl)ethylamino)-6-(5-isopropoxy-1H-pyrazol-3-ylamino)nicotinonitrile

2-Chloro-5-fluoro-6-(5-isopropoxy-1H-pyrazol-3-ylamino)nicotinonitrile (Method 2; 5 1.4g, 5.0 mmol) and (S)-1-(4-fluorophenyl)ethanamine (1.0g, 9.0 mmol) were added to a solution of *n*-BuOH (8 ml) and DIEA (0.8g, 6.0 mmol) in a sealed tube. The reaction was heated to 135 °C for 48 hrs, cooled to 25 °C, and concentrated. The resulting residue was purified by column chromatography (DCM - MeOH = 80 : 1) to give the title compound (0.90g, 48%). ¹H NMR (400 MHz, CD₃OD) δ 7.43 (d, *J* = 10.5 Hz, 1H), 7.39-7.35 (m, 2H), 10 7.04-6.99 (m, 2H), 5.47 (s, 1H), 5.12-5.11 (m, 1H), 4.60-4.51 (m, 1H), 1.56 (d, *J* = 7.0 Hz, 3H), 1.33-1.30 (m, 6H). MS: Calcd.: 398; Found: [M+H]⁺ 399.

Example 17

(S)-5-Fluoro-2-(1-(4-fluorophenyl)ethylamino)-6-(5-isopropoxy-1H-pyrazol-3-ylamino)nicotinamide

(S)-5-Fluoro-2-(1-(4-fluorophenyl)ethylamino)-6-(5-isopropoxy-1H-pyrazol-3-ylamino)nicotinonitrile (Example 16; 0.15g, 0.38 mmol), was placed in MeOH (7 ml) at 25 °C. A 25% aqueous solution (0.4 ml) of KOH (0.11 g, 1.9 mmol) was then added, followed by the addition of 0.1 ml of 30% H₂O₂. The resulting dark red solution was heated to 20 65 °C for 1h, cooled to 25 °C, and concentrated. The resulting residue was dissolved in EtOAc (50 ml), washed with water (30 ml), dried, filtered, and concentrated. The resulting solid was purified by column chromatography (DCM - MeOH = 25 : 1) to give the title compound (0.044g, 28%). ¹H NMR (400 MHz, CD₃OD) δ 7.75 (d, *J* = 11.7 Hz, 1H), 7.39-7.36 (m, 2H), 7.04-7.00 (m, 2H), 5.37 (s, 1H), 5.11-5.00 (m, 1H), 4.61-4.52 (m, 1H), 1.53 (d, 25 *J* = 7.0 Hz, 3H), 1.31 (m, 6H). MS: Calcd.: 416; Found: [M+H]⁺ 417.

Example 18

(S)-3-(Aminomethyl)-5-fluoro-*N*²-(1-(4-fluorophenyl)ethyl)-*N*⁶-(5-isopropoxy-1H-pyrazol-3-yl)pyridine-2,6-diamine

30 The mixture of (S)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino)-6-(5-isopropoxy-1H-pyrazol-3-ylamino)nicotinonitrile (Example 16; 0.90g, 2.26 mmol), conc. HCl (0.3 ml), and Pd (10 wt. %, dry basis, on activated carbon, 0.55g) in MeOH (20 ml) was flushed with N₂, evacuated, and then placed under H₂ (40 psi) for 6 hrs. The reaction was then evacuated,

62
61

flushed with N₂, filtered, washed with MeOH (3 x 30 ml), and concentrated. The resulting solid was dissolved in the mixture of DCM - MeOH (50 : 1, 100 ml) and treated with a saturated aqueous Na₂CO₃ solution (100 ml). The mixture was shaken vigorously for 30 min and allowed to separate. The aqueous layer was extracted with DCM (3 x 100 ml). The combined organic layers were dried, filtered and concentrated. The resulting solid was purified by reverse-phase column chromatography (5-50% CH₃CN in H₂O over 400 ml) to give the title compound (0.7g, 77%). ¹H NMR (400 MHz, CD₃OD) δ 7.45-7.41 (m, 2H), 7.35 (d, J = 10.9 Hz, 1H), 7.03-6.99 (m, 2H), 5.35 (s, 1H), 5.09-5.04 (m, 1H), 4.55-4.49 (m, 1H), 4.18 (d, J = 14.2 Hz, 1H), 4.08 (d, J = 14.2 Hz, 1H), 1.59 (d, J = 6.8 Hz, 3H), 1.31 (d, J = 8.3 Hz, 6H). MS: Calcd.: 402; Found: [M+H]⁺ 403.

Example 19

(S)-N-((5-Fluoro-2-(1-(4-fluorophenyl)ethylamino)-6-(5-isopropoxy-1H-pyrazol-3-ylamino)pyridin-3-yl)methyl)acetamide

(S)-3-(Aminomethyl)-5-fluoro-N²-(1-(4-fluorophenyl)ethyl)-N⁶-(5-isopropoxy-1H-pyrazol-3-yl)pyridine-2,6-diamine (Example 18; 0.20g, 0.49 mmol) and acetic acid loaded TFP resin (1.4 mmol/g loading, 0.49 mmol) were placed in a THF - DCM solution (1 : 1, 6 ml) at 0 °C. The resulting solution was shaken vigorously at 0 °C for 45 min and filtered. The resulting resin was washed with a THF - DCM solution (1 : 1, 3 x 5 ml for 30 min. each). The resulting organic layers were combined and concentrated. The resulting solid was purified by reverse-phase column chromatography (5-50% CH₃CN in H₂O over 400 ml) to give the title compound (0.010g, 49%). ¹H NMR (400 MHz, CD₃OD) δ 7.37-7.34 (m, 2H), 7.14 (d, J = 10.9 Hz, 1H), 7.02-6.98 (m, 2H), 5.25 (s, 1H), 4.96-4.95 (m, 1H), 4.55-4.52 (m, 1H), 4.30 (d, J = 14.8 Hz, 1H), 4.21 (d, J = 14.8 Hz, 1H), 2.01 (s, 3H), 1.51 (d, J = 6.8 Hz, 3H), 1.31 (d, J = 6.0 Hz, 6H). MS: Calcd.: 444; Found: [M+H]⁺ 445.

Example 20

(S)-N-((5-Fluoro-2-(1-(4-fluorophenyl)ethylamino)-6-(5-isopropoxy-1H-pyrazol-3-ylamino)pyridin-3-yl)methyl)methanesulfonamide

A round bottom flask was charged with (S)-3-(aminomethyl)-5-fluoro-N²-(1-(4-fluorophenyl)ethyl)-N⁶-(5-isopropoxy-1H-pyrazol-3-yl)pyridine-2,6-diamine (Example 18; 0.10g, 0.25 mmol), methanesulfonic acid loaded TFP resin (0.9 mmol/g loading, 0.25 mmol), DIEA (0.064g, 0.50 mmol), DMAP (0.033g, 0.27 mmol), and THF (5 ml). The resulting

62

suspension was shaken vigorously at 60 °C for 8 hrs and filtered. The resulting resin was washed with a THF - DCM solution (1 : 1, 3 x 5 ml for 30 min. each). The resulting organic layers were combined and concentrated. The resulting solid was purified by reverse-phase column chromatography (5-50% CH₃CN in H₂O over 400 ml) to give (0.82g, 67%). ¹H NMR (400 MHz, CD₃OD) δ 7.44-7.41 (m, 2H), 7.17 (d, *J* = 10.7 Hz, 1H), 7.02-6.97 (m, 2H), 5.26 (s, 1H), 5.01-4.99 (m, 1H), 4.56-4.53 (m, 1H), 4.16-4.08 (m, 1H), 3.01 (s, 3H), 1.52 (d, *J* = 7.0 Hz, 3H), 1.31 (d, *J* = 6.0 Hz, 6H). MS: Calcd.: 480; Found: [M+H]⁺ 481.

Example 21

10 (S)-3,5-Dichloro-N²-(5-cyclopropyl-1H-pyrazol-3-yl)-N⁶-(1-(4-fluorophenyl)ethyl)pyridine-2,6-diamine

3,5,6-Trichloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)pyridin-2-amine (Method 3; 0.05g, 0.2 mmol) and (S)-1-(4-fluorophenyl)ethanamine (0.05g, 0.4 mmol) were dissolved in NMP (2 ml) with DIEA (0.03g, 0.22 mmol). The reaction was heated in a microwave at 200 °C for 15 30 min. The reaction was cooled to 25 °C, quenched with water (10 ml), and extracted with MTBE (4 x 30 ml). The combined organic fractions were then dried, filtered, and concentrated. The resulting solid was purified by reverse-phase column chromatography (5-50% CH₃CN in H₂O over 400 ml) to give the title compound (0.008g, 11%). ¹H NMR (400 MHz, CD₃OD) δ 7.41 (s, 1H), 7.33-7.30 (m, 2H), 7.02-6.98 (m, 2H), 6.03 (s, 3H), 5.17 (q, *J* = 20 6.8 Hz, 1H), 2.02-1.98 (m, 1H), 1.59 (d, *J* = 6.8 Hz, 3H), 1.21-1.65 (m, 2H), 0.86-0.82 (m, 2H). MS: Calcd.: 406; Found: [M+H]⁺ 407.

Example 22

25 N-(5-Cyclopropyl-1H-pyrazol-3-yl)-N'-[(1S)-1-(4-fluorophenyl)ethyl]pyridine-2,6-diamine
tert-Butyl 5-cyclopropyl-3-[(6-{[(1S)-1-(4-fluorophenyl)ethyl]amino}pyridin-2-yl)amino]-1H-pyrazole-1-carboxylate (Method 21; 146mg) was dissolved in a solution of hydrogen chloride in ether (2.0 M, 2 ml, 4 mmol) and the reaction mixture was stirred at room temperature for 4 hours. The solvent was removed and semi-prep HPLC (Gilson) purification gave the title compound (37 mg, 25%). ¹H NMR (CDCl₃) δ 0.55 (m, 2H), 0.70 (m, 2H), 1.35 (m, 3H), 1.65 (m, 1H), 4.53 (m, 2H), 4.91 (br s, 1H), 6.10 (br s, 1H), 6.70 (m, 1H), 7.00 (m, 30 2H), 7.25 (m, 3H).

Example 23

(S)-2-Amino-N-((6-(5-cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino)pyridin-3-yl)methyl)acetamide

To a solution of *tert*-butyl (2-{[(6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-5-fluoro-2-5
2-{[(1S)-1-(4-fluorophenyl)ethyl]amino}pyridin-3-yl)methyl]amino}-2-oxoethyl)carbamate
(Method 22; 0.035g, 0.065 mmol) in dioxane (4 ml), was added an HCl/dioxane solution (4.0
M, 30eq.). The resulting solution was stirred at 25 °C for 3 hrs. The reaction was then
concentrated, re-dissolved in MeOH (0.5 ml), and quickly treated with ether (50 ml). The
resulting solid was collected to give the HCl salt of the title compound (0.025g, 87%). ¹H
10 NMR (400 MHz, CD₃OD) δ 7.60 (d, *J* = 10.7 Hz, 1H), 7.47-7.44 (m, 2H), 7.07-7.03 (m, 2H),
5.78 (s, 1H), 5.04 (q, *J* = 6.6 Hz, 1H), 4.43-4.40 (m, 2H), 3.79 (s, 2H), 2.01-1.96 (m, 1H),
1.66 (d, *J* = 6.6 Hz, 3H), 1.17-1.13 (m, 2H), 0.82-0.81 (m, 2H). MS: Calcd.: 441; Found:
[M+H]⁺ 442.

Example 24

N-((6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-((S)-1-(4-fluorophenyl)ethylamino)pyridin-3-yl)methyl)-5-oxopyrrolidine-2-carboxamide

A round bottom flask was charged with (S)-3-(aminomethyl)-N⁶-(5-cyclopropyl-1H-
pyrazol-3-yl)-5-fluoro-N²-(1-(4-fluorophenyl)ethyl)pyridine-2,6-diamine (Example 3; 0.08g,
20 0.2 mmol), 5-oxopyrrolidine-2-carboxylic acid loaded TFP resin (1.4 mmol/g loading, 0.2
mmol), and a THF - DCM solution (3 ml) at 0 °C. The resulting solution was shaken
vigorously at 0 °C for 45 min and filtered. The resulting resin was washed with a THF - DCM
solution (1 : 1, 3 x 5 ml for 30 min. each). The resulting organic layers were combined and
concentrated. The resulting solid was purified by reverse-phase column chromatography (5-
25 50% CH₃CN in H₂O over 400 ml) to give the title compound (0.013g, 10%). ¹H NMR (400
MHz, CD₃OD) δ 7.41-7.32 (m, 2H), 7.21-7.13 (m, 1H), 7.05-6.97 (m, 2H), 6.05 (s, 1H), 5.21-
5.02 (m, 1H), 4.34-4.19 (m, 3H), 2.44-2.28 (m, 3H), 2.11-1.98 (m, 1H), 1.88-1.81 (m, 1H),
1.51 (d, *J* = 5.2 Hz, 3H), 0.99-0.86 (m, 2H), 0.69-0.61 (m, 2H). MS: Calcd.: 495 Found:
[M+H]⁺ 496.

Example 25*N*⁴-(5-Cyclopropyl-1*H*-pyrazol-3-yl)-*N*²-[(*S*)-1-(4-fluoro-phenyl)-ethyl]-pyridine-2,4-diamine

A mixture of (2-chloro-pyridin-4-yl)-(5-cyclopropyl-1*H*-pyrazole-3-yl)-amine (Method 4; 0.116 g, 0.49 mmol), DIEA (0.20 ml, 1.18 mmol), and (*S*)-1-(4-fluoro-phenyl)-ethylamine (1.0 ml, 7.4 mmol) was heated to 160 °C in a sealed tube for 2 days. The reaction mixture was concentrated under reduced pressure and purified by reverse-phase prep HPLC (column: mC-PACK- ODS-AQ, 250 x 20 nm, 3.0 x 50 mm; 5-95 % gradient MeCN (0.05% TFA) in water (0.1% TFA); flow rate: 10.0 ml/min). ¹H NMR (400 MHz) δ 0.696 (m, 2H), 0.958 (m, 2H), 1.49 (m, 4H), 4.75 (q, 1H), 5.60 (s, 1H), 7.19 (t, 2H), 7.29 (t, 1H), 7.42 (t, 3H), 7.6 (s, 1H), 9.89 (s, 1H). MS: Calcd.: 337; Found: [M+H]⁺ 338.

Example 26(*S*)-*N*⁶-(5-Cyclopropyl-1*H*-pyrazol-3-yl)-*N*²-(1-(4-fluorophenyl)ethyl)-3-nitropyridine-2,6-diamine

A mixture of (*S*)-6-chloro-*N*-(1-(4-fluorophenyl)ethyl)-3-nitropyridin-2-amine (Method 5; 1.74 g, 5.88 mmol), 5-cyclopropyl-1*H*-pyrazol-3-amine (0.91 g, 7.36 mmol), and DIEA (1.28 ml, 7.36 mmol) in *n*-BuOH (10 ml) was heated in a sealed tube at 160 °C for 60 hrs. The solvent was removed under reduced pressure and the residue was purified by chromatography (hexane - EtOAc = 1 : 1) to give the title compound as a yellow solid (1.35 g, 60%). ¹H NMR (400 MHz) δ 12.15 (s, 1H), 10.43 (br, 1H), 9.19 (br, 1H), 8.12 (d, *J* = 9.2 Hz, 1H), 7.45 (m, 2H), 7.17 (m, 2H), 6.25 (br, 1H), 6.14 (br, 1H), 5.45 (m, 1H), 1.87 (m, 1H), 1.60 (d, *J* = 6.8 Hz, 3H), 0.95 (m, 2H), 0.65 (m, 2H). MS: Calcd.: 382; Found: [M+H]⁺ 383.

Examples 27-30

Following a similar procedure to Example 26, the following compounds were synthesized from a chloronitropyridine by reacting it with an amine.

65

Ex	Product	NMR/MS	Amine	SM
27	N ⁶ -(5-Cyclopropyl-1H-pyrazol-3-yl)-N ² -(4-fluorobenzyl)-3-nitropyridine-2,6-diamine	(400 MHz) 12.10 (br s, 1H), 10.40 (br s, 1H), 9.43 (br, 1H), 8.09 (d, J = 6.8 Hz, 1H), 7.37 (m, 2H), 7.15 (m, 2H), 6.24 (br s, 1H), 6.04 (br s, 1H), 4.80 (d, J = 5.6 Hz, 2H), 1.772 (m, 1H), 0.85 (m, 2H), 0.46 (m, 2H). MS: Calcd.: 368; Found: [M+H] ⁺ 369	5-cyclopropyl-1H-pyrazol-3-amine	Method 6
28	(2R)-2-({6-[(5-Cyclopropyl-1H-pyrazol-3-yl)amino]-3-nitropyridin-2-yl}amino)-2-(4-fluorophenyl)ethanol	(400 MHz) 12.10 (s, 1H), 10.39 (br s, 1H), 9.57 (br s, 1H), 8.11 (d, J = 9.2 Hz, 1H), 7.28 (m, 2H), 7.15 (m, 2H), 6.23 (br s, 1H), 5.76 (s, 1H), 5.35 (br s, 1H), 5.19 (t, J = 4.8 Hz, 1H), 3.86 (m, 1H), 3.75 (m, 1H), 1.87 (m, 1H), 0.95 (m, 2H), 0.64 (m, 2H). MS: Calcd.: 398; Found: [M+H] ⁺ 399	5-cyclopropyl-1H-pyrazol-3-amine	Method 7
29	2-({6-[(5-Cyclopropyl-1H-pyrazol-3-yl)amino]-3-nitropyridin-2-yl}amino)-2-(4-fluorophenyl)propane-1,3-diol	(400 MHz) 11.94 (s, 1H), 10.15 (br s, 1H), 9.85 (s, 1H), 8.12 (d, J = 9.2 Hz, 1H), 7.40 (m, 2H), 7.13 (m, 2H), 6.19 (br s, 1H), 2.86 (br s, 2H), 4.44 (m, 4H), 1.65 (m, 1H), 0.87 (m, 2H), 0.47 (m, 2H). MS: Calcd.: 428; Found: [M+H] ⁺ 429.	5-cyclopropyl-1H-pyrazol-3-amine	Method 8

5/66

Ex	Product	NMR/MS	Amine	SM
30	N ⁶ -(5-Cyclopropyl-1H-pyrazol-3-yl)-N ² -[(1R)-1-(4-fluorophenyl)ethyl]-3-nitropyridine-2,6-diamine	MS: Calcd.: 382; Found: [M+H] ⁺ 383.	5-cyclopropyl-1H-pyrazol-3-amine	Method 9

Example 31

(S)-N⁶-(5-Cyclopropyl-1H-pyrazol-3-yl)-N²-(1-(4-fluorophenyl)ethyl)pyridine-2,3,6-triamine

To a suspension of (S)-N⁶-(5-cyclopropyl-1H-pyrazol-3-yl)-N²-(1-(4-fluorophenyl)ethyl)-3-nitropyridine-2,6-diamine (Example 26; 0.40 g, 1.05 mmol) and zinc dust (0.342 g, 5.23 mmol) in MeOH - THF (1 : 1, 16 ml) was slowly added a saturated aqueous ammonium chloride solution (2.5 ml). The mixture was stirred at 25 °C for 1 hr, then treated with saturated ammonium acetate solution (4 ml). The resulting mixture was stirred for another 30 min. The Zn dust was removed by filtration and the cake was washed with EtOAc (20 ml). The organic layer was separated, washed with brine (10 ml), and dried over Na₂SO₄. Removal of the solvent gave the title compound at quantitative yield. ¹H NMR (400 MHz) δ 11.5 (br, 1H), 7.98 (br, 1H), 7.43 (m, 2H), 7.07 (m, 2H), 6.67 (d, J = 8 Hz, 1H), 6.09 (s, 1H), 5.63-5.70 (m, 2H), 5.19 (m, 1H), 4.04 (br, 2H), 1.77 (m, 1H), 1.46 (d, J = 6.8 Hz, 3H), 0.85 (m, 2H), 0.59 (m, 2H). MS: Calcd.: 352; Found: [M+H]⁺ 353.

15

Examples 32-35

Following a similar procedure to Example 31, the following compounds were synthesized from a nitropyridine by reacting it with zinc dust.

Ex	Product	MS	SM
32	N ⁶ -(5-Cyclopropyl-1H-pyrazol-3-yl)-N ² -(4-fluorobenzyl)pyridine-2,3,6-triamine	Calcd.: 338; Found: [M+H] ⁺ 339	Example 27

Ex	Product	MS	SM
33	(2R)-2-({3-Amino-6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyridin-2-yl}amino)-2-(4-fluorophenyl)ethanol	Calcd.: 368; Found: [M+H] ⁺ 369	Example 28
34	2-({3-Amino-6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyridin-2-yl}amino)-2-(4-fluorophenyl)propane-1,3-diol	Calcd.: 398; Found: [M+H] ⁺ 399	Example 29
35	N ⁶ -(5-Cyclopropyl-1H-pyrazol-3-yl)-N ² -[(1R)-1-(4-fluorophenyl)ethyl]pyridine-2,3,6-triamine	Calcd.: 352; Found: [M+H] ⁺ 353	Example 30

Example 36

(S)-3-Chloro-N²-(5-cyclopropyl-1H-pyrazol-3-yl)-N⁶-(1-(4-fluorophenyl)ethyl)-5-nitropyridin-2,6-diamine

5 A mixture of (S)-5,6-chloro-N-(1-(4-fluorophenyl)ethyl)-3-nitropyridin-2-amine (Method 13; 0.61 g, 79% pure, 1.46 mmol), 5-cyclopropyl-1H-pyrazol-3-amine (0.27 g, 2.19 mmol), and DIEA (0.38 ml, 2.19 mmol) in *n*-BuOH (5 ml) was heated in a sealed tube at 100 °C for 48 hours. The solvent was removed under reduced pressure and the residue was purified by column chromatography (hexane : EtOAc = 2 : 1) to give the title compound as a

10 yellow solid (0.57 g, 94%). NMR (400 MHz) 12.34 (s, 1H), 9.34 (s, 1H), 8.93 (d, *J* = 7.6 Hz, 1H), 8.26 (s, 1H), 7.32 (m, 2H), 7.12 (m, 2H), 6.01 (s, 1H), 5.29 (m, 1H), 1.91 (m, 1H), 1.56 (d, *J* = 7.2 Hz, 3H), 0.96 (m, 2H), 0.65 (m, 2H). MS: Calcd.: 416; Found: [M+H]⁺ 417.

Examples 37-40

15 Following a similar procedure to Example 36, the following compounds were synthesized from a chloronitropyridine by reacting it with an amine.

58

Ex	Product	NMR/MS	Amine	SM
37	(2R)-2-({5-Chloro-6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-3-nitropyridin-2-yl}amino)-2-(4-fluorophenyl)ethanol	(400 MHz) 12.28 (s, 1H), 9.33 (d, J = 7.6 Hz, 1H), 9.28 (s, 1H), 8.27 (s, 1H), 7.30 (m, 2H), 7.13 (m, 1H), 5.94 (s, 1H), 5.22 (br s, 2H), 3.84-3.73 (m, 2H), 1.90 (m, 1H), 0.97 (m, 2H), 0.68 (m, 2H). MS: Calcd.: 432; Found: [M+H] ⁺ 433	5-cyclopropyl-1H-pyrazol-3-amine	Method 14
38	(2R)-2-({5-Chloro-6-[(5-methyl-1H-pyrazol-3-yl)amino]-3-nitropyridin-2-yl}amino)-2-(4-fluorophenyl)ethanol	(400 MHz) 12.23 (s, 1H), 9.35 (d, J = 7.2 Hz, 1H), 9.30 (s, 1H), 8.27 (s, 1H), 7.32 (m 2H), 7.14 (m, 2H), 5.86 (s, 1H), 5.23 (t, J = 4.8 Hz, 1H), 5.18 (m, 1H), 3.81 (m, 1H), 3.74 (m, 1H), 2.23 (s, 3H). MS: Calcd.: 406; Found: [M+H] ⁺ 407	5-methyl-1H-pyrazol-3-amine	Method 14
39	(2R)-2-({6-[(5-tert-Butyl-1H-pyrazol-3-yl)amino]-5-chloro-3-nitropyridin-2-yl}amino)-2-(4-fluorophenyl)ethanol	(400 MHz) 12.36 (s, 1H), 9.30 (s, 1H), 9.29 (d, J = 7.6 Hz, 1H), 8.27 (s, 1H), 7.26 (m 2H), 7.08 (m, 2H), 6.18 (s, 1H), 5.29 (m, 1H), 5.21 (t, J = 4.8 Hz, 1H), 3.81 (m, 2H), 1.28 (s, 9H). MS: Calcd.: 448; Found: [M+H] ⁺ 449	5-tert-butyl-1H-pyrazol-3-amine	Method 14
40	3-Chloro-N ² -(5-cyclopropyl-1H-pyrazol-3-yl)-N ⁶ -(4-fluorobenzyl)-5-nitropyridine-2,6-diamine	(400 MHz) 12.33 (s, 1H), 9.32 (br s, 1H), 8.26 (s, 1H), 8.20 (br s, 1H), 7.53 (m, 2H), 7.11 (m, 1H), 5.96 (s, 1H), 4.69 (d, J = 6.0 Hz, 2H), 1.79 (m, 1H), 0.87 (m, 2H), 0.47 (m, 2H). sMS: Calcd.: 402; Found: [M+H] ⁺ 403	(4-fluorophenyl)methanamine	Method 15

Example 41
(S)-5-Chloro-N⁶-(5-cyclopropyl-1H-pyrazol-3-yl)-N²-(1-(4-fluorophenyl)ethyl)pyridine-2,3,6-triamine

5 To a suspension of (S)-3-chloro-N²-(5-cyclopropyl-1H-pyrazol-3-yl)-N⁶-(1-(4-fluorophenyl)ethyl)-5-nitropyridin-2,6-diamine (Example 36; 0.57 g, 1.37 mmol) and zinc

206

dust (0.447 g, 6.84 mmol) in MeOH : THF (1 : 1, 24 ml) was slowly added saturated ammonium chloride solution (3.5 ml). The reaction mixture was stirred at 25 °C for 2 hours, followed by addition of saturated ammonium acetate solution (5 ml). The resulting mixture was stirred for another 30 minutes. Zn dust was removed by filtration and washed with EtOAc (20 ml). The organic layer was separated, washed with brine (10 ml), dried over Na₂SO₄ and the solvent removed to give the title compound. MS: Calcd.: 386; Found: [M+H]⁺ 387.

Examples 42-45

Following a similar procedure to Example 41, the following compounds were synthesized from a nitropyridine by reacting it with zinc dust.

Ex	Product	NMR/MS	SM
42	(2R)-2-({3-Amino-5-chloro-6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyridin-2-yl}amino)-2-(4-fluorophenyl)ethanol	MS: Calcd.: 402; Found: [M+H] ⁺ 403	Example 37
43	(2R)-2-({3-Amino-5-chloro-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyridin-2-yl}amino)-2-(4-fluorophenyl)ethanol	MS: Calcd.: 376; Found: [M+H] ⁺ 377	Example 38
44	(2R)-2-({3-Amino-6-[(5-tert-butyl-1H-pyrazol-3-yl)amino]-5-chloropyridin-2-yl}amino)-2-(4-fluorophenyl)ethanol	MS: Calcd.: 418; Found: [M+H] ⁺ 419	Example 39
45	5-Chloro-N ⁶ -(5-cyclopropyl-1H-pyrazol-3-yl)-N ² -(4-fluorobenzyl)pyridine-2,3,6-triamine	MS: Calcd.: 372; Found: [M+H] ⁺ 373	Example 40

Example 46

(S)-6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino)nicotinic acid

(S)-6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino)nicotinamide (Example 2; 1.0g, 2.5 mmol) was dissolved in a 10% aqueous EtOH solution (10 ml) at 25 °C, followed by addition of solid KOH (2.8g, 50.0 mmol). The reaction solution was heated to 95 °C for 4 days, cooled to 25 °C, and extracted with DCM (2 x 50 ml). The aqueous layer was then acidified to pH 3. The resulting solid

2/20

(0.55 g), was collected by filtration and dried under vacuum to give the title compound. MS: Calcd.: 399; Found: $[M+H]^+$ 400.

Example 47

5 (S)-N²-(5-Cyclopropyl-1H-pyrazol-3-yl)-N⁶-(1-(4-fluorophenyl)ethyl)-3-nitropyridine-2,6-diamine

A mixture of 6-chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)-3-nitropyridin-2-amine (Method 16; 0.30 g, 1.07 mmol), (S)-1-(4-fluoro-phenyl)-ethylamine (0.23 g, 1.61 mmol), and DIEA (0.23 ml, 1.34 mmol) in *n*-BuOH (5 ml) was heated in a sealed tube at 165 °C for 18
10 hrs. The solvent was removed under reduced pressure and the residue was purified by column chromatography (hexane - EtOAc = 1 : 1) to give the title compound as a yellow solid (0.41 g, 99%). ¹H NMR (400 MHz) δ 12.22 (s, 1H), 10.98 (s, 1H), 8.70 (d, *J* = 7.2 Hz, 1H), 8.10 (d, *J* = 9.2 Hz, 1H), 7.39 (m, 2H), 7.18 (m, 2H), 6.22 (d, *J* = 9.2 Hz, 1H), 6.17 (s, 1H), 5.27 (m, 1H), 1.89 (m, 1H), 1.52 (d, *J* = 6.4 Hz, 3H), 0.95 (m, 2H), 0.64 (m 2H). MS: Calcd.: 382;
15 Found: $[M+H]^+$ 383.

Examples 48-50

Following a similar procedure to Example 47, the following compounds were synthesized from 6-chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)-3-nitropyridin-2-amine
20 (Method 16) and the appropriate amine.

Ex.	Product	NMR/MS	Amine
48	N ⁶ -(4-Fluorobenzyl)-N ² -(5-cyclopropyl-1H-pyrazol-3-yl)-3-nitropyridine-2,6-diamine	(400 MHz) 12.24 (s, 1H), 10.98 (s, 1H), 8.29 (br s, 1H), 8.11 (d, <i>J</i> = 9.2 Hz, 1H), 7.36 (m, 2H), 7.18 (m, 2H), 6.20 (d, <i>J</i> = 9.6 Hz, 1H), 6.19 (s, 1H), 4.66 (d, <i>J</i> = 5.2 Hz, 2H), 1.79 (m, 1H), 0.86 (m, 2H), 0.45 (m, 2H). MS: Calcd.: 368; Found: $[M+H]^+$ 369	(4-fluorobenzyl) amine

72
71

Ex.	Product	NMR/MS	Amine
49	(R)-2-[6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-nitropyridin-2-ylamino]-2-(4-fluorophenyl)ethanol	(400 MHz) 12.21 (s, 1H), 10.97 (s, 1H), 8.74 (d, J = 7.6 Hz, 1H), 8.09 (d, J = 9.6 Hz, 1H), 7.38 (m, 2H), 7.18 (m, 2H), 6.31 (d, J = 9.2 Hz, 1H), 6.20 (s, 1H), 5.21 (d, J = 5.6 Hz, 1H), 5.09 (t, J = 5.2 Hz, 1H), 3.64-3.75 (m, 2H), 1.91 (m, 1H), 0.98 (m, 2H), 0.66 (m, 2H). MS: Calcd.: 398; Found: [M+H] ⁺ 399.	(R)-2-amino-2-(4-fluorophenyl)ethanol
50	2-[6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-nitropyridin-2-ylamino]-2-(4-fluorophenyl)propane-1,3-diol	(400 MHz) 12.02 (s, 1H), 10.95 (s, 1H), 8.07 (d, J = 9.2 Hz, 1H), 7.93 (s, 1H), 7.35 (m, 2H), 7.14 (m, 2H), 6.48 (d, J = 9.2 Hz, 1H), 5.04 (s, 1H), 4.81 (s, 2H), 4.04 (m, 2H), 3.90 (m, 2H), 1.68 (m, 1H), 0.90 (m, 2H), 0.51 (m, 2H). MS: Calcd.: 428; Found: [M+H] ⁺ 429.	2-amino-2-(4-fluorophenyl)propane-1,3-diol

Example 51

(S)-3-Chloro-N⁶-(5-cyclopropyl-1H-pyrazol-3-yl)-N²-[1-(4-fluorophenyl)ethyl]-5-nitropyridin-2,6-diamine

5 A mixture of 5,6-chloro-*N*-(5-cyclopropyl-1*H*-pyrazol-3-yl)-3-nitropyridine-2-amine (Method 17; 0.26 g, 0.83 mmol), (*S*)-1-(4-fluoro-phenyl)ethylamine (0.17 g, 1.25 mmol), and DIEA (0.22 ml, 1.25 mmol) in *n*-BuOH (5 ml) was heated in a sealed tube at 165 °C for 3 hours. The solvent was removed under reduced pressure and the residue was purified by column chromatography (hexane : EtOAc = 1 : 1) to give the title compound as a yellow solid

10 (0.34 g, 99%). NMR (400 MHz) 12.29 (s, 1H), 10.68 (s, 1H), 8.27 (s, 1H), 8.24 (d, *J* = 8.0 Hz, 1H), 7.39 (m, 2H), 7.16 (m, 2H), 6.11 (s, 1H), 5.42 (m, 1H), 1.89 (m, 1H), 1.60 (d, *J* = 7.2 Hz, 3H), 0.95 (m, 2H), 0.61 (m, 2H). MS: Calcd.: 416; Found: [M+H]⁺ 417.

Examples 52-54

15 Following a similar procedure to Example 51, the following compounds were synthesized from the appropriate starting material and amine.

2
72

Ex.	Product	NMR/MS	SM	Amine 2
52	N ² -(4-Fluorobenzyl)-3-chloro-N ⁶ -(5-cyclopropyl-1H-pyrazol-3-yl)-5-nitropyridin-2,6-diamine	(400 MHz) 12.29 (s, 1H), 10.73 (s, 1H), 8.70 (t, J = 6.0 Hz, 1H), 8.12 (b, 1H), 7.30 (m, 2H), 7.16 (m, 2H), 6.02 (s, 1H), 4.71 (d, J = 6.0 Hz, 2H), 1.77 (m, 1H), 0.86 (m, 2H), 0.41 (m, 2H). MS: Calcd.: 402; Found: [M+H] ⁺ 403.	Method 17	(4-fluoro-phenyl)methanamine
53	(R)-2-[3-Chloro-6-(5-cyclopropyl-1H-pyrazol-3-ylamino)-5-nitropyridin-2-ylamino]-2-(4-fluorophenyl)ethanol	(400 MHz) 12.27 (s, 1H), 10.70 (s, 1H), 8.29 (d, J = 1.6 Hz, 1H), 8.03 (d, J = 7.6 Hz, 1H), 7.39 (m, 2H), 7.14 (m, 2H), 6.15 (s, 1H), 5.31 (m, 1H), 5.13 (t, J = 4.8 Hz, 1H), 3.32-3.86 (m, 2H), 1.92 (m, 1H), 0.98 (m, 2H), 0.68 (m, 2H). MS: Calcd.: 432; Found: [M+H] ⁺ 433.	Method 18	5-cyclopropyl-1H-pyrazol-3-amine
54	(2R)-2-({3-Chloro-6-[(5-methyl-1H-pyrazol-3-yl)amino]-5-nitropyridin-2-yl}amino)-2-(4-fluorophenyl)ethanol	(400 MHz) 12.23 (s, 1H), 10.69 (s, 1H), 8.30 (s, 1H), 8.00 (d, J = 7.6 Hz, 1H), 7.41 (m 2H), 7.17 (m, 2H), 6.12-5.26 (m, 1H), 5.13 (t, J = 5.2 Hz, 1H), 3.73-3.86 (m, 2H), 2.25 (s, 3H). MS: Calcd.: 406; Found: [M+H] ⁺ 407	Method 18	5-methyl-1H-pyrazol-3-amine

Example 55

(S)-N²-(5-Cyclopropyl-1H-pyrazol-3-yl)-N⁶-[1-(4-fluorophenyl)ethyl]pyridine-2,3,6-triamine

To a suspension of (S)-N²-(5-cyclopropyl-1H-pyrazol-3-yl)-N⁶-[1-(4-fluorophenyl)ethyl]-3-nitropyridine-2,6-diamine (Example 47; 0.26 g, 0.68 mmol) and zinc dust (0.223 g, 3.41 mmol) in MeOH : THF (1 : 1, 12 ml) was slowly added saturated ammonium chloride solution (1.5 ml). The reaction mixture was stirred at 25 °C for 1 hour, to which was then added saturated ammonium acetate solution (5 ml). The resulting mixture was stirred for another 30 minutes. Zn dust was removed by filtration and washed with EtOAc (20

2/33

ml). The organic layer was separated, washed with brine (10 ml), dried over Na₂SO₄, and concentrated to give the title compound.

Examples 56-62

5 Following a similar procedure to Example 55, the following compounds were synthesized from a suitable nitro-pyridine.

Ex.	Compound	NMR/MS	SM
56	<i>N</i> ² -(5-Cyclopropyl-1 <i>H</i> -pyrazol-3-yl)- <i>N</i> ⁶ -(4-fluorobenzyl)pyridine-2,3,6-triamine	MS: Calcd.: 338; Found: [M+H] ⁺ 339	Example 48
57	(2 <i>R</i>)-2-({5-Amino-6-[(5-cyclopropyl-1 <i>H</i> -pyrazol-3-yl)amino]pyridin-2-yl}amino)-2-(4-fluorophenyl)ethanol	MS: Calcd.: 368; Found: [M+H] ⁺ 369	Example 49
58	2-({5-Amino-6-[(5-cyclopropyl-1 <i>H</i> -pyrazol-3-yl)amino]pyridin-2-yl}amino)-2-(4-fluorophenyl)propane-1,3-diol	MS: Calcd.: 398; Found: [M+H] ⁺ 399	Example 50
59	5-Chloro- <i>N</i> ² -(5-cyclopropyl-1 <i>H</i> -pyrazol-3-yl)- <i>N</i> ⁶ -[(1 <i>S</i>)-1-(4-fluorophenyl)ethyl]pyridine-2,3,6-triamine	MS: Calcd.: 386; Found: [M+H] ⁺ 387	Example 51
60	5-Chloro- <i>N</i> ² -(5-cyclopropyl-1 <i>H</i> -pyrazol-3-yl)- <i>N</i> ⁶ -(4-fluorobenzyl)pyridine-2,3,6-triamine	MS: Calcd.: 372; Found: [M+H] ⁺ 373	Example 52
61	(2 <i>R</i>)-2-({5-Amino-3-chloro-6-[(5-cyclopropyl-1 <i>H</i> -pyrazol-3-yl)amino]pyridin-2-yl}amino)-2-(4-fluorophenyl)ethanol	MS: Calcd.: 402; Found: [M+H] ⁺ 403	Example 53
62	(2 <i>R</i>)-2-({5-Amino-3-chloro-6-[(5-methyl-1 <i>H</i> -pyrazol-3-yl)amino]pyridin-2-yl}amino)-2-(4-fluorophenyl)ethanol	MS: Calcd.: 376; Found: [M+H] ⁺ 377	Example 54

Example 63

N-(5-Cyclopropyl-1*H*-pyrazol-3-yl)-*N*'-(4-fluorobenzyl)pyridine-2,6-diamine

10 To a flask was added Pd(OAc)₂ (22.4 mg, 0.1 mmol), (biphenyl-2-ylmethylene)bis(dimethylphosphine) (60 mg, 0.2 mmol) and sodium tert-butoxide (240 mg, 2.5 mmol). The flask was sealed and refilled with N₂. To the mixture was added a solution of

6-bromo-*N*-(4-fluorobenzyl)pyridin-2-amine (Method 19; 281 mg, 1.0 mmol) and 5-cyclopropyl-1*H*-pyrazol-3-amine (123 mg, 1.0 mmol) in toluene (5 ml). The reaction mixture was heated at 110°C overnight. The solvent was removed and EtOAc was added and the mixture was washed with brine and was concentrated. Semi-prep HPLC (Gilson) purification gave the title compound (6.4 mg, 2%). ¹H NMR (CDCl₃) δ 0.65 (m, 2H), 0.95 (m, 2H), 1.80 (m, 1H), 4.43 (m, 2H), 4.91 (br s, 1H), 5.60 (br s, 1H), 5.80 (m, 1H), 6.18 (m, 1H), 6.73 (m, 1H), 7.00 (m, 2H), 7.25 (m, 3H).

Example 64

10 (*S*)-5-Chloro-6-(5-cyclopropyl-1*H*-pyrazol-3-ylamino)-2-(1-(5-fluoropyridin-2-yl)ethylamino)nicotinonitrile

A solution of 2,5-dichloro-6-(5-cyclopropyl-1*H*-pyrazol-3-ylamino)nicotinonitrile (Method 43, 0.60 g, 2.04 mmol), DIEA (0.34 g, 2.65 mmol), and (*S*)-1-(5-fluoropyridin-2-yl)ethanamine (Method 33; 0.90 g, 6.12 mmol) in *n*-BuOH was heated to 120 °C for 9 hours. The reaction was then cooled to room temperature, diluted with water (20 ml), and extracted with DCM (2 x 50 ml). The combined organic fractions were dried over Na₂SO₄, filtered, and then concentrated. The resulting oil was purified by column chromatography (DCM-MeOH = 100 : 1) to give the title compound (0.42 g, 52%). ¹H NMR (400 MHz, CD₃OD) δ 8.42 (d, *J* = 2.7 Hz, 1H), 7.61 (s, 1H), 7.51-7.49 (m, 1H), 7.38-7.32 (m, 1H), 6.06 (br s, 1H), 5.28-5.22 (m, 1H), 1.94-1.88 (m, 1H), 1.58 (d, *J* = 6.9 Hz, 3H), 1.01 (br s, 2H), 0.76-0.75 (m, 2H). MS: Calcd.: 397; Found: [M+H]⁺ 398.

Example 65

25 (*S*)-*N*²-(5-Cyclopropyl-1*H*-pyrazol-3-yl)-3-fluoro-*N*⁶-(1-(4-fluorophenyl)ethyl)-5-nitropyridine-2,6-diamine

To a solution of (*S*)-5,6-difluoro-*N*-(1-(4-fluorophenyl)ethyl)-3-nitropyridin-2-amine (Method 23, 0.60g, 2.0mmol) in THF (10ml) at room temperature was added 5-cyclopropyl-1*H*-pyrazol-3-amine (0.50g, 4.0mmol), and DIEA (0.26g, 2.0mmol). The reaction was then heated to 55 °C for 24 hours, cooled to room temperature, and quenched with water. The reaction was then extracted with DCM (2 x 75 ml), and the combined organic fractions were dried over Na₂SO₄, filtered, and then concentrated. The resulting oil was purified by column chromatography (DCM-MeOH = 100 : 1) to give the title compound (0.53 g, 66%). ¹H NMR (400 MHz, CD₃OD) δ 8.00 (d, *J* = 11.1Hz, 1H), 7.38-7.35 (m, 2H), 7.07-7.02 (m, 2H), 6.17

(s, 1H), 5.41-5.39 (m, 1H), 1.93-1.87 (m, 1H), 1.61 (d, $J = 7.0$ Hz, 3H), 1.02-1.00 (m, 2H), 0.69-0.66 (m, 2H). MS: Calcd.: 400; Found: $[M+H]^+$ 401.

Example 66

5 (S)-3-Fluoro-N⁶-(1-(4-fluorophenyl)ethyl)-N²-(5-isopropoxy-1H-pyrazol-3-yl)-5-nitropyridine-2,6-diamine

To a solution of (S)-5,6-difluoro-N-(1-(4-fluorophenyl)ethyl)-3-nitropyridin-2-amine (Method 23; 0.60 g, 2.0 mmol) in THF (10 ml) at room temperature was added 5-isopropoxy-1H-pyrazol-3-amine (0.50 g, 3.0 mmol), and DIEA (0.29 g, 2.2 mmol). The reaction was then
10 heated to 55 °C for 24 hours, cooled to room temperature, and quenched with water. The reaction was then extracted with DCM (2 x 75 ml), and the combined organic fractions were dried over Na₂SO₄, filtered, and then concentrated. The resulting oil was purified by column chromatography (DCM-MeOH = 100 : 1) to give the title compound (0.34 g, 40%). ¹H NMR (400 MHz, CD₃OD) δ 8.00 (d, $J = 10.9$ Hz, 1H), 7.45-7.35 (m, 2H), 7.07-7.03 (m, 2H), 5.88-
15 5.71 (m, 1H), 5.48-5.30 (m, 1H), 4.58-4.29 (m, 1H), 1.68-1.56 (m, 3H), 1.34-1.28 (m, 6H). MS: Calcd.: 418; Found: $[M+H]^+$ 419.

Example 67

20 (R)-2-(6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-3-nitropyridin-2-ylamino)-2-(4-fluorophenyl)ethanol

To a solution of (S)-2-(5,6-difluoro-3-nitropyridin-2-ylamino)-2-(4-fluorophenyl) ethanol (Method 25, 0.40 g, 1.3 mmol) in THF (10 ml) at room temperature was added 5-cyclopropyl-1H-pyrazol-3-amine (0.31 g, 2.6 mmol), and DIEA (0.18 g, 1.4 mmol). The reaction was then heated to 55 °C for 12 hours, cooled to room temperature, and quenched
25 with water. The reaction was then extracted with DCM (2 x 75 ml), and the combined organic fractions were dried over Na₂SO₄, filtered, and then concentrated. The resulting oil was purified by column chromatography (DCM-MeOH = 100 : 1) to give the title compound (0.45 g, 85%). ¹H NMR (400 MHz, CDCl₃) δ 10.84 (s, 1H), 8.02 (d, $J = 10.7$ Hz, 1H), 7.35-7.31 (m, 2H), 7.10-7.06 (m, 2H), 6.21-6.19 (m, 1H), 5.80 (br s, 1H), 4.07 (dd, $J = 11.3, 3.9$ Hz, 1H), 3.99 (dd, $J = 11.3, 6.4$ Hz, 1H), 1.88-1.86 (m, 1H), 1.62 (br s, 1H), 0.98-0.95 (m, 2H),
30 0.70-0.68 (m, 2H). MS: Calcd.: 416; Found: $[M+H]^+$ 417.

Example 68

(R)-2-(5-Fluoro-6-(5-methyl-1H-pyrazol-3-ylamino)-3-nitropyridin-2-ylamino)-2-(4-fluorophenyl)ethanol

To a solution of (S)-2-(5,6-difluoro-3-nitropyridin-2-ylamino)-2-(4-fluorophenyl) ethanol (Method 25; 0.60 g, 1.9 mmol) in THF (10 ml) at room temperature was added 5-methyl-1H-pyrazol-3-amine (0.37 g, 3.8 mmol), and DIEA (0.27 g, 2.1 mmol). The reaction was heated to 55 °C for 12 hours, cooled to room temperature, and quenched with water. The reaction was then extracted with DCM (2 x 75 ml), and the combined organic fractions were dried over Na₂SO₄, filtered, and then concentrated. The resulting oil was purified by column chromatography (DCM-MeOH = 100 : 1) to give the title compound (0.51 g, 68%). ¹H NMR (400 MHz, CDCl₃) δ 10.85 (br s, 1H), 8.02 (d, *J* = 10.5 Hz, 1H), 7.34-7.31 (m, 2H), 7.10-7.06 (m, 2H), 6.26-6.25 (m, 1H), 5.86 (br s, 1H), 5.30-5.27 (m, 1H), 4.07 (dd, *J* = 11.3 and 3.9 Hz, 1H), 3.97 (dd, *J* = 11.1, 6.2 Hz, 1H), 2.27 (s, 3H), 1.61 (br s, 1H). MS: Calcd.: 390; Found: [M+H]⁺ 391.

Example 69

(S)-3-Chloro-N²-(1-(4-fluorophenyl)ethyl)-N⁶-(5-isopropoxy-1H-pyrazol-3-yl)-5-nitropyridine-2,6-diamine

A mixture of 5,6-dichloro-N-(5-isopropoxy-1H-pyrazol-3-yl)-3-nitropyridin-2-amine (Method 26, 0.25 g, 0.75 mmol), (S)-1-(4-fluoro-phenyl)-ethylamine (0.13 g, 0.90 mmol) and DIEA (0.16 ml, 0.94 mmol) in *n*-BuOH (3 ml) was heated in a sealed tube at 145 °C for 4 hours. The solvent was removed under reduced pressure and the residue was purified by column chromatography (hexane-EtOAc = 1 : 1) to give the title compound as a yellow solid (0.32 g, 98%). ¹H NMR (400 MHz) δ 12.16 & 11.72 (s, 1H), 10.64 & 10.58 (s, 1H), 8.30 (m, 2H), 7.37 & 7.31 (m, 2H), 7.16 & 7.08 (m, 2H), 5.81 & 5.71 (s, 1H), 5.48 & 5.33 (m, 1H), 4.60 & 4.21 (m, 1H), 1.61 & 1.57 (d, *J* = 6.8 Hz, 3H), 1.25 (m, 6H). MS: Calcd.: 434; Found: [M+H]⁺ 435.

Example 70

(S)-3-Chloro-N⁶-(1-(4-fluorophenyl)ethyl)-N²-(5-isopropoxy-1H-pyrazol-3-yl)-5-nitropyridine-2,6-diamine

A mixture of 3,6-dichloro-N-(5-isopropoxy-1H-pyrazol-3-yl)-5-nitropyridin-2-amine (Method 27, 0.25 g, 0.75 mmol), (S)-1-(4-fluoro-phenyl)-ethylamine (0.13 g, 0.90 mmol) and

DIEA (0.16 ml, 0.94 mmol) in *n*-BuOH (3 ml) was heated in a sealed tube at 145 °C for 2 hours. The solvent was removed under reduced pressure and the residue was purified by column chromatography (hexane-EtOAc = 1 : 1) to give the title compound as a yellow solid (0.32 g, 98%). ¹H NMR (400 MHz) δ 12.22 & 11.40 (s, 1H), 9.74 & 9.37 (s, 1H), 8.93 (d, *J* = 7.6 Hz, 1H), 8.33 & 8.27 (s, 1H), 7.34 & 7.27 (m, 2H), 7.12 & 7.05 (m, 2H), 5.75 & 5.62 (s, 1H), 5.35 & 5.25 (m, 1H), 4.66 & 4.03 (m, 1H), 1.55 (d, *J* = 6.4 Hz, 3H), 1.29 (d, *J* = 6.0 Hz, 6H). MS: Calcd.: 434; Found: [M+H]⁺ 435.

Example 71

10 (*S*)-*N*⁶-(1-(4-Fluorophenyl)ethyl)-*N*²-(5-isopropoxy-1*H*-pyrazol-3-yl)-3-nitropyridine-2,6-diamine

A mixture of 6-chloro-*N*-(5-isopropoxy-1*H*-pyrazol-3-yl)-3-nitropyridin-2-amine (Method 28, 0.33 g, 1.1 mmol), (*S*)-1-(4-fluoro-phenyl)-ethylamine (0.16 g, 1.2 mmol) and DIEA (0.21 ml, 1.2 mmol) in *n*-BuOH (3 ml) was heated in a sealed tube at 165 °C for 4 hours. The solvent was removed under reduced pressure and the residue was purified by column chromatography (hexane-EtOAc = 1 : 1) to give the title compound as a yellow solid (0.43 g, 97%). ¹H NMR (400 MHz) δ 12.09, 12.05 & 11.64 (s, 1H), 10.94, 10.87 & 10.72 (s, 1H), 8.98, 8.76 & 8.70 (d, *J* = 7.6 Hz, 1H), 8.16 & 8.11 (d, *J* = 9.6 Hz, 1H), 7.40-7.33 (m, 2H), 7.22-7.10 (m, 2H), 6.25 & 6.04 (d, *J* = 9.6 Hz, 1H), 6.23 & 5.86 (d, *J* = 13.6 Hz, 1H), 5.31, 5.21 & 4.89 (m, 1H), 4.71, 4.59 & 4.27 (m, 1H), 1.52 (m, 3H), 1.26 (m, 6H). MS: Calcd.: 400; Found: [M+H]⁺ 401.

Example 72

25 (*S*)-*N*-((6-(5-Cyclopropyl-1*H*-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino)pyridin-3-yl)methyl)-2-morpholinoacetamide

A solution of (*S*)-3-(aminomethyl)-*N*⁶-(5-cyclopropyl-1*H*-pyrazol-3-yl)-5-fluoro-*N*²-(1-(4-fluorophenyl)ethyl)pyridine-2,6-diamine (Example 3, 0.16 g, 0.42 mmol), 2-morpholinoacetic acid (0.06 g, 0.42 mmol), HBTU (0.16 g, 0.42 mmol) and DIEA (0.16 g, 1.2 mmol) in DCM (3 ml) was stirred at room temperature for 1 hour. The reaction was then quenched with a saturated aqueous solution of NaHCO₃, and extracted with DCM (2 x 50 ml). The combined organic fractions were dried over Na₂SO₄, filtered, and then concentrated. The resulting oil was purified by column chromatography (DCM-MeOH = 100 : 1) to give the title compound (0.02 g, 10%). ¹H NMR (400 MHz, CD₃OD) δ 7.35 (br s, 2H), 7.17 (br s, 1H),

278

7.01-6.97 (m, 2H), 6.06 (br s, 1H), 5.16-4.99 (m, 1H), 4.30 (br s, 2H), 3.68 (br s, 4H), 3.06 (br s, 2H), 2.48 (br s, 4H), 1.87-1.82 (m, 1H), 1.51 (d, $J = 6.4$ Hz, 3H), 0.91 (br s, 2H), 0.64 (br s, 2H). MS: Calcd.: 511; Found: $[M+H]^+$ 512.

5 **Example 73**

(S)-6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino)nicotinaldehyde

(S)-6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino)nicotinonitrile (Example 1, 0.4 g, 1.1 mmol) was dissolved in the mixture
10 pyridine-acetic acid-water (1 : 1 : 1, 18 ml total volume) at room temperature, to which was added Raney nickel (0.09 g, 1.1 mmol). The reaction was purged with nitrogen, evacuated, and then placed under hydrogen filled balloon for 18 hours. The reaction mixture was flushed with nitrogen, and filtered to remove the catalyst, which was washed with MeOH (30 ml). The filtrate was then extracted with DCM (5 x 50 ml), washed with aq. NaHCO_3 , and purified
15 by reverse phase column chromatography (5-30% ACN) to give the title compound (0.18 g, 45%). ^1H NMR (400 MHz, CD_3OD) δ 9.40 (s, 1H), 7.45 (d, $J = 10.4$ Hz, 1H), 7.34-7.31 (m, 2H), 7.05-7.01 (m, 2H), 6.11 (s, 1H), 5.26 (s, 1H), 1.92-1.86 (m, 1H), 1.55 (d, $J = 7.0$ Hz, 3H), 1.00-0.98 (m, 2H), 0.71-0.64 (m, 2H). MS: Calcd.: 383; Found: $[M+H]^+$ 384.

20 **Example 74**

(S)-6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino)pyridin-3-yl)methanol

To a solution of (S)-6-(5-cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino)nicotinaldehyde (Example 73; 0.10 g, 0.26 mmol) in MeOH (5 ml)
25 at 0 °C was added NaBH_4 (0.012 g, 0.33 mmol). The reaction was stirred for 10 minutes, and then quenched with water and extracted with DCM (2 x 20 ml). The combined organic fractions were dried over Na_2SO_4 , filtered, and then concentrated. The resulting oil was purified by column chromatography (DCM-MeOH = 100 : 1) to give the title compound (0.088 g, 88%). ^1H NMR (400 MHz, CD_3OD) δ 7.42-7.39 (m, 2H), 7.16-7.01 (m, 1H), 7.01
30 (br s, 2H), 6.06-5.41 (m, 1H), 5.19-5.02 (m, 1H), 4.52 (br s, 2H), 1.88-1.81 (m, 1H), 1.53 (d, $J = 6.6$ Hz, 3H), 0.97-0.91 (m, 2H), 0.65 (br s, 2H). MS: Calcd.: 385; Found: $[M+H]^+$ 386.

79

Example 75

(S)-N²-(5-Cyclopropyl-1H-pyrazol-3-yl)-3-fluoro-N⁶-(1-(4-fluorophenyl)ethyl)-5-(morpholinomethyl)pyridine-2,6-diamine

To a solution of (S)-6-(5-cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino)nicotinaldehyde (Example 73, 0.12 g, 0.31 mmol) in DCE (5 ml) was added morpholine (0.1 g, 1.14 mmol) and NaBH(OAc)₃ (0.30 g, 1.5 mmol). The reaction was then stirred for 2 days, quenched with aq. Na₂CO₃ (10 ml), and extracted with DCM (2 x 20 ml). The combined organic fractions were dried over Na₂SO₄, filtered, and then concentrated. The resulting oil was purified by reverse-phase column chromatography (5-35% ACN) to give the title compound (0.09 g, 67%). ¹H NMR (400 MHz, CD₃OD) δ 7.41 (br s, 2H), 7.06-7.02 (m, 3H), 6.13 & 5.44 (s, 1H), 5.12 & 4.97 (s, 1H), 3.63 (br s, 4H), 3.42 (br s, 2H), 2.41 (br s, 4H), 1.87-1.82 (m, 1H), 1.54 (d, J = 6.5 Hz, 3H), 0.96-0.90 (m, 2H), 0.65-0.64 (m, 2H). MS: Calcd.: 454; Found: [M+H]⁺ 455.

Example 76

(R)-2-(4-Fluorophenyl)-2-(6-(5-methyl-1H-pyrazol-3-ylamino)-3-nitropyridin-2-ylamino)ethanol

A mixture of (R)-2-(6-chloro-3-nitropyridin-2-ylamino)-2-(4-fluorophenyl) ethanol (Method 29, 0.36 g, 1.2 mmol), 5-methyl-1H-pyrazol-3-amine (0.14 g, 1.4 mmol), and DIEA (0.25 ml, 1.4 mmol) in *n*-BuOH (5 ml) was heated in a sealed tube at 90 °C for 6 days. The solvent was removed under reduced pressure and the residue was purified by column chromatography (EtOAc) to give the title compound as a yellow solid (0.31 g, 73%). ¹H NMR (400 MHz) δ 12.06 (s, 1H), 10.40 (br, 1H), 9.58 (br, 1H), 8.11 (d, J = 9.2 Hz, 1H), 7.40 (m, 2H), 7.16 (m, 2H), 6.20 (br, 1H), 6.02 (s, 1H), 5.29 (br, 1H), 5.24 (t, J = 4.4 Hz, 1H), 3.85 (m, 1H), 3.74 (m, 1H), 2.20 (s, 3H). MS: Calcd.: 372; Found: [M+H]⁺ 373.

Example 77

(S)-N²-(1-(4-Fluorophenyl)ethyl)-N⁶-(5-isopropoxy-1H-pyrazol-3-yl)-3-nitropyridine-2,6-diamine

A mixture of (S)-6-chloro-N-(1-(4-fluorophenyl)ethyl)-3-nitropyridin-2-amine (Method 30, 1.08 g, 3.7 mmol), 5-isopropoxy-1H-pyrazol-3-amine (0.57 g, 4.0 mmol), and DIEA (0.80 ml, 4.6 mmol) in *n*-BuOH (10 ml) was heated in a sealed tube at 115 °C for 72 hours. The solvent was removed under reduced pressure and the residue was purified by

8/88

chromatography (hexane-EtOAc = 3 : 1) to give the title compound as a yellow solid (0.32 g, 22%). MS: Calcd.: 400; Found: $[M+H]^+$ 401.

Example 78

5 (R)-2-(4-Fluorophenyl)-2-(6-(5-isopropoxy-1H-pyrazol-3-ylamino)-5-nitropyridin-2-ylamino)ethanol

A mixture of 6-chloro-N-(5-isopropoxy-1H-pyrazol-3-yl)-3-nitropyridin-2-amine (Method 28; 0.25 g, 0.84 mmol), (R)-2-amino-2-(4-fluorophenyl)ethanol (0.15 g, 0.97 mmol) and DIEA (0.16 ml, 0.92 mmol) in *n*-BuOH (3 ml) was heated in a sealed tube at 165 °C for 4
10 hours. The solvent was removed under reduced pressure and the residue was purified by column chromatography (hexane-EtOAc = 1 : 2) to give the title compound as a yellow solid (0.30 g, 87%). ¹H NMR (400 MHz) δ 12.12, 12.10 & 11.61 (s, 1H), 10.94, 10.89 & 10.74 (s, 1H), 9.05, 8.82 & 8.73 (d, *J* = 7.2 Hz, 1H), 8.13 & 8.11 (d, *J* = 9.2 Hz, 1H), 7.45-7.32 (m, 2H), 7.20-7.10 (m, 2H), 6.32 & 6.07 (d, *J* = 9.2 Hz, 1H), 5.90, 5.83 & 5.79 (s, 1H), 5.23, 5.12
15 & 4.78 (m, 2H), 4.71, 4.64 & 4.37 (m, 1H), 3.69 (m, 2H), 1.34 & 1.29 (d, *J* = 6.0 Hz, 6H). MS: Calcd.: 416; Found: $[M+H]^+$ 417.

Example 79

20 (S)-N-((6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino)pyridin-3-yl)methyl)isoxazole-5-carboxamide

To a solution of (S)-3-(aminomethyl)-N⁶-(5-cyclopropyl-1H-pyrazol-3-yl)-5-fluoro-N²-(1-(4-fluorophenyl)ethyl)pyridine-2,6-diamine (Example 3, 0.08 g, 0.21 mmol) in DCM-THF mixture (1 : 1, 4 ml) at 0 °C was added 1.0 eq. of isoxazole-5-carboxylic acid loaded TFP resin. The resulting mixture was stirred vigorously for 1 hour at 0 °C, and then filtered.
25 The remaining resin was then washed with DCM-THF (1 : 1, 2 x 10 ml portions) for 30 min, and then filtered. The combined filtrates were concentrated, and the resulting oil was purified by column chromatography to give the title compound (3.4 mg, 4%). MS: Calcd.: 479; Found: $[M+H]^+$ 480.

30 Example 80-103

The following compounds were prepared by the procedure similar to that of Example 79 using (S)-3-(aminomethyl)-N⁶-(5-cyclopropyl-1H-pyrazol-3-yl)-5-fluoro-N²-(1-(4-fluorophenyl)ethyl)pyridine-2,6-diamine (Example 3) and a TFP resin loaded reagent.

81

Ex.	Compound	NMR and/or LC/MS	TFP loaded resin
80	(S)-N-((6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino)pyridin-3-yl)methyl)benzamide	MS: Calcd.: 488; Found: [M+H] ⁺ 489.	benzoic acid
81	(S)-N-((6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino)pyridin-3-yl)methyl)nicotinamide	MS: Calcd.: 489; Found: [M+H] ⁺ 490.	pyridine-3-carboxylic acid
82	(S)-N-((6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino)pyridin-3-yl)methyl)isonicotinamide	MS: Calcd.: 489; Found: [M+H] ⁺ 490.	pyridine-4-carboxylic acid
83	(S)-N-((6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino)pyridin-3-yl)methyl)-5-methylisoxazole-4-carboxamide	MS: Calcd.: 493; Found: [M+H] ⁺ 494.	5-methylisoxazole-4-carboxylic acid
84	(S)-N-((6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino)pyridin-3-yl)methyl)thiophene-2-carboxamide	MS: Calcd.: 494; Found: [M+H] ⁺ 495.	thiophene-2-carboxylic acid

23
82

Ex.	Compound	NMR and/or LC/MS	TFP loaded resin
85	(S)-N-((6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino)pyridin-3-yl)methyl)-2-(4-(dimethylamino)phenyl)acetamide	MS: Calcd.: 545; Found: [M+H] ⁺ 546.	4-(dimethylamino)phenyl acetic acid
86	(S)-N-((6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino)pyridin-3-yl)methyl)-2-(N-(isopropyl)-N-methylsulfonamido)acetamide	MS: Calcd.: 561; Found: [M+H] ⁺ 562.	(isopropylmethanesulfonylamino)acetic acid
87	(S)-N-((6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino)pyridin-3-yl)methyl)-1-(methylsulfonyl)piperidine-4-carboxamide	MS: Calcd.: 573; Found: [M+H] ⁺ 574.	1-methanesulfonyl piperidine-4-carboxylic acid
88	(S)-N-((6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino)pyridin-3-yl)methyl)-6-(dimethylamino)nicotinamide	MS: Calcd.: 532; Found: [M+H] ⁺ 533.	6-dimethylamino nicotinic acid
89	(S)-N-((6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino)pyridin-3-yl)methyl)-6-morpholino nicotinamide	MS: Calcd.: 574; Found: [M+H] ⁺ 575.	(6-morpholin-4-yl)nicotinic acid

27
82

Ex.	Compound	NMR and/or LC/MS	TFP loaded resin
90	(S)-N-(((6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino)pyridin-3-yl)methyl)-2-(pyridin-3-yl)acetamide	MS: Calcd.: 503; Found: [M+H] ⁺ 504.	(3-pyridyl)acetic acid
91	(S)-N-(((6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino)pyridin-3-yl)methyl)tetrahydro-2H-thiopyran-4-carboxamide	MS: Calcd.: 512; Found: [M+H] ⁺ 513.	tetrahydrothiopyran-4-carboxylic acid
92	(S)-N-(((6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino)pyridin-3-yl)methyl)-2-(thiophen-2-yl)acetamide	MS: Calcd.: 508; Found: [M+H] ⁺ 509.	2-thiophene acetic acid
93	(S)-N-(((6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino)pyridin-3-yl)methyl)-2-(thiophen-3-yl)acetamide	MS: Calcd.: 508; Found: [M+H] ⁺ 509.	3-thiophene acetic acid
94	(S)-N-(((6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino)pyridin-3-yl)methyl)-3-phenylpropanamide	MS: Calcd.: 516; Found: [M+H] ⁺ 517.	hydrocinnamic acid

Ex.	Compound	NMR and/or LC/MS	TFP loaded resin
95	(S)-N-(2-((6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino)pyridin-3-yl)methylamino)-2-oxoethyl)-N-methylbenzamide	MS: Calcd.: 559; Found: [M+H] ⁺ 560.	N-methylhippuric acid
96	(S)-N-((6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino)pyridin-3-yl)methyl)-2-(N-phenethyl-N-methylsulfonamido)acetamide	MS: Calcd.: 623; Found: [M+H] ⁺ 624.	(methanesulfonylphe nethylamino)acetic acid
97	(S)-N-((6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino)pyridin-3-yl)methyl)-4-(dimethylamino)benzamide	MS: Calcd.: 531; Found: [M+H] ⁺ 532.	4- (dimethylamino)benz oic acid
98	(S)-N-((6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino)pyridin-3-yl)methyl)benzenesulfonamide	¹ H NMR (400 MHz, CD ₃ OD) δ 7.90-7.88 (m, 2H), 7.65-7.55 (m, 3H), 7.44-7.41 (m, 2H), 7.03-6.99 (m, 3H), 5.75 (br s, 1H), 5.10-5.08 (m, 1H), 3.88 (dd, J = 35.2, 14.2 Hz, 2H), 1.88-1.84 (m, 1H), 1.55 (d, J = 6.8 Hz, 3H), 0.95-0.93 (m, 2H), 0.67-0.64 (m, 2H). MS: Calcd.: 524; Found: [M+H] ⁺ 525.	benzenesulfonyl chloride

85

Ex.	Compound	NMR and/or LC/MS	TFP loaded resin
99	(S)-N-((6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino)pyridin-3-yl)methyl)cyclopropanecarboxamide	MS: Calcd.: 452; Found: [M+H] ⁺ 453.	cyclopropane carboxylic acid
100	(S)-N-((6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino)pyridin-3-yl)methyl)-1H-pyrrole-2-carboxamide	MS: Calcd.: 477; Found: [M+H] ⁺ 478.	pyrrole-2-carboxylic acid
101	N-((6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-((S)-1-(4-fluorophenyl)ethylamino)pyridin-3-yl)methyl)tetrahydrofuran-2-carboxamide	MS: Calcd.: 482; Found: [M+H] ⁺ 483.	tetrahydrofuran-3- carboxylic acid
102	(S)-N-((6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino)pyridin-3-yl)methyl)furan-2-carboxamide	MS: Calcd.: 478; Found: [M+H] ⁺ 479.	2-furoic acid

87
86

Ex.	Compound	NMR and/or LC/MS	TFP loaded resin
103	(S)-N-((6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino)pyridin-3-yl)methyl)cyclopropanesulfonamide	¹ H NMR (400 MHz, CD ₃ OD) δ 7.41 (br s, 2H), 7.15 (br s, 1H), 7.01-6.97 (m, 2H), 6.07 & 5.42 (s, 1H), 5.17 & 5.03 (s, 1H), 4.14 (br s, 2H), 2.58 (br s, 1H), 1.88-1.84 (m, 1H), 1.52 (d, J = 6.8 Hz, 3H), 1.10-0.92 (m, 6H), 0.66 (br s, 2H). MS: Calcd.: 488; Found: [M+H] ⁺ 489.	cyclopropylsulfonyl chloride

Example 104

(S)-2-Amino-N-((6-(5-cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-((S)-1-(4-fluorophenyl)ethylamino)pyridin-3-yl)methyl)-3-methylbutanamide

- 5 A solution of (S)-3-(aminomethyl)-N⁶-(5-cyclopropyl-1H-pyrazol-3-yl)-5-fluoro-N²-(1-(4-fluorophenyl)ethyl)pyridine-2,6-diamine (Example 3; 0.10 g, 0.26 mmol), (S)-2-(tert-butoxycarbonylamino)-3-methylbutanoic acid (0.06 g, 0.26 mmol), and HBTU (0.10 g, 0.26 mmol) in DCM (3 ml) was stirred at room temperature for 1 hour. The reaction was then quenched with a saturated aqueous solution of NaHCO₃, and extracted with DCM (2 x 50 ml).
- 10 The combined organic fractions were dried over Na₂SO₄, filtered, and then concentrated. The resulting oil was then passed through a silica plug. The resulting foam was placed in dioxane (4 ml) and 4 M HCl in dioxane (1 ml) was then added, and the reaction was stirred for 3 hours. The reaction was then concentrated to give a solid which was dissolved in a minimal amount of MeOH (0.5 ml) with stirring, followed by fast addition of ether (50 ml). The resulting solid
- 15 was filtered, washed with ether, and dried to give the title compound (0.033 g, 26%). ¹H NMR (400 MHz, CD₃OD) δ 7.58 (d, J = 10.7 Hz, 1H), 7.49-7.46 (m, 2H), 7.07-7.02 (m, 2H), 5.80 (s, 1H), 5.09-5.04 (m, 1H), 4.58 (dd, J = 15.4, 6.8 Hz, 1H), 4.26 (dd, J = 15.4, 5.2 Hz, 1H), 3.71 (d, J = 6.0 Hz, 1H), 2.23-2.18 (m, 1H), 2.01-1.97 (m, 1H), 1.63 (d, J = 6.8 Hz, 3H), 1.19-1.13 (m, 2H), 1.05-1.03 (m, 6H), 0.85-0.81 (m, 2H). MS: Calcd.: 483; Found: [M+H]⁺ 484.

82

Example 105

(S,E)-N²-(5-Cyclopropyl-1H-pyrazol-3-yl)-5-((cyclopropylimino)methyl)-3-fluoro-N⁶-(1-(4-fluorophenyl)ethyl)pyridine-2,6-diamine

To a solution of (S)-6-(5-cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino)nicotinaldehyde (Example 73, 0.10 g, 0.26 mmol) in THF (5 ml) was added cyclopropanamine (0.03 g, 0.52 mmol) and NaBH(OAc)₃ (0.55 g, 0.26 mmol). The reaction was stirred for 3 hours, quenched with aqueous Na₂CO₃ (10 ml), and extracted with DCM (2 x 20 ml). The combined organic fractions were dried over Na₂SO₄, filtered, and then concentrated. The resulting oil was purified by reverse phase column chromatography (5-35% ACN) to give the title compound (0.068 g, 62%). ¹H NMR (400 MHz) δ 11.92 (s, 1H), 9.62 (s, 1H), 8.93 (s, 1H), 8.35 (s, 1H), 7.39 (d, J = 7.4 Hz, 1H), 7.31-7.27 (m, 2H), 7.16-7.11 (m, 2H), 6.10 (s, 1H), 5.13-5.10 (m, 1H), 2.96-2.94 (m, 1H), 1.89-1.80 (m, 1H), 1.42 (d, J = 6.9 Hz, 3H), 0.98-0.88 (m, 2H), 0.76-0.63 (m, 2H). MS: Calcd.: 422; Found: [M+H]⁺ 423.

Example 106

(S)-N²-(5-Cyclopropyl-1H-pyrazol-3-yl)-3-fluoro-N⁶-(1-(4-fluorophenyl)ethyl)pyridine-2,6-diamine

A mixture of N-(5-cyclopropyl-1H-pyrazol-3-yl)-3,6-difluoropyridin-2-amine (Method 31, 0.10 g, 0.42 mmol) and (S)-1-(4-fluorophenyl)ethanamine (0.3 g, 2.2 mmol) were heated to 185 °C under microwave conditions (30 min x 3 cycles). The resulting dark oil was purified by column chromatography (DCM-MeOH = 80 : 1) to give the title compound (0.04 g, 26%). ¹H NMR (400 MHz, CD₃OD) δ 7.08-6.99 (m, 3H), 6.67-6.62 (m, 2H), 6.22 (dd, J = 8.9, 2.3 Hz, 1H), 5.04 (s, 1H), 4.64-4.59 (m, 1H), 1.16-1.12 (m, 4H), 0.30-0.14 (m, 3H), 0.04-0.02 (m, 1H). MS: Calcd.: 355; Found: [M+H]⁺ 356.

Example 107

(S)-N²-(5-Cyclopropyl-1H-pyrazol-3-yl)-3-fluoro-N⁶-(1-(4-fluorophenyl)ethyl)-5-((methylamino)methyl)pyridine-2,6-diamine

To a solution of (S)-6-(5-cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino)nicotinaldehyde (Example 73, 0.10 g, 0.26 mmol) in THF (5 ml) was added methylamine (2.0 M in THF, 0.52 mmol) and NaBH(OAc)₃ (0.82 g, 0.39 mmol). The reaction was stirred for 3 hours, quenched with water, and extracted with DCM (2 x 20 ml). The combined organic fractions were dried over Na₂SO₄, filtered, and then concentrated.

The resulting crude imine was dissolved in MeOH (5 ml) and NaBH₄ (0.06 g, 0.4 mmol) was added. The reaction was stirred for 10 min, quenched with aq. Na₂CO₃ (10 ml), and extracted with DCM (2 x 20 ml). The combined organic fractions were dried over Na₂SO₄, filtered, and then concentrated. The resulting oil was purified by reverse phase column chromatography (5-35% ACN) to give the title compound (0.05 g, 48%). ¹H NMR (400 MHz, CD₃OD) δ 7.41-7.38 (m, 2H), 7.10 (d, *J* = 9.2 Hz, 1H), 7.02-6.98 (m, 2H), 6.00-5.52 (br s, 1H), 5.05 (s, 1H), 3.63 (s, 2H), 2.37 (s, 3H), 1.87-1.82 (m, 1H), 1.51 (d, *J* = 6.9 Hz, 3H), 0.93-0.91 (m, 2H), 0.67-0.63 (m, 2H). MS: Calcd.: 398; Found: [M+H]⁺ 399.

10 **Example 108**

(R)-6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino)nicotinonitrile

A solution of 2-chloro-6-(5-cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro nicotinonitrile (Method 1, 0.3 g, 1.0 mmol) and (R)-1-(4-fluorophenyl)ethanamine (0.3 g, 2.1 mmol) was added to *n*-BuOH (2 ml) and DIEA (0.18 g, 1.4 mmol) in a sealed tube. The reaction was heated to 140 °C for 48 hours, then cooled to room temperature and concentrated. The resulting residue was purified by column chromatography (DCM-MeOH = 80 : 1) to give the title compound (0.11 g, 26%). ¹H NMR (400 MHz, CDCl₃) δ 8.44 (br s, 1H), 7.37-7.33 (m, 2H), 7.27 (d, *J* = 9.6 Hz, 1H), 7.07-7.03 (m, 2H), 6.11 (s, 1H), 5.24-5.20 (m, 2H), 1.87-1.83 (m, 1H), 1.60 (d, *J* = 6.2 Hz, 3H), 1.01-0.98 (m, 2H), 0.79-0.65 (m, 2H). MS: Calcd.: 380; Found: [M+H]⁺ 381.

Example 109

(S)-N-((6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino)pyridin-3-yl)methyl)-1,1,1-trifluoromethanesulfonamide

To a solution of (S)-3-(aminomethyl)-N⁶-(5-cyclopropyl-1H-pyrazol-3-yl)-5-fluoro-N²-(1-(4-fluorophenyl)ethyl)pyridine-2,6-diamine (Example 3, 0.10 g, 0.26 mmol) in THF (5 ml) at room temperature was added 1.1 equivalent of trifluoromethylsulfonyl chloride loaded TFP resin, and DMAP (0.031 g, 0.26 mmol). The reaction was then stirred at room temperature for 15 hours and filtered. The remaining resin was then washed with THF (2 x 10 ml for 20 min), and then combined organic fractions were concentrated. The resulting oil was purified by reverse-phase column chromatography (5-50% ACN) to give the title compound (0.02 g, 15%). ¹H NMR (400 MHz, CD₃OD) δ 7.40-7.37 (m, 2H), 7.17 (d, *J* = 10.9 Hz, 1H),

20
89

7.02-6.97 (m, 2H), 5.90-5.60 (br s, 1H), 5.14-5.12 (m, 1H), 4.28-4.25 (m, 2H), 1.88-1.84 (m, 1H), 1.54 (d, $J = 7.0$ Hz, 3H), 0.95-0.93 (m, 2H), 0.67-0.64 (m, 2H). MS: Calcd.: 516; Found: $[M+H]^+$ 517.

5 Example 110

(S)-6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(5-fluoropyridin-2-yl)ethylamino)nicotinonitrile

A suspension of 6-(5-cyclopropyl-1H-pyrazol-3-ylamino)-2,5-difluoronicotinonitrile (Method 32, 5.75 g, 22.0 mmol), in *n*-BuOH (28.75 ml) was prepared at room temperature in a 48 ml sealed tube. DIEA (4.98 ml, 28.6 mmol) was then added, followed by the addition of (S)-1-(5-fluoropyridin-2-yl)ethanamine (Method 33; 4.0 g, 28.6 mmol). The tube was then sealed, and the suspension was heated to 130 °C over 45 minutes. The reaction was then allowed to stir at 130 °C for 18 hours. The reaction was then cooled to room temperature and concentrated by rotary evaporation at 60 °C to remove *n*-BuOH. The remaining oil was then taken up in DCM (100 ml) and washed with water (2 x 100 ml). The combined aqueous fractions were then extracted with DCM (100 ml), and the combined organic fractions were dried over Na₂SO₄, filtered and concentrated. The resulting oil was then purified by column chromatography (DCM, then DCM-MeOH = 100 : 1) to give the title compound (5.2 g, 62%).
¹H NMR (400 MHz, CD₃OD) δ 8.43 (d, $J = 2.5$ Hz, 1H), 7.60-7.34 (m, 3H), 6.09-5.63 (m, 1H), 5.24 (q, $J = 7.0$ Hz, 1H), 1.91 (septet, 1H), 1.58 (d, $J = 6.6$ Hz, 3H), 1.08-0.90 (m, 2H), 0.79-0.70 (m, 2H). MS: Calcd.: 381; Found: $[M+H]^+$ 382.

Example 111

(S)-N²-(5-Cyclopropyl-1H-pyrazol-3-yl)-3-fluoro-N⁶-(1-(4-fluorophenyl)ethyl)-5-isopropylpyridine-2,6-diamine

To a solution of (S)-6-(5-cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino)nicotinaldehyde (Example 73, 0.15 g, 0.39 mmol) in THF (6 ml) at 0 °C was added methyl magnesiumbromide (1.4 M THF, 0.50 mmol). The reaction was then stirred for 4 hours at room temperature, quenched with water, and extracted with DCM (2 x 20 ml). The combined organic fractions were dried over Na₂SO₄, filtered, and then concentrated. The resulting oil was purified by reverse phase column chromatography (5-50% ACN) to give the title compound (0.10 g, 64%).
¹H NMR (400 MHz, CD₃OD) δ 7.40-7.37 (m, 2H), 7.12 (d, $J = 11.9$ Hz, 1H), 7.02-6.97 (m, 2H), 5.70 (s, 1H), 5.17-5.12 (m, 1H), 2.99-

9/90

2.96 (m, 1H), 1.87-1.82 (m, 1H), 1.54 (d, $J = 7.0$ Hz, 3H), 1.23-1.21 (m, 6H), 0.94-0.90 (m, 2H), 0.66-0.63 (m, 2H). MS: Calcd.: 397; Found: $[M+H]^+$ 398.

Example 112

5 (S)-6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino)-4-(isopropylamino)nicotinonitrile

To a solution of (S)-6-(5-cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino)-4-iodonicotinonitrile (Example 134, 0.07 g, 0.14 mmol) and DIEA (0.023 g, 0.18 mol) in *n*-BuOH (1.5 ml) was added isopropylamine (0.16 g, 2.7 mmol). The
10 reaction was then heated to 185 °C under microwave conditions (1 hour x 4 cycles). The reaction was then cooled to room temperature, DCM (10 ml) was added, and washed with 10% aqueous $Na_2S_2O_3$. The organic layer was then dried over Na_2SO_4 , filtered, and then concentrated. The resulting oil was purified by reverse-phase column chromatography (5-50% ACN) to give the title compound (0.031 g, 51%). ^1H NMR (400 MHz, CD_3OD) δ 7.36-7.33
15 (m, 2H), 7.04-7.00 (m, 2H), 5.99-5.59 (br s, 1H), 5.14 (s, 1H), 4.29-4.23 (m, 1H), 1.87-1.83 (m, 1H), 1.52 (d, $J = 7.0$ Hz, 3H), 1.25 (d, $J = 6.2$ Hz, 6H), 0.95-0.94 (m, 2H), 0.65-0.63 (m, 2H). MS: Calcd.: 437; Found: $[M+H]^+$ 438.

Example 113

20 (S)-6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino)-4-(methylamino)nicotinonitrile

To a solution of (S)-6-(5-cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino)-4-iodonicotinonitrile (Example 134, 0.10 g, 0.19 mmol) and DIEA (0.03 g, 0.25 mol) in *n*-BuOH (1.5 ml) was added methylamine (2.0 M in THF, 1.9 mmol).
25 The reaction was then heated to 185 °C under microwave conditions (1 hour x 2 cycles). The reaction was then cooled to room temperature, DCM (10 ml) was added, and washed with 10% aqueous $Na_2S_2O_3$. The organic layer was then dried over Na_2SO_4 , filtered, and then concentrated. The resulting oil was purified by reverse-phase column chromatography (5-50% ACN) to give the title compound (0.04 g, 49%). ^1H NMR (400 MHz, CD_3OD) δ 7.35 (br s, 2H), 7.04-7.00 (m, 2H), 5.95 (br s, 1H), 5.14 (br s, 1H), 3.15 (d, $J = 2.7$ Hz, 3H), 1.87-1.82
30 (m, 1H), 1.52 (d, $J = 6.8$ Hz, 3H), 0.95-0.94 (m, 2H), 0.65-0.63 (m, 2H). MS: Calcd.: 409; Found: $[M+H]^+$ 410.

Example 114**(S)-5-Fluoro-2-(1-(4-fluorophenyl)ethylamino)-6-(5-methyl-1H-pyrazol-3-ylamino)nicotinonitrile**

A suspension of 2,5-difluoro-6-(5-methyl-1H-pyrazol-3-ylamino)nicotinonitrile (Method 41, 0.20 g, 0.85 mmol), DIEA (0.14 g, 1.1 mmol), and (S)-1-(4-fluorophenyl)ethanamine (0.23 g, 1.7 mmol) in *n*-BuOH (2 ml) was heated to 130 °C for 18 hours. The reaction was then cooled to room temperature, diluted with water (20 ml), and extracted with DCM (2 x 50 ml). The combined organic fractions were dried over Na₂SO₄, filtered, and then concentrated. The resulting oil was purified by column chromatography (DCM-MeOH = 100 : 1) to give the title compound (0.27 g, 91%). ¹H NMR (400 MHz, CD₃OD) δ 7.38-7.32 (m, 3H), 7.03-6.99 (m, 2H), 5.99 (br s, 1H), 5.15-5.14 (m, 1H), 2.24 (s, 3H), 1.53 (d, *J* = 6.8 Hz, 3H). MS: Calcd.: 354; Found: [M+H]⁺ 355.

Example 115**(S)-5-Fluoro-2-(1-(5-fluoropyridin-2-yl)ethylamino)-6-(5-methyl-1H-pyrazol-3-ylamino)nicotinonitrile**

A suspension of 2,5-difluoro-6-(5-methyl-1H-pyrazol-3-ylamino)nicotinonitrile (Method 41, 0.24 g, 1.02 mmol), DIEA (0.17 g, 1.3 mmol), and (S)-1-(5-fluoropyridin-2-yl)ethanamine (Method 33, 0.21 g, 1.5 mmol) in *n*-BuOH (2 ml) was heated to 130 °C for 18 hours. The reaction was cooled to room temperature, diluted with water (20ml), and extracted with DCM (2 x 50 ml). The combined organic fractions were dried over Na₂SO₄, filtered, and then concentrated. The resulting oil was purified by column chromatography (DCM-MeOH = 100 : 1) to give the title compound (0.20 g, 55%). ¹H NMR (400 MHz, CD₃OD) δ 8.42 (s, 1H), 7.51-7.38 (m, 3H), 6.01 (s, 1H), 5.21-5.19 (m, 1H), 2.27 (s, 3H), 1.58 (d, *J* = 6.7 Hz, 3H). MS: Calcd.: 355; Found: [M+H]⁺ 356.

Example 116**(S)-6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(5-fluoropyridin-2-yl)ethylamino)nicotinamide**

A solution of (S)-6-(5-cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(5-fluoropyridin-2-yl)ethylamino)nicotinonitrile (Example 110, 0.24 g, 0.62 mmol) in MeOH (20 ml) was prepared at room temperature. An aqueous solution (0.7 ml) of KOH (0.17 g, 3.15 mmol) was then added dropwise, followed by the addition of 0.05 ml of 30% H₂O₂. The

reaction was then heated to 65 °C for 3 hours, cooled to room temperature, and concentrated. The resulting residue was dissolved in EtOAc (50 ml), and washed with water (50 ml). The organic fraction was then dried over Na₂SO₄, filtered, and then concentrated. The resulting oil was purified by column chromatography (DCM-MeOH = 30 : 1) to give the title compound
5 (0.13 g, 52%). ¹H NMR (400 MHz, CD₃OD) δ 8.42 (s, 1H), 7.70 (d, *J* = 12.1 Hz, 1H), 7.48-7.38 (m, 2H), 6.02 (s, 1H), 5.25-5.02 (m, 1H), 1.91-1.86 (m, 1H), 1.57 (d, *J* = 7.0 Hz, 3H), 0.97 (br s, 2H), 0.73 (br s, 2H). MS: Calcd.: 399; Found: [M+H]⁺ 400.

Example 117

10 (S)-N-((6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-((S)-1-(4-fluorophenyl)ethylamino)pyridin-3-yl)methyl)-5-oxopyrrolidine-2-carboxamide

To a DCM (10ml) solution of (S)-3-(aminomethyl)-N⁶-(5-cyclopropyl-1H-pyrazol-3-yl)-5-fluoro-N²-(1-(4-fluorophenyl)ethyl)pyridine-2,6-diamine (Example 3, 0.45 g, 1.17 mmol) and HBTU (0.44 g, 1.17 mmol) cooled at 0 °C was added a solution of (S)-5-oxopyrrolidine-2-carboxylic acid (0.15 g, 1.17 mmol) in DMF (5 ml), followed by the
15 addition of DIEA (0.14 g, 1.17 mmol). The reaction was then stirred at room temperature for 1 hour and quenched with 20 ml of aqueous NaHCO₃, and extracted with DCM (2 x 30 ml). The combined organic fractions were dried over Na₂SO₄, filtered, and then concentrated. The resulting oil was purified by column chromatography (DCM-MeOH = 20 : 1) to give the title
20 compound (0.30 g, 51%). ¹H NMR (400 MHz, CD₃OD) δ 7.35-7.32 (m, 2H), 7.10 (d, *J* = 10.9 Hz, 1H), 7.00-6.96 (m, 2H), 5.80-5.65 (br s, 1H), 5.06-5.05 (m, 1H), 4.30-4.15 (m, 3H), 2.45-2.24 (m, 3H), 2.05-2.00 (m, 1H), 1.85-1.80 (m, 1H), 1.48 (d, *J* = 6.8 Hz, 3H), 0.91-0.89 (m, 2H), 0.63-0.62 (m, 2H). MS: Calcd.: 495; Found: [M+H]⁺ 496.

25 Example 118

(R)-N-((6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-((S)-1-(4-fluorophenyl)ethylamino)pyridin-3-yl)methyl)-5-oxopyrrolidine-2-carboxamide

To a DCM (10 ml) solution of (S)-3-(aminomethyl)-N⁶-(5-cyclopropyl-1H-pyrazol-3-yl)-5-fluoro-N²-(1-(4-fluorophenyl)ethyl)pyridine-2,6-diamine (Example 3; 0.45 g, 1.17
30 mmol) and HBTU (0.44 g, 1.17 mmol) cooled at 0 °C was added a solution of (R)-5-oxopyrrolidine-2-carboxylic acid (0.15 g, 1.17 mmol) in DMF (5 ml), followed by the addition of DIEA (0.14 g, 1.17 mmol). The reaction was then stirred at room temperature for 1 hour and quenched with 20 ml aqueous NaHCO₃, and extracted with DCM (2 x 30 ml). The

74/93

combined organic fractions were dried over Na₂SO₄, filtered, and then concentrated. The resulting oil was purified by column chromatography (DCM-MeOH = 20 : 1) to give the title compound (0.25 g, 43%). ¹H NMR (400 MHz, CD₃OD) δ 7.37-7.34 (m, 2H), 7.14 (d, *J* = 10.9 Hz, 1H), 7.02-6.97 (m, 2H), 5.80-5.65 (br s, 1H), 5.07 (br s, 1H), 4.33-4.16 (m, 3H), 2.46-2.22 (m, 3H), 2.05-1.98 (m, 1H), 1.88-1.81 (m, 1H), 1.51 (d, *J* = 6.8 Hz, 3H), 0.93-0.92 (m, 2H), 0.66-0.62 (m, 2H). MS: Calcd.: 495; Found: [M+H]⁺ 496.

Example 119

(S)-5-Fluoro-2-(1-(5-fluoropyridin-2-yl)ethylamino)-6-(5-isopropoxy-1H-pyrazol-3-ylamino)nicotinonitrile

A solution of 2,5-difluoro-6-(5-isopropoxy-1H-pyrazol-3-ylamino)nicotinonitrile (Method 42, 0.30 g, 1.07 mmol), DIEA (0.16 g, 1.29 mmol), and (S)-1-(5-fluoropyridin-2-yl)ethanamine (Method 33; 0.22 g, 1.6 mmol) in *n*-BuOH (3 ml) was heated to 130 °C for 18 hours. The reaction was then cooled to room temperature, diluted with water (20 ml), and extracted with DCM (2 x 50 ml). The combined organic fractions were dried over Na₂SO₄, filtered, and then concentrated. The resulting oil was purified by column chromatography (hexanes-EtOAc = 3 : 1) to give the title compound (0.25 g, 58%). ¹H NMR (400 MHz, CD₃OD) δ 8.40 (s, 1H), 7.56-7.55 (m, 2H), 7.45 (d, *J* = 10.5 Hz, 1H), 5.42 (s, 1H), 5.25-5.22 (m, 1H), 4.63 (br s, 1H), 1.60 (d, *J* = 7.0 Hz, 3H), 1.34 (d, *J* = 6.1 Hz, 6H). MS: Calcd.: 399; Found: [M+H]⁺ 400.

Example 120

6-[(5-Cyclopropyl-1H-pyrazol-3-yl)amino]-2-[[[(1S)-1-(3,5-difluoropyridin-2-yl)ethyl]amino]-5-fluoronicotinonitrile

Following a similar procedure to the synthesis of Example 1, the title compound was synthesized from 6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2,5-difluoronicotinonitrile (Method 32) and (S)-1-(3,5-difluoropyridin-2-yl)ethanamine (Method 50). ¹H NMR (400 MHz) δ 0.68 (m, 2 H), 0.95 (m, 2 H), 1.45 (d, *J* = 6 Hz, 3 H), 1.87 (m, 1 H), 5.48 (m, 1 H), 6.19 (s, 1 H), 6.69 (m, 1 H), 7.63 (d, 1 H), 7.98 (m, 1 H), 8.51 (s, 1 H), 9.58 (s, 1 H), 12.15 (s, 1 H). MS: Calcd.: 399; Found: [M+H]⁺ 400.

Example 121

(S)-5-Chloro-6-(5-cyclopropyl-1H-pyrazol-3-ylamino)-2-(1-(5-fluoropyrimidin-2-yl)ethylamino)nicotinonitrile

A mixture of 2,5-dichloro-6-(5-cyclopropyl-1H-pyrazol-3-ylamino)nicotinonitrile
5 (Method 43, 0.17 g, 0.58 mmol), (S)-1-(5-fluoropyrimidin-2-yl)ethanamine HCl salt (Method
55, 0.186 g, 0.87 mmol), and DIEA (0.60 ml, 3.5 mmol) in *n*-BuOH (3 ml) was heated in a
sealed tube at 130 °C for 44 hours. The solvent was removed under reduced pressure and the
residue was purified by column chromatography (hexane-EtOAc = 1 : 1) to give the title
compound as a white solid (0.095 g, 41%). ¹H NMR (400 MHz) δ 12.16 (s, 1H), 8.88 (s, 2H),
10 8.52 (s, 1H), 7.84 (s, 1H), 7.05 (d, *J*=7.2 Hz, 1H), 5.98 (s, 1H), 5.28 (m, 1H), 1.84 (m, 1H),
1.57 (d, *J*=7.2 Hz, 3H), 0.96 (m, 2H), 0.71 (m, 2H). MS: Calcd.: 398; Found: [M+H]⁺ 399.

Example 122

N-{5-[(1R)-1-({3-Cyano-6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-5-fluoropyridin-2-yl}amino)ethyl]-2-fluorophenyl}methanesulfonamide and

Example 123

N-{5-[(1S)-1-({3-Cyano-6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-5-fluoropyridin-2-yl}amino)ethyl]-2-fluorophenyl}methanesulfonamide

To a 10-ml microwave vessel was added, 2-chloro-6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-5-fluoronicotinonitrile (Method 1, 600 mg, 2.3 mmol), *N*-[5-(1-aminoethyl)-2-fluorophenyl]methanesulfonamide (Method 61, 500 mg, 2.3 mmol), DIEA (0.5 ml, 2.76 mmol), and *n*-butanol (5 ml). The vessel was sealed and subjected to microwave heating at 150 °C for 5 hours (CEM Discover System). The resulting mixture was then purified by silica gel chromatography using 5% MeOH/DCM. The racemic product obtained was then chirally
20 purified by HPLC on Chiralcel OJ column (500 x 50mm, 20 microns) using 50:25:25:0.1% of hexane/MeOH/EtOH/diethylamine at 118 ml/min. The chiral purification gave 220 mg of *N*-{5-[(1R)-1-({3-cyano-6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-5-fluoropyridin-2-yl}amino)ethyl]-2-fluorophenyl}methanesulfonamide ¹H NMR: δ 11.77 - 12.26 (br s, 1H), 9.51 (s, 1H), 9.34 - 9.48 (br s, 1H), 7.62 (d, *J*=10.55 Hz, 1H), 7.39 (d, *J*=8.29 Hz, 1H), 7.02 -
25 7.23 (m, 3H), 6.00 (s, 1H), 5.07 - 5.24 (m, 1H), 2.95 (s, 3H), 1.81 - 1.95 (m, 1H), 1.49 (d, *J*=7.54 Hz, 3H), 0.88 - 0.97 (m, 2H), 0.57 - 0.68 (m, 2H). MS: Calcd.: 473; Found: [M+H]⁺ 474 and 223 mg of *N*-{5-[(1S)-1-({3-cyano-6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-5-fluoropyridin-2-yl}amino)ethyl]-2-fluorophenyl}methanesulfonamide; ¹H NMR: 11.73 -
30

9/6/85

12.38 (br s, 1H), 9.42 (s, 1H), 8.41 - 9.12 (br s, 1H), 7.61 (d, $J=11.30$ Hz, 1H), 7.37 (d, $J=7.54$ Hz, 1H), 6.96 - 7.24 (m, 3H), 6.02 (s, 1H), 5.05 - 5.26 (m, 1H), 2.90 (s, 3H), 1.79 - 1.96 (m, 1H), 1.49 (d, $J=6.78$ Hz, 3H), 0.89 - 0.98 (m, 2H), 0.59 - 0.67 (m, 2H). MS: Calcd.: 473; Found: $[M+H]^+$ 474.

5

Example 124

5-Chloro-2-[(1*S*)-1-(5-fluoropyridin-2-yl)ethyl]amino]-6-[(5-methyl-1*H*-pyrazol-3-yl)amino]nicotinonitrile

To a 10-ml microwave vessel was added, 2,5-dichloro-6-[(5-methyl-1*H*-pyrazol-3-yl)amino]nicotinonitrile (Method 60, 8 mmol), [(1*S*)-1-(5-fluoropyridin-2-yl)ethyl]amine (Method 33, 8 mmol, 97wt% solution in dioxane), DIEA (0.3 ml, 1.66 mmol), and *n*-butanol (4 ml). The vessel was then sealed and subjected to microwave heating at 150 °C for 3 hours. After 3 hours, more 2-pyridyl amine (100 mg, 0.69 mmol) was added. The resulting mixture was purified by silica gel chromatography (Biotage Horizon System) using an isocratic system of 15:0.5:0.5% of DCM/EtOAc/MeOH to give 312 mg of the title compound. ¹H NMR: 12.04 (br s, 1H), 8.41 - 8.63 (m, 2H), 7.84 (s, 1H), 7.56 - 7.71 (m, 1H), 7.40 (dd, $J=8.67, 4.14$ Hz, 1H), 7.28 (s, 1H), 5.86 (s, 1H), 5.06 - 5.25 (m, 1H), 2.17 (s, 3H), 1.51 (d, $J=7.54$ Hz, 3H). MS: Calcd.: 371/373; Found: $[M+H]^+$ 372/374.

20 **Example 125**

N-{5-[1-({3-Cyano-6-[(5-cyclopropyl-1*H*-pyrazol-3-yl)amino]-5-fluoropyridin-2-yl)amino)ethyl]-2-fluorophenyl}acetamide

To a 10-ml microwave reaction vessel was added, 6-[(5-cyclopropyl-1*H*-pyrazol-3-yl)amino]-2,5-difluoronicotinonitrile (Method 32, 300 mg, 1.13 mmol), *N*-[5-(1-aminoethyl)-2-fluorophenyl]acetamide (Method 66, 331 mg, 1.7 mmol), and DIEA (0.8 ml, 4.6 mmol) in *n*-butanol (4 ml). The resulting suspension was set to microwave heating (CEM Discover System) at 150 °C for 3 hours. The reaction was concentrated in vacuo and purified by silica gel chromatography (Biotage Horizon System) using a gradient elution of 25-35% EtOAc (20% v/v MeOH) in hexanes to give 180 mg (36% isolated yield) of the title compound. ¹H NMR: 9.66 (br s, 1 H) 9.43 (s, 1 H) 7.81 (d, $J=6.03$ Hz, 2 H) 7.60 (d, $J=11.30$ Hz, 1 H) 6.92 - 7.21 (m, 3 H) 5.98 (s, 1 H) 5.13 (t, $J=7.16$ Hz, 1 H) 2.05 (s, 3 H) 1.76 - 1.92 (m, 1 H) 1.46 (d, $J=6.78$ Hz, 3 H) 0.82 - 0.95 (m, $J=8.29$ Hz, 2 H) 0.54 - 0.66 (m, 2 H). MS: Calcd.: 437; Found: $[M+H]^+$ 438.

30

Example 126

N-{5-[1-({3-Cyano-6-[(5-cyclopropyl-1*H*-pyrazol-3-yl)amino]-5-fluoropyridin-2-yl}amino)ethyl]-2-fluorophenyl}cyclopropanecarboxamide

To a 10-ml microwave reaction vessel was added 6-[(5-cyclopropyl-1*H*-pyrazol-3-yl)amino]-2,5-difluoronicotinonitrile (Method 32, 431 mg, 1.65 mmol), *N*-[5-(1-aminoethyl)-2-fluorophenyl]cyclopropanecarboxamide (Method 69, 550 mg, 2.5 mmol), and DIEA (1.15 ml, 6.6 mmol) in *n*-butanol (5 ml). The resulting suspension was set to microwave heating (CEM Discover System) at 150 °C for 3 hours. The reaction was concentrated in vacuo and purified by silica gel chromatography (Biotage Horizon System) using a gradient elution of 25-35% EtOAc (20% v/v MeOH) in hexanes to give 267 mg (35% isolated yield) of the title compound. ¹H NMR: 11.99 (s, 1 H) 9.91 (s, 1 H) 9.42 (s, 1 H) 7.88 (d, *J*=6.03 Hz, 1 H) 7.59 (d, *J*=10.55 Hz, 1 H) 6.95 - 7.20 (m, 3 H) 5.99 (s, 1 H) 5.02 - 5.21 (m, 1 H) 1.89 - 2.03 (m, 1 H) 1.76 - 1.89 (m, 1 H) 1.45 (d, *J*=7.54 Hz, 3 H) 0.87 (t, *J*=8.67 Hz, 2 H) 0.75 (d, *J*=6.03 Hz, 4 H) 0.54 - 0.66 (m, 2 H). MS: Calcd.: 463; Found: [M+H]⁺ 464.

Example 127

6-[(5-Cyclopropyl-1*H*-pyrazol-3-yl)amino]-5-fluoro-2-{[(1*S*)-1-(6-fluoropyridin-3-yl)ethyl]amino}nicotinonitrile and

Example 128

6-[(5-Cyclopropyl-1*H*-pyrazol-3-yl)amino]-5-fluoro-2-{[(1*R*)-1-(6-fluoropyridin-3-yl)ethyl]amino}nicotinonitrile

To a 10-ml microwave reaction vessel was added 6-[(5-cyclopropyl-1*H*-pyrazol-3-yl)amino]-2,5-difluoronicotinonitrile (Method 32, 1 g, 4 mmol), 1-(6-fluoropyridin-3-yl)ethanamine (Method 76, 560 mg, 4 mmol), and DIEA (0.84, 4.8 mmol) in *n*-butanol (5 ml). The resulting suspension was set to microwave heating (CEM Discover System) at 150 °C for 3 hours. The reaction was then concentrated in vacuo and purified by silica gel chromatography (Biotage Horizon System) using a gradient elution of 1-4% MeOH in DCM to give 380 mg (25% isolated yield) of 6-[(5-cyclopropyl-1*H*-pyrazol-3-yl)amino]-5-fluoro-2-{[1-(6-fluoropyridin-3-yl)ethyl]amino}nicotinonitrile. The racemic product obtained was then chirally purified by HPLC on Chiralpak AS column (500 x 50mm, 20 microns) using 80:10:10:0.1% of hexane-MeOH-EtOH-diethylamine at 118 ml/min. The chiral purification gave 145 mg of 6-[(5-cyclopropyl-1*H*-pyrazol-3-yl)amino]-5-fluoro-2-{[(1*S*)-1-(6-fluoropyridin-3-yl)ethyl]amino}nicotinonitrile: ¹H NMR: 9.43 (s, 1 H) 8.08 (s, 1 H) 7.84 -

8.00 (m, 1 H) 7.61 (d, $J=11.30$ Hz, 1 H) 7.18 (d, $J=7.54$ Hz, 1 H) 7.04 - 7.13 (m, 1 H) 5.94 (s, 1 H) 5.15 (t, $J=7.54$ Hz, 1 H) 1.81 - 1.97 (m, 1 H) 1.51 (d, $J=7.54$ Hz, 3 H) 0.92 (d, $J=6.03$ Hz, 2 H) 0.64 (s, 2 H). MS: Calcd.: 381; Found: $[M+H]^+$ 382; and 137 mg of 6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-5-fluoro-2-[[1-(6-fluoropyridin-3-yl)ethyl]amino]nicotinonitrile: ^1H NMR: 9.42 (s, 1 H) 8.08 (s, 1 H) 7.93 (t, $J=8.29$ Hz, 1 H) 7.61 (d, $J=10.55$ Hz, 1 H) 7.18 (d, $J=8.29$ Hz, 1 H) 7.08 (dd, $J=8.29, 3.01$ Hz, 1 H) 5.94 (s, 1 H) 5.15 (t, $J=7.54$ Hz, 1 H) 1.81 - 1.96 (m, 1 H) 1.51 (d, $J=7.54$ Hz, 3 H) 0.91 (d, $J=8.29$ Hz, 2 H) 0.64 (s, 2 H). MS: Calcd.: 381; Found: $[M+H]^+$ 382.

10 **Example 129**

5-Fluoro-2-[[1-(5-fluoropyrimidin-2-yl)ethyl]amino]-6-[(5-methyl-1H-pyrazol-3-yl)amino]nicotinonitrile

A mixture of 1-(5-fluoropyrimidin-2-yl)ethanamine (Method 72, 0.05 g, 0.35 mmol), 2,5-difluoro-6-[(5-methyl-1H-pyrazol-3-yl)amino]nicotinonitrile (Method 41, 0.06 g, 0.25 mmol), and DIEA (0.12 ml, 0.7 mmol) in *n*-BuOH (3 ml) was charged into a microwave reaction vessel. The vessel was sealed and heated in microwave reactor at 160 °C for 6 hours. The solvent was removed under reduced pressure and the residue was purified by silica gel chromatography (DCM - EtOAc = 1 : 1) to give the title compound as a yellow solid (0.016 g, 15%). LC-MS, 357 (M+1). ^1H NMR (400 MHz, MeOD) δ 8.70 (s, 2H), 7.45 (d, 1H), 6.40 (br, 1H), 5.45 (q 1H), 2.35 (s, 3H), 1.65 (d, 3H).

Example 130

5-Chloro-2-[[1-(5-fluoropyrimidin-2-yl)ethyl]amino]-6-[(5-methyl-1H-pyrazol-3-yl)amino]nicotinonitrile

A mixture of 1-(5-fluoropyrimidin-2-yl)ethanamine (Method 72, 0.05 g, 0.35 mmol), 2,5-dichloro-6-[(5-methyl-1H-pyrazol-3-yl)amino]nicotinonitrile (Method 60, 0.06 g, 0.25 mmol), and DIEA (0.12 ml, 0.7 mmol) in *n*-BuOH (10 ml) was charged into a microwave reaction vessel. The vessel was sealed and heated in microwave reactor at 160 °C for 6 hours. The solvent was removed under reduced pressure and the residue was purified by silica gel chromatography (DCM - EtOAc = 1 : 1) to give the title compound as a yellow solid (0.017 g, 15%). LC-MS, 373 (M+1). ^1H NMR (400 MHz, MeOD) δ 8.75 (s, 2H), 7.45 (s, 1H), 6.40 (s, 1H), 5.45 (br 1H), 2.35 (s, 3H), 1.60 (d, 3H).

79
98

Example 131

N-{5-[(1*S*)-1-({3-Cyano-5-fluoro-6-[(5-methyl-1*H*-pyrazol-3-yl)amino]pyridin-2-yl}amino)ethyl]-2-fluorophenyl}methanesulfonamide and

Example 132

5 *N*-{5-[(1*R*)-1-({3-Cyano-5-fluoro-6-[(5-methyl-1*H*-pyrazol-3-yl)amino]pyridin-2-yl}amino)ethyl]-2-fluorophenyl}methanesulfonamide

A mixture of *N*-[5-(1-aminoethyl)-2-fluorophenyl]methanesulfonamide (Method 61, 0.2 g, 0.86 mmol), 2,5-difluoro-6-[(5-methyl-1*H*-pyrazol-3-yl)amino]nicotinonitrile (Method 41, 0.2 g, 0.8 mmol), and DIEA (0.3 ml, 2.1 mmol) in *n*-BuOH (4 ml) was charged into a
10 microwave reaction vessel. The vessel was sealed and heated in microwave reactor at 160 °C for 6 hours. The solvent was removed under reduced pressure and the residue was purified by silica gel chromatography (DCM - EtOAc = 1 : 1) to give the title compound as a yellow solid (0.16 g, 35%). The resulting racemic compound was separated by a Chiralpak AS-H SFC HPLC column (25 % MeOH) to two enantiomers (The retention time of the first elute
15 Example 131 (S-isomer) was 7 min, and the retention time of the second elute Example 132 (R-isomer) was 8.5 min). LC-MS, 448 (M+1). ¹H NMR (400 MHz, MeOD) δ 7.45 (d, 1H), 7.40 (d, 1H), 7.20 (s, 1H), 7.10 (t, 1H), 6.00 (s, 1H), 5.20 (br 1H), 2.90 (s, 3H), 2.20 (s, 3H), 1.60 (d, 3H).

20 **Example 133**

5-Fluoro-2-{[1-(5-fluoropyrimidin-2-yl)ethyl]amino}-6-[(5-isopropoxy-1*H*-pyrazol-3-yl)amino]nicotinonitrile

A mixture of 1-(5-fluoropyrimidin-2-yl)ethanamine (Method 72, 0.05 g, 0.35mmol), 2,5-difluoro-6-[(5-methyl-1*H*-pyrazol-3-yl)amino]nicotinonitrile (Method 41, 0.05 g, 0.25
25 mmol), and DIEA (0.12 ml, 0.7 mmol) in *n*-BuOH (4 ml) was charged into a microwave reaction vessel. The vessel was sealed and heated in microwave reactor at 160 °C for 6 hrs. The solvent was removed under reduced pressure and the residue was purified by silica gel chromatography (DCM - EtOAc = 1 : 1) to give the title compound as a yellow solid (0.006 g, 5%). LC-MS, 401 (M+1). ¹H NMR (400 MHz, MeOD) δ 8.70 (s, 2H), 7.50 (d, 1H), 5.50 (s, 1H), 5.45 (br, 1H), 4.60 (m, 1H), 1.60 (d, 3H), 1.25 (d, 6H).
30

100
99**Example 134****(S)-6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino)-4-iodonicotinitrile**

A solution of 2-chloro-6-(5-cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-4-iodonicotinitrile (Method 39, 0.28 g, 0.69 mmol), (S)-1-(4-fluorophenyl)ethanamine (0.19 g, 1.3 mmol), and DIEA (0.11 g, 0.90 mmol) in *n*-BuOH (1 ml) was heated to 140 °C for 18 hours. The reaction was diluted with water (10 ml), extracted with DCM (2 x 20 ml) and the combined organic fractions were dried over Na₂SO₄, filtered, and then concentrated. The resulting oil was purified by column chromatography (DCM-MeOH = 100 : 1) to give the title compound (0.07 g, 20%). MS: Calcd.: 506; Found: [M+H]⁺ 507.

Preparation of starting materials**Method 1****2-Chloro-6-(5-cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoronicotinitrile**

A solution of 5-cyclopropyl-1H-pyrazol-3-amine (1.9g, 16.0 mmol) in CH₃CN (20 ml) was added dropwise to a solution of 2,6-dichloro-5-fluoronicotinitrile (3.0g, 16.0 mmol) and triethylamine (2.1g, 20.0 mmol) in CH₃CN (80 ml) at 25 °C. The resulting solution was then heated to 82 °C for 18 hrs, and then cooled to 25 °C, at which point the product precipitated from solution. The resulting solid was filtered, and washed with CH₃CN (100 ml) to give the title compound (3.2g, 73%). MS: Calcd.: 277; Found: [M+H]⁺ 278.

Method 2**2-Chloro-5-fluoro-6-(5-isopropoxy-1H-pyrazol-3-ylamino)nicotinitrile**

A solution of 5-isopropoxy-1H-pyrazol-3-amine (0.96g, 6.8 mmol), 2,6-dichloro-5-fluoronicotinitrile (1.3g, 6.8 mmol), and triethylamine (0.9g, 8.8 mmol) in THF (30 ml) was heated to 60 °C for 4 days, and then cooled to 25 °C, at which point the product precipitated. The resulting solid was filtered and washed with hexanes (100 ml) to give the title compound (1.0g, 50%). MS: Calcd.: 295; Found: [M+H]⁺ 296.

10/
100

Method 3

3,5,6-Trichloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)pyridin-2-amine

A solution of 2,3,5,6-tetrachloropyridine (0.20g, 0.9 mmol), 5-cyclopropyl-1H-pyrazol-3-amine (0.20g, 1.8 mmol), and triethylamine (0.10g, 1.4 mmol) in NMP (2 ml) was heated in a microwave at 200 °C for 30 min. The reaction was cooled to 25 °C, quenched with water (10 ml), and extracted with MTBE (4 x 30 ml). The combined organic fractions were then dried, filtered, and concentrated. The resulting solid was purified by column chromatography (DCM - MeOH = 50 : 1) to give the title compound (0.035g, 12%). MS: Calcd.: 303; Found: $[M+H]^+$ 303.

Method 4

(2-Chloro-pyridin-4-yl)-(5-cyclopropyl-1H-pyrazole-3-yl)-amine

A mixture of 4-iodo-2-chloropyridine (0.26 g, 1.1 mmol), 3-amino-5-cyclopropyl-pyrazole-1-carboxylic acid *tert*-butyl ester (0.20 g, 0.89 mmol), Pd₂dba₃ (0.016 g, 2 mol%), Xantphos (0.031 g, 6 mol%), and Cs₂CO₃ (0.41 g, 1.3 mmol) in degassed toluene (4 ml) was purged with N₂ and heated to 100 °C in a sealed tube for 2 days. The mixture was diluted with THF and filtered to remove Cs₂CO₃. The filtrate was concentrated under reduced pressure and purified by column chromatography (hexane - EtOAc = 3 : 1) to give the title compound (0.10 g, 48%). MS: Calcd.: 234; Found: $[M+H]^+$ 235.

Method 5

(S)-6-Chloro-N-(1-(4-fluorophenyl)ethyl)-3-nitropyridin-2-amine

To a mixture of 2,6-dichloro-3-nitropyridine (2.26 g, 10.8 mmol) and potassium carbonate (1.29 g, 9.34 mmol) in anhydrous CH₃CN (20 ml), was added (S)-1-(4-fluorophenyl)-ethylamine (1.00 g, 7.19 mmol) dropwise at 0 °C. The reaction mixture was stirred at 25 °C for 17 hrs. The solid was removed by filtration and the resulted cake was washed with EtOAc (20 ml). The combined filtrate was concentrated and purified by column chromatography (hexane - EtOAc = 10 : 1) to give the title compound as a yellow solid (1.74 g, 82%). ¹H NMR (400 MHz) δ 8.65 (d, *J* = 7.6 Hz, 1H), 8.43 (d, *J* = 8.4 Hz, 1H), 7.51 (m, 2H), 7.16 (m, 2H), 6.81 (d, *J* = 8.8 Hz, 1H), 5.37 (m, 1H), 1.59 (d, *J* = 6.8 Hz, 3H).

10
101

Methods 6-9

Following a similar procedure to Method 5, the following compounds were synthesized from a 2,6-dichloro-3-nitropyridine by reacting it with an amine.

Method	Product	NMR/MS	Amine
6	6-Chloro-N-(4-fluorobenzyl)-3-nitropyridin-2-amine	(400 MHz, CDCl ₃) 8.58 (br s, 1H), 8.37 (d, J = 8.4 Hz, 1H), 7.36 (m, 2H), 7.04 (m, 2H), 6.67 (d, J = 8.4 Hz, 1H), 4.78 (d, J = 5.6 Hz, 2H)	(4-fluoro-phenyl) methanamine
7	(2R)-2-[(6-Chloro-3-nitropyridin-2-yl)amino]-2-(4-fluorophenyl)ethanol	(400 MHz) 8.96 (d, J = 7.6 Hz, 1H), 8.46 (d, J = 8.4 Hz, 1H), 7.45 (m, 2H), 7.15 (m, 2H), 6.81 (d, J = 8.8 Hz, 1H), 5.27 (m, 2H), 3.80 (m, 2H)	(R)-2-amino-2-(4-fluorophenyl) ethanol
8	2-[(6-Chloro-3-nitropyridin-2-yl)amino]-2-(4-fluorophenyl)propane-1,3-diol	(400 MHz) 9.13 (s, 1H), 8.44 (d, J = 8.4 Hz, 1H), 7.39 (m, 2H), 7.06 (m, 2H), 6.73 (d, J = 8.8 Hz, 1H), 5.16 (t, J = 5.6 Hz, 2H), 4.07 (m 2H), 3.96 (m, 2H). MS: Calcd.: 341; Found: [M+H] ⁺ 342	Method 10
9	6-Chloro-N-[(1R)-1-(4-fluorophenyl)ethyl]-3-nitropyridin-2-amine	MS: Calcd.: 295; Found: [M+H] ⁺ 296	(R)-1-(4-fluoro phenyl) ethanamine

5 Method 10

2-Amino-2-(4-fluorophenyl)propane-1,3-diol

A suspension of 2-(4-fluorophenyl)-2-nitroproane-1,3-diol (Method 11; 4.5 g, 20.9 mmol) and Raney nickel (0.45 g, 5.23 mmol) in MeOH (50 ml) was degassed and stirred under H₂ (48 psi) for 2 hours. The catalyst was removed by filtration. The filtrate was concentrated and recrystallized from hexane : EtOAc (1 : 1) to give the title compound (2.35 g, 61%) as a white solid. NMR (400 MHz) 7.55 (m, 2H), 7.07 (m, 2H), 4.65 (t, J = 5.2 Hz, 2H), 3.49 (m, 4H), 1.76 (s, 2H).

105
102

Method 11

2-(4-Fluorophenyl)-2-nitropropane-1,3-diol

To a solution of 1-fluoro-4-(nitromethyl)benzene (Method 12; 10.0 g, 80% pure; 52 mmol) and TEA (15.1 ml, 108.3 mmol) in dioxane (50 ml) was added formaldehyde (8.6 ml, 116 mmol) dropwise at 0 °C. After addition, the reaction was slowly warmed up to 25 °C overnight. The solvent was removed under reduced pressure and the residue was purified by column chromatography (hexane : EtOAc = 10 : 1) to give the title compound as a white solid (4.5 g, 41%). NMR (400 MHz) 7.41 (m, 2H), 7.22 (m, 2H), 5.39 (t, $J = 5.2$ Hz, 2H), 4.22 (m, 4H).

Method 12

1-Fluoro-4-(nitromethyl)benzene

A mixture of 1-(bromomethyl)-4-fluorobenzene (11.52 g, 61 mmol) and AgNO₂ (11.3 g, 73 mmol) in benzene (200 ml) was stirred vigorously at 25 °C for 25 hrs. The solid was removed by filtration and washed with ether (500 ml). The combined organic was concentrated to give the title compound (10.0 g, 80% pure; 85%) which was used without further purification. NMR (400 MHz, CDCl₃) 7.44 (m, 2H), 7.18 (m, 2H), 5.42 (s, 2H).

Method 13

(S)-5,6-Chloro-N-(1-(4-fluorophenyl)ethyl)-3-nitropyridin-2-amine

To a mixture of 2,3,6-trichloro-5-nitropyridine (1.00 g, 4.40 mmol) and potassium carbonate (0.79 g, 5.7 mmol) in anhydrous acetonitrile (10 ml) was added (S)-1-(4-fluorophenyl)-ethylamine (0.64 g, 4.62 mmol) dropwise at 0 °C. After addition, the reaction mixture was stirred at 25 °C for 17 hours. The solid was removed by filtration and washed with EtOAc (20 ml). After evaporation of the solvent, the resulted residue was purified by column chromatography (hexane : EtOAc = 10 : 1) to give the title compound as a yellow solid (0.61 g, 79% pure, 33%). NMR (400 MHz, CDCl₃) 8.46 (br s, 2H), 7.36 (m, 2H), 7.03 (m, 2H), 5.40 (m, 1H), 1.63 (d, $J = 6.8$ Hz, 3H).

Methods 14-15

Following a similar procedure to Method 13, the following compounds were synthesized from a 2,3,6-trichloro-5-nitropyridine by reacting it with an amine.

Method	Product	NMR/MS	Amine
14	(2R)-2-[(5,6-Dichloro-3-nitropyridin-2-yl)amino]-2-(4-fluorophenyl)ethanol	(400 MHz) 8.91 (d, J = 7.2 Hz, 1H), 8.66 (s, 1H), 7.45 (m, 2H), 7.15 (m, 2H), 5.25 (m, 2H), 3.80 (m, 2H)	(R)-2-amino-2-(4-fluorophenyl)ethanol
15	3,6-Dichloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)-5-nitropyridin-2-amine	(400 MHz) 12.37 (s, 1H), 9.83 (s, 1H), 8.54 (s, 1H), 6.27 (s, 1H), 1.94 (m, 1H), 0.95 (m, 2H), 0.70 (m, 2H). MS: Calcd.: 313; Found: [M+H] ⁺ 314	5-cyclopropyl-1H-pyrazol-3-amine

Method 16

6-Chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)-3-nitropyridin-2-amine

To a solution of 2,6-dichloro-3-nitropyridine (0.67 g, 3.2 mmol) and DIEA (0.46 ml, 2.65 mmol) in EtOH (20 ml) was added 5-cyclopropyl-1H-pyrazol-3-amine (0.26 g, 2.12 mmol) solution in EtOH (5 ml) dropwise at 0 °C. After addition, the reaction mixture was stirred at 25 °C for 24 hrs. The solvent was removed under reduced pressure and the resulted residue was purified by column chromatography (hexane - EtOAc = 5 : 1) to give the title compound as a yellow solid (0.58 g, 98%). ¹H NMR (400 MHz) δ 12.36 (s, 1H), 10.20 (s, 1H), 8.54 (d, J = 8.4 Hz, 1H), 7.01 (d, J = 8.4 Hz, 1H), 6.39 (d, J = 1.6 Hz, 1H), 1.94 (m, 1H), 0.96 (m, 2H), 0.71 (m, 2H). MS: Calcd.: 279; Found: [M+H]⁺ 280.

Method 17

5,6-Chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)-3-nitropyridine-2-amine

To a solution of 2,3,6-trichloro-5-nitropyridine (1.62 g, 7.10 mmol) and DIEA (1.24 ml, 7.1 mmol) in THF (25 ml) was added dropwise a solution of 5-cyclopropyl-1H-pyrazol-3-amine (0.70 g, 5.68 mmol) in THF (5 ml) at 0 °C. After addition, the reaction mixture was stirred at 25 °C for 24 hours. The solvent was removed under reduced pressure and the resulted residue was purified by column chromatography (hexane : EtOAc = 1.5 : 1) to give the title compound as a yellow solid (0.83 g, 47%). NMR (400 MHz) 12.39 (s, 1H), 10.12 (s, 1H), 8.77 (d, J = 1.2 Hz, 1H), 6.35 (s, 1H), 1.95 (m, 1H), 0.96 (m, 2H), 0.71 (m, 2H). MS: Calcd.: 313; Found: [M+H]⁺ 314.

20
104

Method 18

Following a similar procedure to Method 17, the following compound was synthesized from a 2,3,6-trichloro-5-nitropyridine by reacting it with the appropriate amine.

Meth	Product	NMR/MS	Amine 1
18	(R)-2-(3,6-Dichloro-5-nitropyridin-2-ylamino)-2-(4-fluorophenyl)ethanol	(400 MHz) 8.46 (s, 1H), 8.22 (d, $J = 8.0$ Hz, 1H), 7.45 (m, 2H), 7.16 (m, 2H), 5.22 (m, 1H), 5.05 (t, $J = 6.0$ Hz, 1H), 3.87 (m, 1H), 3.72 (m, 1H)	(R)-2-amino-2-(4-fluorophenyl)ethanol

5 **Method 19**

6-Bromo-N-(4-fluorobenzyl)pyridin-2-amine

To a suspension of 6-bromopyridin-2-amine (500 mg, 2.89 mmol), sodium tert-butoxide (695 mg, 7.24 mmol) in anhydrous toluene (20 ml) was added 4-fluorobenzylchloride (415 mg, 2.90 mmol) at room temperature. The reaction mixture was heated at 100 °C overnight. EtOAc was added and the mixture was washed with brine and was concentrated. Flash chromatography (10-14% EtOAc in hexanes) gave the title compound (506 mg, 63%). ¹H NMR (CDCl₃) δ 4.40 (m, 2H), 4.95 (br s, 1H), 6.20 (m, 1H), 6.73 (m, 1H), 7.00 (m, 2H), 7.25 (m, 3H).

15 **Method 20**

6-Chloro-N-[(1S)-1-(4-fluorophenyl)ethyl]pyridin-2-amine

To a 25 ml round bottom flask was added Pd(OAc)₂ (45 mg, 0.2 mmol), (biphenyl-2-ylmethylene)bis(dimethylphosphine) (120 mg, 0.4 mmol) and sodium tert-butoxide (480 mg, 5.0 mmol). The flask was sealed and refilled with N₂. To the mixture was added a solution of 2,6-dichloropyridine (300 mg, 2.0 mmol) and [(1S)-1-(4-fluorophenyl)ethyl]amine (306 mg, 2.2 mmol) in toluene (4 ml). The reaction mixture was heated at 85 °C overnight. The solvent was removed and EtOAc was added and the mixture was washed with brine and was concentrated. Flash chromatography (10-40% EtOAc in hexanes) gave the title compound (339 mg, 68%). ¹H NMR (CDCl₃) δ 1.55 (m, 3H), 4.66 (m, 1H), 5.07 (br s, 1H), 6.01 (m, 1H), 6.54 (m, 1H), 7.00 (m, 2H), 7.25 (m, 3H).

406
105

Method 21

tert-Butyl 5-cyclopropyl-3-[(6-{[(1*S*)-1-(4-fluorophenyl)ethyl]amino}pyridin-2-yl)amino]-1*H*-pyrazole-1-carboxylate

To a 25 ml round bottom flask was added Pd₂(dba)₃ (84 mg, 0.092 mmol), (biphenyl-2-ylmethylene)bis(dimethylphosphine) (55 mg, 0.184 mmol) and sodium *tert*-butoxide (132 mg, 1.38 mmol). The flask was sealed and refilled with N₂. To the mixture was added a solution of 6-chloro-*N*-[(1*S*)-1-(4-fluorophenyl)ethyl]pyridin-2-amine (Method 20; 230 mg, 0.92 mmol) and *tert*-butyl 3-amino-5-cyclopropyl-1*H*-pyrazole-1-carboxylate (223 mg, 1.0 mmol) in toluene (4 ml). The reaction mixture was heated at 110 °C overnight. Solvent was removed and EtOAc was added and the mixture was washed with brine and was concentrated. Flash chromatography (15-40% EtOAc in hexanes) gave the title compound (146 mg, 36%). ¹H NMR (CDCl₃) δ 0.80 – 1.00 (m, 4H), 1.60 (m, 3H), 1.65 (s, 9H), 1.95 (m, 1H), 4.71 (m, 1H), 4.75 (m, 1H), 5.75 (m, 1H), 6.09 (m, 1H), 6.21 (s, 1H), 7.00 (m, 2H), 7.23 (m, 2H), 7.30 (m, 1H), 9.40 (s, 1H).

Method 22

tert-Butyl (2-{[(6-{[(5-cyclopropyl-1*H*-pyrazol-3-yl)amino]-5-fluoro-2-{[(1*S*)-1-(4-fluorophenyl)ethyl]amino}pyridin-3-yl)methyl]amino}-2-oxoethyl)carbamate

A round bottom flask was charged with (*S*)-3-(aminomethyl)-*N*⁶-(5-cyclopropyl-1*H*-pyrazol-3-yl)-5-fluoro-*N*²-(1-(4-fluorophenyl)ethyl)pyridine-2,6-diamine (Example 3; 0.07g, 0.18 mmol), 2-(*tert*-butoxycarbonyl)acetic acid loaded TFP resin (1.15 mmol/g loading, 0.18 mmol), and a THF - DCM solution (1 : 1, 4 ml) at 0 °C. The resulting solution was shaken vigorously at 0 °C for 2 hrs and filtered. The resulting resin was washed with a THF - DCM solution (1 : 1, 3 x 5 ml for 30 min. each). The resulting organic layers were combined and concentrated. The resulting solid was purified by reverse-phase column chromatography (5-50% CH₃CN in H₂O over 400 ml) to give the title compound (0.035g, 35%). MS: Calcd.: 541; Found: [M+H]⁺ 542.

Method 23

(*S*)-5,6-Difluoro-*N*-(1-(4-fluorophenyl)ethyl)-3-nitropyridin-2-amine

A solution of 2,3,6-trifluoro-5-nitropyridine (Method 24, 2.0g, 11.2 mmol) in THF (50ml) was cooled to 0 °C. (*S*)-1-(4-Fluorophenyl)ethanamine (1.56g, 11.2mmol) was added and the reaction was stirred at 0 °C for 30 minutes. The reaction was quenched with water (50

107
106

ml) and then extracted with DCM (2 x 75 ml). The combined organic fractions were dried over Na₂SO₄, filtered, and then concentrated. The resulting oil was purified by column chromatography (hexane-DCM = 1 : 1) to give the title compound (2.3 g, 70%).

5 **Method 24**

2,3,6-Trifluoro-5-nitropyridine

To neat 2,3,6-trifluoropyridine (12.0g, 90mmol) was slowly added fuming HNO₃ (142g, 2254 mmol) and H₂SO₄ (133g, 1353mmol) slow enough to keep the internal temperature below 40 °C. Upon completion of the addition, the resulting solution was heated to 60 °C for 30minutes, and then cooled to 0 °C. Ice water (2l) was added, and the reaction was extracted with hexanes (2 x 300 ml) and then DCM (1 x 300 ml). The combined organic fractions were dried over Na₂SO₄, filtered, and concentrated to give the title compound (8.1 g, 50%), which was used without further purification.

15 **Method 25**

(S)-2-(5,6-Difluoro-3-nitropyridin-2-ylamino)-2-(4-fluorophenyl)ethanol

A solution of 2,3,6-trifluoro-5-nitropyridine (1.2 g, 6.7 mmol) in THF (40 ml) was cooled to 0 °C. (R)-2-amino-2-(4-fluorophenyl)ethanol (1.0 g, 6.7 mmol) was then added and the reaction was stirred at 0 °C for 30 minutes. The reaction was quenched with water (50 ml) and then extracted with DCM (2 x 75 ml). The combined organic fractions were dried over Na₂SO₄, filtered, and then concentrated. The resulting oil was purified by column chromatography (DCM-MeOH = 100 : 1) to give the title compound (1.2 g, 57%). The product was carried over to the next step without characterization.

25 **Method 26**

5,6-Dichloro-N-(5-isopropoxy-1H-pyrazol-3-yl)-3-nitropyridin-2-amine

To a mixture of 2,3,6-trichloro-5-nitropyridine (2.61 g, 11.4 mmol) and DIEA (1.90 ml, 11.4 mmol) in THF (50 ml) was added the 5-isopropoxy-1H-pyrazol-3-amine (1.20 g, 8.50 mmol) at 0 °C. After addition, the reaction mixture was stirred at 25 °C for 5 days. The solvent was removed under reduced pressure and the resulting residue was purified by column chromatography (hexane-EtOAc = 2.5 : 1) to give the title compound as a yellow solid (0.77 g, 27%). ¹H NMR (400 MHz) δ 12.26 & 11.64 (s, 1H), 10.42 & 10.04 (s, 1H), 8.81 & 8.77 (s,

102
107

1H), 6.02 & 5.94 (s, 1H), 4.70 & 4.48 (m, 1H), 1.32 (d, $J = 6.0$ Hz, 3H), 1.27 (d, $J = 6.0$ Hz, 1H). MS: Calcd.: 331; Found: $[M+H]^+$ 332.

Method 27

5 3,6-Dichloro-*N*-(5-isopropoxy-1*H*-pyrazol-3-yl)-5-nitropyridin-2-amine

To a mixture of 2,3,6-trichloro-5-nitropyridine (2.61 g, 11.4 mmol) and DIEA (1.90 ml, 11.4 mmol) in THF (50 ml) was added 5-isopropoxy-1*H*-pyrazol-3-amine (1.20 g, 8.50 mmol) at 0 °C. After addition, the reaction mixture was stirred at 25 °C for 5 days. The solvent was removed under reduced pressure and the resulted residue was purified by column chromatography (hexane-EtOAc = 1 : 1) to give the title compound as a yellow solid (0.51 g, 18%). ¹H NMR (400 MHz) δ 12.22 & 11.35 (s, 1H), 10.12 & 9.80 (s, 1H), 8.64 & 8.54 (s, 1H), 5.95 & 5.84 (s, 1H), 4.70 & 4.46 (m, 1H), 1.27-1.32 (m, 6H). MS: Calcd.: 331; Found: $[M+H]^+$ 332.

15 Method 28

6-Chloro-*N*-(5-isopropoxy-1*H*-pyrazol-3-yl)-3-nitropyridin-2-amine

To a solution of 2,6-dichloro-3-nitropyridine (0.51 g, 2.7 mmol) and DIEA (0.39 ml, 2.2 mmol) in THF (10 ml) was added the 5-isopropoxy-1*H*-pyrazol-3-amine (0.25 g, 1.8 mmol) solution at 0 °C. After addition, the reaction mixture was stirred at 25 °C for 3 days and 60 °C for 24 hours. The solvent was removed under reduced pressure and the resulting residue was purified by column chromatography (hexane-EtOAc = 3 : 1) to give the title compound as a yellow solid (0.33 g, 63%). ¹H NMR (400 MHz) δ 12.25 & 11.66 (s, 1H), 10.46 & 10.13 (s, 1H), 8.58 & 8.55 (d, $J = 8.8$ Hz, 1H), 7.11 & 7.02 (d, $J = 8.8$ Hz, 1H), 6.08 & 5.97 (s, 1H), 4.70 & 4.48 (m, 1H), 1.32 & 1.27 (d, $J = 6.0$ Hz, 6 H). MS: Calcd.: 297; Found: $[M+H]^+$ 298.

25

Method 29

(*R*)-2-(6-Chloro-3-nitropyridin-2-ylamino)-2-(4-fluorophenyl)ethanol

To a mixture of 2,6-dichloro-3-nitropyridine (0.933 g, 4.83 mmol) and potassium carbonate (0.58 g, 4.19 mmol) in anhydrous acetonitrile (10 ml) was added (*R*)-2-amino-2-(4-fluoro phenyl)ethanol (1.00 g, 7.19 mmol) at 0 °C. The resulting reaction mixture was stirred at 25 °C for 18 hours. The solid was removed by filtration and washed with EtOAc (20 ml). After evaporation of the solvent, the resulting residue was purified by column chromatography (hexane-EtOAc = 5 : 1) to give the title compound as a yellow solid (0.77 g,

30

209
108

61%). ¹H NMR (400 MHz) δ 8.96 (d, *J* = 7.6 Hz, 1H), 8.46 (d, *J* = 8.4 Hz, 1H), 7.45 (m, 2H), 7.15 (m, 2H), 6.81 (d, *J* = 8.8 Hz, 1H), 5.27 (m, 2H), 3.80 (m, 2H).

Method 30

5 (*S*)-6-Chloro-*N*-(1-(4-fluorophenyl)ethyl)-3-nitropyridin-2-amine

To a mixture of 2,6-dichloro-3-nitropyridine (2.26 g, 10.8 mmol) and potassium carbonate (1.29 g, 9.34 mmol) in anhydrous CH₃CN (20 ml), was added (*S*)-1-(4-fluorophenyl)-ethylamine (1.00 g, 7.19 mmol) dropwise at 0 °C. The reaction mixture was stirred at 25 °C for 17 hours. The solid was removed by filtration and the resulted cake was washed
10 with EtOAc (20 ml). The combined filtrate was concentrated and purified by column chromatography (hexane-EtOAc = 10 : 1) to give the title compound as a yellow solid (1.74 g, 82%). ¹H NMR (400 MHz) δ 8.65 (d, *J* = 7.6 Hz, 1H), 8.43 (d, *J* = 8.4 Hz, 1H), 7.51 (m, 2H), 7.16 (m, 2H), 6.81 (d, *J* = 8.8 Hz, 1H), 5.37 (m, 1H), 1.59 (d, *J* = 6.8 Hz, 3H).

15 Method 31

N-(5-Cyclopropyl-1*H*-pyrazol-3-yl)-3,6-difluoropyridin-2-amine

A solution of *tert*-butyl 5-amino-3-cyclopropyl-1*H*-pyrazole-1-carboxylate (1.00 g, 4.49 mmol) in THF (15ml) was cooled to -78 °C. *t*-BuLi (1.7 M in THF, 4.15 mmol) was added dropwise and the resulting solution was stirred for 30 min. at -78 °C. A solution of
20 2,3,6-trifluoropyridine (0.46 g, 3.4mmol) in THF (5ml) was added, and the resulting solution was stirred for 5 min at -78 °C, and then the reaction was warmed to 0 °C, and stirred at that temperature for 30 min. The reaction was quenched with aq. NH₄Cl and extract with EtOAc (2 x 20 ml). The organic fractions were dried over Na₂SO₄, filtered, and concentrated. The resulting oil was then placed in ACN (15 ml) at 0 °C, and *N*-trimethylsilylimidazole (0.5 ml)
25 was added. The reaction was stirred for 20 min, and then concentrated. The resulting oil was purified by column chromatography (DCM-MeOH = 100 : 1) to give the title compound (0.10 g, 12%). MS: Calcd.: 236; Found: [M+H]⁺ 237.

Method 32

30 6-(5-Cyclopropyl-1*H*-pyrazol-3-ylamino)-2,5-difluoronicotinonitrile

A solution of 2,5,6-trifluoronicotinonitrile (30.0 g, 189.8 mmol) in ACN (240 ml) was prepared in a 1 l 3-neck flask at room temperature and then cooled to -5 °C using an ice-salt bath. An addition funnel containing triethylamine (29.1 ml, 208.8 mmol) and a second

He
109

addition funnel containing a solution of 5-cyclopropyl-1*H*-pyrazol-3-amine (25.7 g, 208.8 mmol) in ACN (160 ml) were placed on top of the reaction flask. A total of 5 ml of triethylamine was added quickly dropwise to the reaction. The reaction was allowed to stir for 5 min, followed by the simultaneous dropwise addition of the remaining triethylamine and 5-cyclopropyl-1*H*-pyrazol-3-amine solution at a rate slow enough to keep the internal temperature at or below 5 °C. Upon completion of the addition, the reaction was allowed to stir for 1 hour at 0 °C, at which point no starting material remained, and the reaction was filtered through a fritted funnel. The remaining solids were washed with 0 °C ACN (3 x 100 ml). The solid product was then dried under vacuum for 30 minutes to give the title compound (25.2 g, 51%) which was used without further purification. ¹H NMR (400 MHz, CD₃OD) δ 7.81-7.77 (m, 1H), 6.33 (s, 1H), 1.91 (septet, 1H), 0.99-0.98 (m, 2H), 0.76-0.73 (m, 2H). MS: Calcd.: 261; Found: [M+H]⁺ 262.

Method 33

15 (*S*)-1-(5-Fluoropyridin-2-yl)ethanamine

To the solution of (*S*)-*tert*-butyl-1-(5-fluoropyridin-2-yl)ethylcarbamate (Method 34, 12.8 g, 53.3 mmol) in DCM (100 ml) was added HCl/dioxane solution (107 ml, 4 N, 428 mmol). The reaction was stirred at room temperature for 3 hours. The solvent was removed and 50 ml of saturated sodium bicarbonate was added. The resulting aqueous solution was extracted with ether (6 x 400 ml), dried over sodium sulfate and concentrated to give the title compound (7.30 g, 98%) as pale yellow oil. ¹H NMR (400 MHz) δ 8.44 (d, *J* = 2.8 Hz, 1H), 7.66 (m, 1H), 7.53 (m, 1H), 4.01 (q, *J* = 6.8 Hz, 1H), 1.94 (b, 2H), 1.26 (d, *J* = 6.8 Hz, 3H). MS: Calcd.: 140; Found: [M+H]⁺ 141.

25 Method 34

(*S*)-*tert*-Butyl-1-(5-fluoropyridin-2-yl)ethylcarbamate

The solution of (*S*)-*N*-(1-(5-fluoropyridin-2-yl)ethyl)acetamide (Method 35, 11.0 g, 60.37 mmol), DMAP (1.48 g, 12.07 mmol) and Boc₂O (26.35 g, 120.7 mmol) in THF (100 ml) was stirred at 50 °C for 20 hours. After cooled to room temperature, lithium hydroxide monohydrate (5.19 g, 123.8 mmol) and water (100 ml) were added. The reaction was stirred at room temperature for 5 hours and diluted with ether (200 ml). The organic layer was separated, washed with brine (100 ml), and dried over sodium sulfate. After removal of solvent, the resulted residue was purified by column chromatography (Hexane-EtOAc = 5 : 1)

47
110

to give the title compound as a pale yellow oil (13.6 g, 94%). ¹H NMR (400 MHz) δ 8.46 (d, *J* = 2.8 Hz, 1H), 7.69 (m, 1H), 7.35-7.41 (m, 2H), 4.67 (m, 1H), 1.37 (s, 9H), 1.32 (d, *J* = 7.2 Hz, 3H). MS: Calcd.: 240; Found: [M+H]⁺ 241.

5 Method 35

(S)-N-(1-(5-Fluoropyridin-2-yl)ethyl)acetamide

N-(1-(5-fluoropyridin-2-yl)vinyl)acetamide (Method 36, 11.0 g, 61.1 mmol) in MeOH (120 ml) under N₂ was added (+)-1,2-bis((2S, 5S)-2,5-diethylphospholano)benzene (cyclooctadiene)rhodium(I)trifluoromethanesulfonate (0.441 g, 0.611 mmol). The solution
10 was transferred to a high pressure bomb and charged 150 psi H₂. The reaction stirred at room temperature and maintained inside pressure between 120-150 psi for 7 hours. The solvent was removed and the resulted residue was purified by column chromatography (EtOAc) to give the title compound as a white solid (9.8 g, 88%). ¹H NMR (400 MHz) δ 8.49 (d, *J* = 2.4 Hz, 1H), 8.32 (d, *J* = 7.6 Hz, 1H), 7.66 (m, 1H), 7.39 (dd, *J* = 4.4 and 8.8 Hz, 1H), 4.95 (m, 1H),
15 1.85 (s, 3H), 1.34 (d, *J* = 7.2 Hz, 3H). MS: Calcd.: 182; Found: [M+H]⁺ 183. Enantiomeric excess determined by HPLC (Chiralpak IA; 70:30 CO₂/MeOH), 95.3% ee.

Method 36

N-(1-(5-Fluoropyridin-2-yl)vinyl)acetamide

20 A solution of MeMgBr (170.3 ml, 510.98 mmol) in ether was diluted with 170 ml of anhydrous THF and cooled to 0 °C. 5-Fluoropicolinonitrile (Method 37, 53.6 g, 425.82 mmol) in THF (170 ml) was added dropwise. The reaction was stirred at 0 °C for 30 minutes, then diluted with DCM (170 ml). Acetic anhydride (48.3 ml, 510.98 mmol) in DCM (100 ml) was added dropwise at 0 °C. After addition, the reaction was warmed to room temperature and
25 stirred at room temperature for 8 hours. Saturated sodium bicarbonate solution (50 ml) was added and extracted with EtOAc (2 x 200 ml). The combined organic was dried over sodium sulfate. After removal of solvent, the resulted residue was purified by column chromatography (hexane-EtOAc = 2.5 : 1) to give the title compound as a white solid (26.6 g, 35%). ¹H NMR (400 MHz) δ 9.37 (s, 1H), 8.57 (d, *J* = 2.8 Hz, 1H), 7.81 (m, 2H), 6.01 (s,
30 1H), 5.52 (s, 1H), 2.08 (s, 3H). MS: Calcd.: 180; Found: [M+H]⁺ 181.

Method 37**5-Fluoropicolinonitrile**

2-Bromo-5-fluoropyridine (93.0 g, 528 mmol), Zn dust (8.29 g, 127 mmol), zinc cyanide (40.3 g, 343 mmol), diphenylphosphinoferrocene (11.7 g, 21.1 mmol) and Pd₂dba₃ (9.68 g, 10.6 mmol) in anhydrous DMA (300 ml) was heated at 95 °C for 3 hours. After cooled to room temperature, brine (100 ml) and ether (500 ml) was added. The solid formed was removed by filtration and washed with ether (300 ml). The organic layer was separated, washed with brine (200 ml) and dried over sodium sulfate, and concentrated. After removal of solvent, the resulted residue was purified by column chromatography (hexane-DCM = 1:1) to give the title compound as a white solid (49 g, 72%). ¹H NMR (400 MHz) δ 8.82 (d, *J* = 2.8 Hz, 1H), 8.21 (dd, *J* = 4.4 and 8.8 Hz, 1H), 8.05 (dd, *J* = 2.8 and 8.8 Hz, 1H).

Method 38**6-Fluoro-*N*-methoxy-*N*-methylnicotinamide**

To a solution of 6-fluoronicotinic acid (10 g, 70.9 mmol) in DCM (200 ml), was added *N,O*-Dimethylhydroxylamine hydrochloride (7.3 g, 74.8 mmol), *N*-(3-Dimethylaminopropyl)-*N'*-ethylcarbodiimide hydrochloride (15 g, 78.5 mmol), and triethylamine (22 ml, 156 mmol). The reaction mixture was allowed to stir at room temperature for 16 hours. The reaction was partitioned with water, layers were cut, and organic layer was dried over Na₂SO₄, filtered, and concentrated in vacuo. The crude residue obtained was purified by a silica gel filtration using EtOAc-DCM (4:1) to give 7.2 g (55% isolated yield) of the title compound. ¹H NMR: 8.48 (s, 1 H) 8.21 (t, *J*=8.29 Hz, 1 H) 7.27 (dd, *J*=8.29, 3.01 Hz, 1 H) 3.54 (s, 3 H) 3.27 (s, 3 H).

Method 39**2-Chloro-6-(5-cyclopropyl-1*H*-pyrazol-3-ylamino)-5-fluoro-4-iodonicotinonitrile**

The crude 2,6-dichloro-5-fluoro-4-iodonicotinonitrile (8.0 g, 25.2 mmol), Et₃N (3.3 g, 32.8 mmol) and 5-cyclopropyl-1*H*-pyrazol-3-amine (3.1 g, 25.2 mmol) were placed in ACN (50 ml) and the resulting solution was heated to 80 °C for 24 hours. The reaction was cooled to room temperature, filtered, and the resulting solid was washed with cold ACN, dried, and collected to give the title compound (3.0 g, 29%). MS: Calcd.: 403; Found: [M+H]⁺ 404.

712

Method 40**2,6-Dichloro-5-fluoro-4-iodonicotinonitrile**

To a solution of diisopropylamine (15.9 g, 157 mmol) in THF (400 ml) at -78 °C was added *n*-butyllithium (2.5 M hexanes, 154 mmol), and the solution was stirred at -78 °C for 30 minutes. The lithium diisopropylamide solution was then added slowly dropwise to a -78 °C solution of 2,6-dichloro-5-fluoronicotinonitrile (10.0 g, 52.3 mmol) and iodine (26.5 g, 104 mmol) in THF (175 ml). Upon completion of the addition, the reaction was allowed to warm slowly to room temperature, and stirred at room temperature for 12 hours. An aqueous 10% Na₂S₂O₃ solution (500 ml) was added and the reaction was extracted with EtOAc (3 x 300 ml). The combined organic fractions were dried over Na₂SO₄, filtered, and then concentrated to give the title compound (14.5 g, 87%) as a brown solid that was used without further purification.

Method 41**2,5-Difluoro-6-(5-methyl-1*H*-pyrazol-3-ylamino)nicotinonitrile**

To a solution of 2,5,6-trifluoronicotinonitrile (1.0 g, 6.3 mmol) and triethylamine (0.83 g, 8.2 mmol) in ACN (30 ml) at 0 °C was added 5-methyl-1*H*-pyrazol-3-amine (0.67 g, 6.9 mmol). The reaction was stirred at 0 °C for 1 hour, at which point the reaction was filtered. The resulting solid was washed with cold ACN, dried and collected to give the title compound (0.44 g, 29%). MS: Calcd.: 235; Found: [M+H]⁺ 236.

Method 42**2,5-Difluoro-6-(5-isopropoxy-1*H*-pyrazol-3-ylamino)nicotinonitrile**

To a solution of 2,5,6-trifluoronicotinonitrile (3.0 g, 19.0 mmol) and triethylamine (2.5 g, 24.7 mmol) in ACN (30 ml) at 0 °C was added 5-isopropoxy-1*H*-pyrazol-3-amine (2.95 g, 20.9 mmol) in ACN (15 ml). The reaction was stirred at 0 °C for 1 hour, at which point the reaction was diluted with water (50 ml) and extracted with DCM (2 x 50 ml). The combined organic fractions were dried over Na₂SO₄, filtered, and then concentrated. The resulting oil was purified by column chromatography (DCM-MeOH = 100 :1) to give the title compound (0.48 g, 9%). MS: Calcd.: 279; Found: [M+H]⁺ 280.

113

Method 42 (alternative procedure)

2,5-Difluoro-6-(5-isopropoxy-1H-pyrazol-3-ylamino)nicotinonitrile

tert-Butyl 5-(5-cyano-3,6-difluoropyridin-2-ylamino)-3-isopropoxy-1H-pyrazole-1-carboxylate (Method 79, 10.6g, 27.9mmol), was placed in DCM (500ml) at room temperature. A 4.0 M solution of HCl (16.3g, 447mmol) in dioxane was added dropwise, and upon completion of the addition the reaction was allowed to stir for an additional 30 minutes. The reaction was concentrated to dryness, and dissolved in DCM (300ml) with a minimal amount of MeOH (5ml) to aid solubility. A saturated aqueous solution of Na₂CO₃ (300ml) was added, and the reaction was stirred vigorously for 30 minutes. The layers were allowed to separate, and the organic fraction was dried (Na₂SO₄), filtered, and concentrated. The resulting residue was slurried with cold DCM (approx. 50ml), filtered, and the remaining solid was washed with DCM and dried to give the title compound (5.5g, 70%). MS: Calcd.: 279; Found: [M+H]⁺ 280.

Method 43

2,5-Dichloro-6-(5-cyclopropyl-1H-pyrazol-3-ylamino)nicotinonitrile

To a solution of 2,5,6-trichloronicotinonitrile (Method 44, 1.0 g, 4.8 mmol) and DIEA (0.81 g, 6.2 mmol) in *n*-BuOH (5 ml) was added 5-cyclopropyl-1H-pyrazol-3-amine (2.3 g, 19.3 mmol). The reaction was heated to 60 °C for 2 hours, at which point the reaction was cooled to room temperature and concentrated. The resulting residue was diluted with 10 ml ACN, and stored at 0 °C for 1 hour. The solids that formed were then filtered, washed with cold ACN, dried and collected to give the title compound (0.62 g, 43%). MS: Calcd.: 294; Found: [M+H]⁺ 295.

Method 44

2,5,6-Trichloronicotinonitrile

A suspension of 2,5,6-trichloronicotinamide (Method 45, 2.3 g, 10.2 mmol) in POCl₃ (20 ml) was heated to 90 °C for 1 hour. The reaction was then cooled to room temperature, and the POCl₃ was removed under vacuum. The resulting residue was taken up in DCM (50 ml) and ice water (50 ml) was then added, followed by the careful addition of an aqueous solution of Na₂CO₃ until pH 8 was achieved. The organic fraction was then dried over Na₂SO₄, filtered, and concentrated to give the title compound (2.1 g, 80%) which was used without further purification. ¹H NMR (400 MHz, CD₃OD) δ 8.54 (s, 1H).

4/11/14

Method 44 (alternative procedure)

2,5,6-Trichloronicotinonitrile

To a solution of 2,4,5,6-tetrachloronicotinonitrile (7.6 g, 31.4 mmol) in MeOH/THF (230ml/230 ml) was added zinc dust (4.0 g, 62.8 mmol) slowly at 0°C and the saturated
5 NH₄Cl solution (105 ml) and the mixture was stirred for 30 minutes. TLC indicated that the reaction is complete. Saturated NH₄OAc solution (180 ml) was added to the mixture and the mixture was allowed to stir at room temperature for 30 minutes. The mixture was filtered and was washed with EtOAc (500 ml). The filtrate was washed with brine and dried and concentrated to give a solid. ISCO column purification gave the title compound (4.63 g,
10 71%). ¹H NMR (CDCl₃): δ 8.97 (s, 1 H).

Method 45

2,5,6-Trichloronicotinamide

A solution of 2,5,6-trichloronicotinoyl chloride (Method 46, 2.5 g, 10.2 mmol) in
15 dioxane (20 ml) was added dropwise to 10 ml ammonium hydroxide (28% NH₃ in water) at 0 °C. Upon completion of the addition, the reaction was allowed to stir for an additional 10 minutes, and then extracted with DCM (3 x 50 ml). The combined organic fractions were dried over Na₂SO₄, filtered, and concentrated to give the title compound (2.3 g, 100%), which was used without further purification.

20

Method 46

2,5,6-Trichloronicotinoyl chloride

To a suspension of 2,5,6-trichloronicotinic acid (Method 47, 2.3 g, 10.2 mmol) in
DCM (25 ml) at room temperature was added oxalyl chloride (3.0 g, 24.4 mmol) and 3 drops
25 of dry DMF. After 30 minutes, the resulting clear solution was concentrated to dryness to give the title compound (2.5 g, 100%), which was immediately used without further purification.

Method 47

2,5,6-Trichloronicotinic acid

30 A suspension of 2,3,6-trichloro-5-methylpyridine (Method 48, 11.8 g, 60.0 mmol) in water (400 ml) was heated to 100 °C. Portionwise, KMnO₄ (28.5 g, 180.2 mmol) was then added over 12 hours. The reaction was then allowed to stir for 2 days at 100 °C, over which time an additional 10 g of KMnO₄ was added portionwise. When no starting material

24
115

remained, the hot reaction was filtered, washed with hot water (2 x 75 ml), and the resulting filtrate was allowed to cool to room temperature. The aqueous filtrate was then extracted with EtOAc (3 x 100 ml), and then concentrated to a 50 ml volume. This aqueous solution was then cooled to 0 °C and adjusted to pH 1-2 with 6.0 M HCl. The resulting solid was then
5 collected by filtration, washed with cold water, and dried to give the title compound (2.5 g, 18%) that was used without further purification.

Method 48

2,3,6-Trichloro-5-methylpyridine

10 A well powdered mixture of 3-methylpiperidine-2,6-dione (Method 49, 15.0 g, 118 mmol) and PCl₅ (155.0 g, 743 mmol) was slowly heated to 150 °C and kept at that temperature for 2 hours. The resulting solution was then cooled to room temperature, and slowly poured onto ice. The resulting precipitate was filtered, washed with cold water, and dried. The resulting precipitate was then recrystallized from a mixture of EtOH-petroleum
15 ether (1 : 8) to give the title compound (11.8 g, 51%).

Method 49

3-Methylpiperidine-2,6-dione

A solution of H₂SO₄ (80ml), acetic acid (500ml) and 2-methylpentanedinitrile (128.0
20 g, 1184 mmol) was stirred at room temperature. An aqueous solution of acetic acid (100 ml in 32 ml water) was then added dropwise. Upon completion of the addition, the reaction was heated to 130 °C for 1 hour. The reaction was then allowed to cool to room temperature and filtered to remove solids, which were washed with acetic acid (100 ml). The filtrate was then concentrated until a residue resulted. This residue was poured into water (0.75 l), and adjusted
25 to pH 5 with Na₂CO₃. The resulting solid was collected by filtration and washed with cold water to give the title compound (101 g, 67%) which was used without further purification.

Method 50

(S)-1-(3,5-Difluoropyridin-2-yl)ethanamine

30 To a solution of (S)-*tert*-butyl-1-(3,5-difluoropyridin-2-yl)ethylcarbamate (Method 51, 2.05 g, 7.94 mmol) in DCM (15 ml) was added HCl/dioxane (15.9 ml, 4 N, 63.5 mmol). The reaction was stirred at room temperature for 3 hours. The solvent was removed and 10 ml of saturated sodium bicarbonate was added. The resulting aqueous solution was extracted with

112
116

ether (5 x 100 ml), dried over sodium sulfate and concentrated to give the title compound (1.1 g, 88%) as a pale yellow oil. ¹H NMR (400 MHz) δ 8.46 (d, *J* = 2.0 Hz, 1H), 7.85 (m, 1H), 4.23 (q, *J* = 6.8 Hz, 1H), 1.90 (b, 2H), 1.27 (d, *J* = 6.8 Hz, 3H). MS: Calcd.: 158; Found: [M+H]⁺ 159.

5

Method 51

(S)-tert-Butyl-1-(3,5-difluoropyridin-2-yl)ethylcarbamate

A solution of (S)-*N*-(1-(3,5-difluoropyridin-2-yl)ethyl)acetamide (Method 52, 2.0 g, 9.99 mmol), DMAP (0.244 g, 2.00 mmol), and Boc₂O (6.54 g, 30.0 mmol) in THF (20 ml) was stirred at 50 °C for 40 hours. After cooling to room temperature, lithium hydroxide monohydrate (0.671 g, 16.0 mmol) and water (20 ml) were added. The reaction was stirred at room temperature for 18 hours. To which was added ether (100 ml). The organic layer was separated, washed with brine (50 ml) and dried over sodium sulfate. After removal of solvent, the resulted residue was purified by column chromatography (hexane-EtOAc = 5:1) to give the title compound as a colourless oil (2.05 g, 79%). ¹H NMR (400 MHz) δ 8.45 (s, 1H), 7.87 (m, 1H), 7.24 (d, *J* = 7.6 Hz 1H), 4.92 (m, 1H), 1.34 (s, 9H), 1.32 (d, *J* = 7.2 Hz, 3H). MS: Calcd.: 258; Found: [M+H]⁺ 259. Enantiomeric excess was determined by HPLC (Chiralpak ADH; 98:2 CO₂/MeOH), 93.6 % ee.

Method 52

(S)-N-(1-(3,5-Difluoropyridin-2-yl)ethyl)acetamide

To a solution of *N*-(1-(3,5-difluoropyridin-2-yl)vinyl)acetamide (Method 53, 2.2 g, 11.1 mmol) in MeOH (20 ml) under N₂ was added (+)-1,2-bis((2*S*, 5*S*)-2,5-dimethyl phospholano)benzene (cyclooctadiene)rhodium(I)trifluoromethanesulfonate (0.074 g, 0.111 mmol). The solution was transferred to a high-pressure bomb and charged 150 psi H₂. The reaction stirred at room temperature and maintained inside pressure between 120-150 psi for 24 hours. The solvent was removed and the resulted residue was purified by column chromatography (EtOAc) to give the title compound as a white solid (2.0 g, 90%). ¹H NMR (400 MHz) δ 8.47 (d, *J* = 2.4 Hz, 1H), 8.34 (d, *J* = 7.2 Hz, 1H), 7.89 (m, 1H), 5.21 (m, 1H), 1.81 (s, 3H), 1.34 (d, *J* = 6.8 Hz, 3H). MS: Calcd.: 200; Found: [M+H]⁺ 201.

30

112
112**Method 53****N-(1-(3,5-Difluoropyridin-2-yl)vinyl)acetamide**

To a mixture of (Z)-1-(3,5-difluoropyridin-2-yl)ethanone oxime (Method 54, 12.5 g, 72.6 mmol), acetic anhydride (54.8 ml, 581 mmol), and iron powder (32.4 g, 581 mmol) in
5 DMF (100 ml) was added TMSCl (0.01 ml, 0.073 mmol). The reaction mixture was stirred at room temperature for 18 hours, then diluted with ether (300 ml) and filtered through a short pad of celite. The filtrate was concentrated and the residue was partitioned between 200 ml of EtOAc and 50 ml of saturated sodium bicarbonate. The organic layer was separated and dried over sodium sulfate. After removal of solvent, the resulted residue was purified by column
10 chromatography (hexane-EtOAc = 2:1) to give the title compound as a white solid (2.70 g, 19%). ¹H NMR (400 MHz) δ 9.55 (s, 1H), 8.51 (d, *J* = 2.0 Hz, 1H), 7.97 (m, 1H), 5.87 (s, 1H), 5.14 (s, 1H), 1.99 (s, 3H). MS: Calcd.: 198; Found: [M+H]⁺ 199.

Method 54**(Z)-1-(3,5-Difluoropyridin-2-yl)ethanone oxime**

To a solution of 3,5-difluoropicolinonitrile (10.0 g, 71.4 mmol) in THF (200 ml) was added methylmagnesium bromide (61.2 ml, 85.7 mmol) in THF solution at 0 °C. The reaction was stirred at room temperature for 1.5 hours. Saturated sodium bicarbonate solution (50 ml) was added, extracted with ether (100 ml), and dried over sodium sulfate. The solvent was
20 removed. The residue (11.2 g, 71.28 mmol), hydroxylamine hydrochloride (9.907 g, 142.6 mmol) and sodium acetate (11.70 g, 142.6 mmol) in EtOH (100 ml) and water (50 ml) was heated at reflux for 3 hours. The solvent was removed and diluted with 50 ml of saturated sodium bicarbonate and extracted with EtOAc (2 x 200 ml). After dried over sodium sulfate, the solvent was removed and the title compound was used directly in next step without
25 purification.

Method 55**(S)-1-(5-Fluoropyrimidin-2-yl)ethanamine**

To a solution of (S)-*tert*-butyl-1-(5-fluoropyrimidin-2-yl)ethylcarbamate (Method 56, 30 0.21 g, 0.87 mmol) in DCM (5 ml) was added HCl (1.3 ml, 5.2 mmol) in dioxane. The reaction was stirred at room temperature for 3 hours. The solvent was removed give (S)-1-(5-fluoropyrimidin-2-yl)ethanamine as HCl salt as white solid (quantitative). MS: Calcd.: 141; Found: [M+H]⁺ 142.

Method 56**(S)-tert-Butyl-1-(5-fluoropyrimidin-2-yl)ethylcarbamate**

(S)-N-(1-(5-fluoropyrimidin-2-yl)ethyl)acetamide (Method 57, 0.20 g, 1.09 mmol), DMAP (0.027 g, 0.22 mmol) and Boc₂O (0.60 g, 2.73 mmol) in THF (10 ml) was stirred at 50 °C for 40 hours. After cooled to room temperature, lithium hydroxide monohydrate (0.094 g, 2.24 mmol) and water (10 ml) was added. The reaction was stirred at room temperature for 9 hours. Ether (30 ml) was added, organic layer was separated, washed with brine (20 ml) and dried over sodium sulfate. After removal of solvent, the resulted residue was purified by column chromatography (Hex-EtOAc=5:1) to give the title compound as a pale yellow oil (0.21 g, 80%). ¹H NMR (400 MHz) 8.84 (s, 2H), 7.24 (d, *J* = 7.6 Hz, 1H), 4.74 (m, 1H), 1.35 (s, 12H). MS: Calcd.: 241; Found: [M+H]⁺ 242.

Method 57**(S)-N-(1-(5-Fluoropyrimidin-2-yl)ethyl)acetamide**

N-(1-(5-Fluoropyrimidin-2-yl)vinyl)acetamide (Method 58, 0.10 g, 0.55 mmol) in MeOH (5 ml) under N₂ was added (+)-1,2-bis((2*S*, 5*S*)-2,5-diethylphospholano)benzene (cyclooctadiene)rhodium(I)trifluoromethanesulfonate (0.04 g, 0.0055 mmol). The solution was transferred to a high pressure bomb and charged 150 psi H₂. The reaction stirred at room temperature for 4 hours. The solvent was removed and the resulted residue was purified by column chromatography (EtOAc) to give the title compound as a white solid (0.096 g, 95%). ¹H NMR (400 MHz) 8.84 (d, *J* = 0.8 Hz, 2H), 8.34 (d, *J* = 7.6 Hz, 1H), 5.00 (m, 1H), 1.84 (s, 3H), 1.37 (d, *J* = 6.8 Hz, 3H). MS: Calcd.: 183; Found: [M+H]⁺ 184. Enantiomeric excess determined by HPLC (Chiralpak IA; 95:5 CO₂/MeOH), >99% ee.

Method 58**N-(1-(5-Fluoropyrimidin-2-yl)vinyl)acetamide**

5-Fluoropyrimidine-2-carbonitrile (Method 59, 1.0 g, 8.1 mmol) in THF (10 ml) was added a solution of MeMgBr (3.3 ml, 9.75 mmol) in ether drop wise at 0 °C. After addition, the reaction was warmed to room temperature, stirred at room temperature for 1 hour and then diluted with DCM (10 ml). Acetic anhydride (1.23 ml, 13.0 mmol) was added in one portion. The reaction was stirred at room temperature for 1 hour and 40 °C for 1 hour. Saturated sodium bicarbonate solution (10 ml) was added and extracted with EtOAc (2x20 ml). The combined organic was dried over sodium sulfate. After removal of solvent, the resulted

residue was purified by column chromatography (hexane-EtOAc = 2.5 : 1) to give the title compound as a white solid (0.38 g, 26%). ¹H NMR (400 MHz) 9.34 (s, 1H), 8.95 (s, 2H), 6.25 (s, 1H), 6.03 (s, 1H), 2.11 (s, 3H). MS: Calcd.: 181; Found: [M+H]⁺ 182.

5 Method 59

5-Fluoropyrimidine-2-carbonitrile

A 10 ml microwave vial was charged with 2-chloro-5-fluoropyrimidine (2.0 g, 15.09 mmol), Pd₂(dba)₃ (0.549 g, 0.6 mmol), DPPF (0.67 g, 1.21 mmol), zinc cyanide (1.15 g, 9.81 mmol), and zinc dust (0.237 mg, 3.62 mmol). The flask was evacuated and backfilled with N₂, and anhydrous dimethylacetamide. The vial was mounted onto a Personal Chemistry microwave reactor and heated at 100 °C for 10 hours. The reaction mixture was diluted with EtOAc and then washed with brine three times. The organic layer was obtained and evaporated to dryness. The dried residue was purified by silica gel chromatography (By ISCO Combiflash with gradient EtOAc and hexanes) to afford the title compound as a creamy solid (1.50 g, 80%). GC-MS: 123 (M); ¹H NMR (CDCl₃) δ 8.80 (s, 2H).

Method 60

2,5-Dichloro-6-[(5-methyl-1H-pyrazol-3-yl)amino]nicotinonitrile

To a 25-ml, round-bottom flask, was added 2,5,6-trichloronicotinonitrile (Method 44, 1 g, 4.8 mmol), 5-methyl-1H-pyrazol-3-amine (466 mg, 4.8 mmol), DIEA (1.1 ml, 6.3 mmol), and EtOH (5 ml) and set to heat at 55 °C for 16 hours. The resulting mixture was then purified by silica gel chromatography (Biotage Horizon System) using 25-75% EtOAc/hexanes to give 770 mg of the title compound. ¹H NMR: 12.36 (s, 1H) 9.68 (s, 1H) 8.39 (s, 1H) 6.32 (s, 1H) 2.29 (s, 3H). MS: Calcd.: 268; Found: [M+H]⁺ 267/269.

Method 61

N-[5-(1-Aminoethyl)-2-fluorophenyl]methanesulfonamide

N-{2-Fluoro-5-[(1Z)-N-hydroxyethanimidoyl]phenyl}methanesulfonamide (Method 62, 200 mg, 812 μmol) was dissolved in 15 ml THF, to which was added Raney nickel 2800 slurry in water (200 μl). The mixture was charged with nitrogen and stirred over 1 atm of hydrogen. After 1 hour, MeOH (4 ml) was added and the reaction mixture was stirred overnight. The following morning the solution was filtered through celite, and the cake washed with MeOH, and the organic layer was concentrated to a yellow solid which was

dried under high vacuum (181 mg, 96%). ¹H NMR: 1.26 (d, 3 H, CH₃), 2.92 (s, 3 H, SO₂Me), 3.33 (HOD), 4.04 (q, 1 H, CH), 5.70 (br, 2 H, NH₂), 7.06-7.16 (m, 2 H, Ar), 7.35 (m, 1 H, Ar). LC/MS: 0.79 min, 231.08 (M-H)⁻.

5 **Method 62**

N-{2-Fluoro-5-[(1Z)-N-hydroxyethanimidoyl]phenyl}methanesulfonamide

In a 100 ml Round bottom flask was added. N-(5-acetyl-2-fluorophenyl)methanesulfonamide (Method 63, 1.41 g, 6.10 mmol), hydroxylamine hydrochloride (847 mg, 12.2 mmol), sodium acetate (1.25 g, 15.24 mmol) and 30 ml water.

- 10 The mixture was heated to 50°C and then 10 ml EtOH was added to dissolve the contents. The mixture was continued heating at 50 °C for 1 hour, then fitted with a reflux condenser and refluxed at 80 °C for 2 hours. (note: the solution turns homogeneous at 80°C). The solution was cooled to room temperature (note: crystals develop), rotovapped to remove traces of EtOH, cooled on an ice bath and filtered off-white crystals. The crystalline product
- 15 was washed with ice cold water and air dried to obtain the white crystalline product (1.47 g, 98%.) TLC (1:1 Hexanes:EtOAc): R_f 0.50. ¹H NMR: 2.12 (s, 3 H, Me), 3.02 (s, 3 H, SO₂Me), 3.32 (HOD), 7.29 (m, 1 H, Ar), 7.48 (m, 1 H, Ar), 7.68 (m, 1 H, Ar), 9.67 (s, 1 H, NH), 11.31 (s, 1 H, OH). LC/MS: 1.70 min, 247.04 (M+1)⁺.

20 **Method 63**

N-(5-Acetyl-2-fluorophenyl)methanesulfonamide

3-Amino-4-fluoroacetophenone (Method 64, 1.00 g, 6.53 mmol) and pyridine (503 µl, 6.53 mmol) were stirred in 10 ml DCM over a blanket of nitrogen at 0°C.

- Methanesulfonylchloride (505 µl, 6.53 mmol) was added dropwise and the reaction was
- 25 stirred at 0°C for 5 minutes and warmed to room temperature and stirred for 3 hours. Quenched with 30 ml 1N HCl, and extracted with 30 ml DCM. Washed organic layer with Brine, dried over Na₂SO₄ and concentrated to orange oil, and dried under high vacuum. Yellow solid/crystals develop which were triturated with hexanes, redissolved in DCM and evaporated and dried under high vacuum to obtain an off-white/yellow solid (1.42 g, 94%.)
- 30 TLC (1:1 Hexanes:EtOAc): R_f 0.46. ¹H NMR (CDCl₃): δ 2.60 (s, 3 H, COMe), 3.08 (s, 3 H, SO₂Me), 6.56 (br, 1 H, NH), 7.23 (dd, 1 H, Ar), 7.81 (m, 1 H, Ar), 8.16 (m, 1 H, Ar). LC/MS: 1.66 min, 230.08 (M-1)⁻

Method 64**3-Amino-4-fluoroacetophenone**

In a 250 ml round bottom flask was added 3-nitro-4-Fluoroacetophenone (5.00 g, 27.3 mmol) and HCl (12M, 13ml.) The solution was cooled to 0°C on an ice bath, and SnCl₂ (15.5 g, 81.9 mmol) dissolved in 20 ml of water, was added dropwise over a 15 minute period. (Note: The reference material indicates the reaction is exothermic after 1 equivalent addition of Tin Chloride.) After complete addition the reaction mixture was stirred at 0°C for 10 min, warmed to room temp, brought to reflux for 15 minutes, cooled back to room temp and stirred for 2 hours. The mixture was poured over ice (150 g) and adjusted to pH 12 with 50% NaOH at 0°C. The resulting yellow emulsion was extracted with ether (2x150 ml), washed with brine (1x30 ml), dried over sodium sulfate and concentrated to a yellow solid. The solid was triturated with hexanes and dried to obtain a yellow solid (3.61 g, 86%). TLC (1:1 Hexanes:EtOAc): R_f 0.63. ¹H NMR (CDCl₃): δ 7.44 (m, 1 H, Ar), 7.34 (m, 1 H, Ar), 7.04 (m, 1 H, Ar), 4.32 (br, 2 H, NH), 2.54 (s, 3 H, Me). LC/MS 1.67 min, 154.07 (M+1)⁺.

Method 65**1-(6-Fluoropyridin-3-yl)ethanone**

To a cold solution (-78 °C) of 6-fluoro-*N*-methoxy-*N*-methylnicotinamide (Method 38, 7.2 g, 39 mmol) in THF (130 ml), was added methyl magnesium bromide (20 ml, 59 mmol, 3M solution in ether) dropwise. The cooling bath was removed and reaction mixture was allowed to warm to room temperature and stir for 2 hours. The reaction was quenched with 3N HCl solution, layers were cut, and organic layer was dried over Na₂SO₄, filtered, and concentrated in vacuo to afford 3.8 g (70% yield) of the title compound. ¹H NMR (CDCl₃) δ 8.80 (s, 1 H) 8.29 - 8.43 (m, 1 H) 6.98 - 7.06 (m, 1 H) 2.62 (s, 3 H).

Method 66***N*-[5-(1-Aminoethyl)-2-fluorophenyl]acetamide**

To a round, bottom flask was added *N*-(2-fluoro-5-[(1*Z*)-*N*-hydroxyethanimidoyl]phenyl)acetamide (Method 67, 715 mg, 3.4 mmol) and AcOH (0.5 ml) in EtOH (20 ml), followed by the addition of Palladium on carbon (146 mg, 10wt%) under N₂ atmosphere. Once the catalyst was added, the system was evacuated and purged with hydrogen (atmospheric pressure). This process was performed several times to ensure complete saturation of hydrogen to the system. The reaction was then allowed to stir for 16 hours at

room temperature. The heterogeneous mixture was then filtered over a pad of Celite and the filtrate was concentrated in vacuo to give quantitative yield of the title compound. ¹H NMR: 9.67 (s, 1 H) 7.80 (d, *J*=7.54 Hz, 1 H) 7.07 - 7.19 (m, 2 H) 4.00 (q, *J*=6.28 Hz, 1 H) 2.06 (s, 3 H) 1.15 - 1.30 (m, 3 H).

5

Method 67*N*-{2-Fluoro-5-[(1*Z*)-*N*-hydroxyethanimidoyl]phenyl}acetamide

To a round, bottom flask was added *N*-(5-acetyl-2-fluorophenyl)acetamide (Method 68, 1.17 g, 6 mmol), hydroxyl amine hydrochloride salt (834 mg, 12 mmol), and NaOAc (1.2 g, 15 mmol) in water:EtOH solution (20 ml, 3:1). The resulting mixture was then set to heat at 50 °C for 1 hour. The reaction was allowed to cool to room temperature and partitioned with EtOAc. The layers were cut and the organic layer was then dried over Na₂SO₄, filtered and concentrated in vacuo. The crude residue obtained was then purified by silica gel chromatography (Biotage Horizon System) using a gradient elution of 5-50% EtOAc in DCM to give 815 mg of the title compound (60% overall yield, 2 steps). ¹H NMR: 11.22 (s, 1 H) 9.75 (s, 1 H) 8.22 (dd, *J*=7.54, 1.88 Hz, 1 H) 7.30 - 7.46 (m, 1 H) 7.24 (dd, *J*=10.93, 8.67 Hz, 1 H) 1.98 - 2.18 (m, 6 H).

Method 68*N*-(5-Acetyl-2-fluorophenyl)acetamide

To a round, bottom flask was added 3-amino-4-fluoroacetophenone (Method 64, 1 g, 6.54 mmol) in DMF (15 ml), followed by the addition of acetyl chloride (0.56 ml, 7.84 mmol) and DIEA (2.3 ml, 13.08 mmol). The solution was set to stir at room temperature. The reaction appeared complete by TLC after 30 min. The reaction was then quenched with water and partitioned with EtOAc. The layers were cut, followed by an additional wash of the aqueous with EtOAc. The combined organic layers were dried over Na₂SO₄, filtered and concentrated in vacuo. The crude residue obtained (1.17 g), was used directly in the next step. ¹H NMR (CDCl₃) δ 8.94 (d, *J*=7.54 Hz, 1 H) 7.71 (d, 1 H) 7.43 (s, 1 H) 7.15 (s, 1 H) 2.56 - 2.60 (m, 3 H) 2.21 - 2.28 (m, 3 H).

123

Method 69

N-[5-(1-Aminoethyl)-2-fluorophenyl]cyclopropanecarboxamide

To a round, bottom flask was added *N*-{2-fluoro-5-[(1*Z*)-*N*-hydroxyethanimidoyl]phenyl}cyclopropanecarboxamide (Method 70, 458 mg, 1.94 mmol) and HOAc (1 ml) in EtOH (25 ml), followed by the addition of Palladium on carbon (100 mg, 10wt%) under N₂ atmosphere. Once the catalyst was added, the system was evacuated and purged with hydrogen (atmospheric pressure). This process was performed several times to ensure complete saturation of hydrogen to the system. The reaction was then allowed to stir for 16 hours at room temperature. The heterogenous mixture was then filtered over a pad of celite and the filtrate was concentrated in vacuo to give quantitative yield of the title compound. ¹H NMR: 9.99 (s, 1 H) 7.85 (d, *J*=8.29 Hz, 1 H) 7.17 (s, *J*=8.29 Hz, 2 H) 4.03 (d, *J*=6.03 Hz, 1 H) 1.90 - 2.04 (m, 1 H) 1.26 (d, *J*=6.78 Hz, 3 H) 0.78 (d, *J*=6.03 Hz, 4 H)

Method 70

N-{2-Fluoro-5-[(1*Z*)-*N*-hydroxyethanimidoyl]phenyl}cyclopropanecarboxamide

To a round, bottom flask was added *N*-(5-acetyl-2-fluorophenyl)cyclopropanecarboxamide (Method 71, 458 mg, 2.07 mmol), hydroxyl amine hydrochloride salt (288 mg, 4.14 mmol), and NaOAc (424 mg, 5.17 mmol) in water-EtOH solution (7 ml, 3:1). The reaction mixture was set to heat at 50 °C for 1 hour. As the reaction reached desired temperature, no dissolution was observed, thus more EtOH (7 ml) was added for dissolution to occur. The reaction was complete after 1 hour and concentrated in vacuo. The title compound (458 mg, 94% yield) was used directly in next step. ¹H NMR: 11.32 (s, 1 H) 10.10 (s, 1 H) 8.19 (d, *J*=6.03 Hz, 1 H) 7.30 - 7.44 (m, 1 H) 7.23 (s, 1 H) 2.09 (s, 3 H) 2.01 (s, 1 H) 0.79 (s, 4 H).

Method 71

N-(5-Acetyl-2-fluorophenyl)cyclopropanecarboxamide

To a round, bottom flask was added 3-amino-4-fluoroacetophenone (Method 64, 1 g, 6.54 mmol), cyclopropyl carboxylic acid (0.62 ml, 7.84 mmol), HATu (2.5 g (6.57 mmol), and DIEA (2.3 ml, 13.08 mmol) in DMF (15 ml). The reaction mixture was allowed to stir at room temperature for 16 hours. The reaction mixture was quenched with water and partitioned with EtOAc. The layers were cut, followed by an additional wash of the aqueous with EtOAc. The combined organic layers were dried over Na₂SO₄, filtered and concentrated

in vacuo. The crude residue obtained was then purified by silica gel chromatography (Biotage Horizon System) using a gradient elution of 5-15% EtOAc in DCM to give 458 mg of the title compound (32% isolated yield). ¹H NMR: 10.16 (s, 1 H) 8.53 (dd, *J*=7.91, 2.26 Hz, 1 H) 7.67 - 7.82 (m, 1 H) 7.40 (dd, *J*=10.55, 8.67 Hz, 1 H) 2.54 (s, 3 H) 1.95 - 2.09 (m, 1 H) 0.78 - 0.88 (m, 4 H).

Method 72

1-(5-Fluoropyrimidin-2-yl)ethanamine

A round-bottom flask containing 2-(1-azidoethyl)-5-fluoropyrimidine (Method 73, 0.60 g, 3.59 mmol) was charged with 10% Pd/C (0.191 g) and was evacuated and backfilled with H₂ via a filled balloon. MeOH (10 ml) was added, and the mixture was allowed to stir at room temperature for 3 hours. The mixture was filtered through a plug of diatomaceous earth, which was subsequently washed well with MeOH. The filtrates were concentrated to give the title compound as a pale yellow oil (0.50 g, 99%). ¹H NMR (CDCl₃) δ 8.60 (s, 2H), 4.65 (br s 2H), 4.10 (m, 1H), 1.20 (d, 3H).

Method 73

2-(1-Azidoethyl)-5-fluoropyrimidine

A round-bottom flask containing 1-(5-fluoropyrimidin-2-yl)ethanol (Method 74, 0.79 g, 5.55 mmol) was charged with triethylamine (0.67 g, 6.66 mmol) and anhydrous DCM (10 ml). The solution was cooled to 0 °C, and methanesulfonyl chloride (0.70 g, 4.1 mmol) was added dropwise. The resulting mixture was allowed to stir at room temperature for 2 hours, at which point the volatile components were removed using a rotary evaporator. The residue was dissolved in DMF (15 ml) and treated with sodium azide (0.72 g, 11.1 mmol). The resulting mixture was stirred at room temperature for 60 hours. It was then partitioned between EtOAc and brine. The organic layer was obtained, dried (Na₂SO₄), and evaporated to dryness. The crude material was purified by silica gel chromatography (by ISCO Combiflash with gradient EtOAc and hexanes) to afford the title compound as a colourless oil (0.60 g, 65% yield over two steps). GC-MS, 167 (M), 138 (M-N₂), 125 (M-N₃); ¹H NMR (CDCl₃) δ 8.60 (s, 2H), 4.60 (m, 1H), 1.65 (d, 3H).

126
125**Method 74****1-(5-Fluoropyrimidin-2-yl)ethanol**

1-(5-Fluoropyrimidin-2-yl)ethanone (Method 75, 0.77 g) was dissolved in MeOH (15 ml), and the solution was cooled to 0 °C. NaBH₄ (0.210 g, 5.55 mmol) was added. The mixture was stirred at room temperature for 1 hour and then partitioned between EtOAc and H₂O. The organic extract was washed with brine, dried (Na₂SO₄), filtered, and concentrated to give the title compound as a yellowish oil (0.79 g, 99%). ¹H NMR (CDCl₃) δ 8.65 (s, 2H), 5.20 (m, 1H), 4.00 (br s, 1H), 1.80 (d, 3H).

Method 75**1-(5-Fluoropyrimidin-2-yl)ethanone**

A round-bottom-flask containing 5-fluoropyrimidine-2-carbonitrile (Method 59, 1.50 g, 12.19 mmol) was charged with anhydrous THF (30 ml) under N₂. The solution was cooled to 0 °C, and a solution of MeMgBr (4.90 ml of a 3.0 M solution in ether, 14.62 mmol) was added dropwise. After 2 hours at 0 °C, the reaction mixture was quenched with ice water and extracted with EtOAc. The organic extract was washed with brine, dried over Na₂SO₄, and evaporated to dryness to give the title compound as an oil (0.778 g, yield 46%). GC-MS, 140 (M); ¹H NMR (CDCl₃) δ 8.65 (s, 2H), 2.65 (s, 2H).

Method 76**1-(6-Fluoropyridin-3-yl)ethanamine**

To a slurry of Raney Nickel in EtOH solution (75 ml), under inert atmosphere, was added 1-(6-fluoropyridin-3-yl)ethanone oxime (Method 77, 2.3 g, 14.9 mmol). The system was purged with hydrogen and evacuated several times to ensure complete saturation with hydrogen. The reaction, after 2 hours stirring at room temperature, was filtered over celite and filtrate collected was concentrated in vacuo to give 2 g (95% isolated yield) of the title compound. ¹H NMR: 8.16 (s, 1 H) 7.97 (t, J=8.29 Hz, 1 H) 7.09 (dd, J=8.29, 3.01 Hz, 1 H) 4.03 (q, J=6.78 Hz, 1 H) 1.23 (d, J=6.03 Hz, 3 H).

Method 77**1-(6-Fluoropyridin-3-yl)ethanone oxime**

To a 200-ml, round bottom flask was added, 1-(6-fluoropyridin-3-yl)ethanone (Method 65, 2.5 g, 17.9 mmol), hydroxylamine hydrochloride (2.5 g, 35.8 mmol), and NaOAc

(3.7 g, 44.8 mmol) in a solution of water-EtOH (65 ml, 3.3:1). The resulting mixture was heated to 50 °C for 1 hour. The reaction was then allowed to cool to room temperature, partitioned with EtOAc, layers were cut, and organic layer was dried over Na₂SO₄, filtered, and concentrated in vacuo to afford the title compound in quantitative yield. ¹H NMR: 11.49 (s, 1 H) 8.47 (s, 1 H) 8.17 - 8.27 (m, 1 H) 7.21 (dd, *J*=8.29, 3.01 Hz, 1 H) 2.17 (s, 3 H).

Method 78

tert-Butyl 5-amino-3-isopropoxy-1H-pyrazole-1-carboxylate

A solution of 5-isopropoxy-1H-pyrazol-3-amine (3.5g, 24.8mmol) in DCM (100ml) was prepared at room temperature. A 4.5M aqueous KOH solution (11.1g, 198mmol) was added dropwise, followed by the addition of di-tert-butyl dicarbonate (5.68g, 26mmol) in DCM (20ml). The resulting reaction was then stirred vigorously for 30 hours, at which point water (200ml) was added and the layers were allowed to separate. The organic fraction was separated, dried (Na₂SO₄), filtered, and then concentrated. The resulting oil was purified by column chromatography (100:1 DCM:MeOH) to give the title compound (5.4g, 90%). MS: Calcd.: 241; Found: [M+H]⁺ 242.

Method 79

tert-Butyl 5-(5-cyano-3,6-difluoropyridin-2-ylamino)-3-isopropoxy-1H-pyrazole-1-carboxylate

A solution of tert-butyl 5-amino-3-isopropoxy-1H-pyrazole-1-carboxylate (Method 78, 4.0g, 16.4mmol) in THF (45ml) was cooled to -78°C. A 1.0M THF solution of LiHMDS (2.61g, 15.6mmol) was added dropwise and the reaction was stirred at -78°C for 30 minutes. A -78°C solution of 2,5,6-trifluoronicotinonitrile (1.3g, 8.2mmol) in THF (20ml) was added dropwise via cannula to the above anion solution. Upon completion of the addition, the resulting reaction was allowed to stir for 10 minutes at -78°C, and was then quenched with water (100ml). The reaction was allowed to warm to room temperature, extracted with DCM (3 x 100ml), dried (Na₂SO₄), filtered, and then concentrated to give the title compound (95% conversion by LCMS) which was used without further purification. MS: Calcd.: 379; Found: [M+H]⁺ 380.

128
127

Utility

The compounds of the present invention have utility for the treatment of cancer by inhibiting the tyrosine kinases, particularly the Trks and more particularly Trk A and B. Methods of treatment target tyrosine kinase activity, particularly the Trk activity and more particularly Trk A and B activity, which is involved in a variety of cancer related processes. Thus, inhibitors of tyrosine kinase, particularly the Trks and more particularly Trk A and B, are expected to be active against neoplastic disease such as carcinoma of the breast, ovary, lung, colon, prostate or other tissues, as well as leukemias and lymphomas, tumours of the central and peripheral nervous system, and other tumour types such as melanoma, fibrosarcoma and osteosarcoma. Tyrosine kinase inhibitors, particularly the Trk inhibitors and more particularly Trk A and B inhibitors are also expected to be useful for the treatment other proliferative diseases including but not limited to autoimmune, inflammatory, neurological, and cardiovascular diseases.

In addition, the compounds of the invention are expected to be of value in the treatment or prophylaxis of cancers selected with up regulated or constitutively activated Trk kinases, including but not limited to, oncogenic rearrangements leading to ETV6-TrkC fusions, TRP-TrkA fusion proteins, AML-ETO (t8;21), autocrine or paracrine signalling leading to elevated serum levels of NGF, BDNF, neurotrophins or tumours with constitutively active Trk associated with disease aggressiveness, tumour growth and proliferation or survival signalling.

Compounds of the present invention have been shown to inhibit tyrosine kinases, particularly the Trks and more particularly Trk A and B, as determined by the Trk A Assay described herein.

Compounds provided by this invention should also be useful as standards and reagents in determining the ability of a potential pharmaceutical to inhibit tyrosine kinases, particularly the Trks and more particularly Trk A and B. These would be provided in commercial kits comprising a compound of this invention

Trk A Assay Format

Trk A kinase activity was measured for its ability to phosphorylate synthetic tyrosine residues within a generic polypeptide substrate using an Amplified Luminescent Proximity Assay (Alphascreen) technology (PerkinElmer, 549 Albany Street, Boston, MA).

To measure Trk A kinase activity, the intracellular domain of a HIS-tagged human Trk A kinase (amino acids 442-796 of Trk A, Swiss-Prot Primary Accession Number P04629)

128

5 was expressed in SF9 cells and purified using standard nickel column chromatography. After incubation of the kinase with a biotinylated substrate and adenosine triphosphate (ATP) for 20 minutes at room temperature, the kinase reaction was stopped by the addition of 30 mM ethylenediaminetetraacetic acid (EDTA). The reaction was performed in 384 well microtitre plates and the reaction products were detected with the addition of strepavidin coated Donor Beads and phosphotyrosine-specific antibodies coated Acceptor Beads using the EnVision Multilabel Plate Reader after an overnight incubation at room temperature.

Peptide substrate	PolyEY-biotin (PGT-bio.)
ATP Km	70 μ M
Assay conditions	0.838 ng/ml Trk A, 9mM HEPES, 45 μ g/ml BSA, 10mM MnCl ₂ , 5nM PGT-bio, 0.01% Triton® X-100, 70 μ M ATP
Incubation	20 minutes, room temperature
Termination/Detection conditions	6.3mM HEPES, 30mM EDTA, 525 μ g/ml BSA, 40mM NaCl, 0.007%Triton® X-100, 12ng/ml of Donor Beads, 12ng/ml of Acceptor Beads
Detection incubation	overnight, room temperature
Fluometer settings	Excitation = 680 nM Emission = 570 nM Excitation Time = 180ms Total Measurement Time=550ms


10 Although the pharmacological properties of the compounds of the formula (I) vary with structural change, in general activity possessed by compounds of the formula (I) may be demonstrated at IC₅₀ concentrations (concentrations to achieve 50% inhibition) or doses in the range of (0.01 μ M to 10 μ M).

When tested in the above in-vitro assay the Trk inhibitory activity of the following examples was measured at the following IC₅₀s.

Ex	IC ₅₀ (μ M)
21	0.611
24	0.109
47	0.063

Claim

1. A compound of formula (I):



wherein:

R^1 and R^2 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, C_{1-6} alkanoyl, C_{1-6} alkanoyloxy, N -(C_{1-6} alkyl)amino, N,N -(C_{1-6} alkyl) $_2$ amino, C_{1-6} alkanoylamino, N -(C_{1-6} alkyl)carbamoyl, N,N -(C_{1-6} alkyl) $_2$ carbamoyl, C_{1-6} alkylS(O) $_a$ wherein a is 0 to 2, C_{1-6} alkoxycarbonyl, N -(C_{1-6} alkyl)sulphamoyl, N,N -(C_{1-6} alkyl) $_2$ sulphamoyl, C_{1-6} alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R^1 and R^2 independently of each other may be optionally substituted on carbon by one or more R^6 ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^7 ;

one of X^1 , X^2 , X^3 and X^4 is =N-, the other three are independently selected from =CR ^{8} -, =CR ^{9} - and =CR ^{10} -;

R^3 is hydrogen or optionally substituted C_{1-6} alkyl; wherein said optional substituents are selected from one or more R^{11} ;

R^4 and R^{34} are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, C_{1-6} alkanoyl, C_{1-6} alkanoyloxy, N -(C_{1-6} alkyl)amino, N,N -(C_{1-6} alkyl) $_2$ amino, C_{1-6} alkanoylamino, N -(C_{1-6} alkyl)carbamoyl, N,N -(C_{1-6} alkyl) $_2$ carbamoyl, C_{1-6} alkylS(O) $_a$ wherein a is 0 to 2, C_{1-6} alkoxycarbonyl, N -(C_{1-6} alkyl)sulphamoyl, N,N -(C_{1-6} alkyl) $_2$ sulphamoyl, C_{1-6} alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R^4 and R^{34} may be independently optionally substituted on carbon by

130

one or more R¹²; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R¹³;

A is a direct bond or C₁₋₂alkylene; wherein said C₁₋₂alkylene may be optionally substituted by one or more R¹⁴;

5 **Ring C** is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R¹⁵;

R⁵ is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, *N*-(C₁₋₆alkyl)amino, *N,N*-(C₁₋₆alkyl)₂amino, C₁₋₆alkanoylamino, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)₂carbamoyl, C₁₋₆alkylS(O)_a 10 wherein a is 0 to 2, C₁₋₆alkoxycarbonyl, *N*-(C₁₋₆alkyl)sulphamoyl, *N,N*-(C₁₋₆alkyl)₂sulphamoyl, C₁₋₆alkylsulphonylamino, carbocyclyl-R³⁷- or heterocyclyl-R³⁸-; wherein R⁵ may be optionally substituted on carbon by one or more R¹⁶; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group 15 selected from R¹⁷;

n is 0, 1, 2 or 3; wherein the values of R⁵ may be the same or different;

R⁸, R⁹ and R¹⁰ are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, *N*-(C₁₋₆alkyl)amino, *N,N*-(C₁₋₆alkyl)₂amino, C₁₋₆alkanoylamino, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)₂carbamoyl, C₁₋₆alkylS(O)_a wherein a is 0 to 2, C₁₋₆alkoxycarbonyl, *N*-(C₁₋₆alkyl)sulphamoyl, *N,N*-(C₁₋₆alkyl)₂sulphamoyl, C₁₋₆alkylsulphonylamino, carbocyclyl-R²⁵- or heterocyclyl-R²⁶-; wherein R⁸, R⁹ and R¹⁰ independently of each other 20 may be optionally substituted on carbon by one or more R¹⁸; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R¹⁹;

R⁶, R¹¹, R¹², R¹⁴, R¹⁶ and R¹⁸ are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, *N*-(C₁₋₆alkyl)amino, *N,N*-(C₁₋₆alkyl)₂amino, C₁₋₆alkanoylamino, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)₂carbamoyl, C₁₋₆alkylS(O)_a wherein a is 0 to 2, C₁₋₆alkoxycarbonyl, *N*-(C₁₋₆alkyl)sulphamoyl, *N,N*-(C₁₋₆alkyl)₂sulphamoyl, C₁₋₆alkylsulphonylamino, carbocyclyl-R²⁷- or heterocyclyl-R²⁸-; wherein R⁶, R¹¹, R¹², R¹⁴, R¹⁶ and R¹⁸ independently of 30

132
131

each other may be optionally substituted on carbon by one or more R^{20} ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^{21} ;

$R^7, R^{13}, R^{15}, R^{17}, R^{19}$ and R^{21} are independently selected from C_{1-6} alkyl, C_{1-6} alkanoyl, C_{1-6} alkylsulphonyl, C_{1-6} alkoxycarbonyl, carbamoyl, N -(C_{1-6} alkyl)carbamoyl, N,N -(C_{1-6} alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; wherein $R^7, R^{13}, R^{15}, R^{17}, R^{19}$ and R^{21} independently of each other may be optionally substituted on carbon by one or more R^{22} ;

R^{20} and R^{22} are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, C_{1-6} alkanoyl, C_{1-6} alkanoyloxy, N -(C_{1-6} alkyl)amino, N,N -(C_{1-6} alkyl)₂amino, C_{1-6} alkanoylamino, N -(C_{1-6} alkyl)carbamoyl, N,N -(C_{1-6} alkyl)₂carbamoyl, C_{1-6} alkylS(O)_a wherein a is 0 to 2, C_{1-6} alkoxycarbonyl, N -(C_{1-6} alkyl)sulphamoyl, N,N -(C_{1-6} alkyl)₂sulphamoyl, C_{1-6} alkylsulphonylamino, C_{1-6} alkylsulphonyl- N -(C_{1-6} alkyl)amino, carbocyclyl- R^{35} - or heterocyclyl- R^{36} -; wherein R^{20} and R^{22} independently of each other may be optionally substituted on carbon by one or more R^{23} ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^{24} ;

$R^{25}, R^{26}, R^{27}, R^{28}, R^{35}, R^{36}, R^{37}$ and R^{38} are independently selected from a direct bond, -O-, -N(R^{29})-, -C(O)-, -N(R^{30})C(O)-, -C(O)N(R^{31})-, -S(O)_s-, -NH=CH-, -SO₂N(R^{32})- or -N(R^{33})SO₂-; wherein $R^{29}, R^{30}, R^{31}, R^{32}$ and R^{33} are independently selected from hydrogen or C_{1-6} alkyl and s is 0-2;

R^{23} is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxymethyl, methylamino, ethylamino, dimethylamino, diethylamino, N -methyl- N -ethylamino, acetylamino, N -methylcarbamoyl, N -ethylcarbamoyl, N,N -dimethylcarbamoyl, N,N -diethylcarbamoyl, N -methyl- N -ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, N -methylsulphamoyl, N -ethylsulphamoyl, N,N -dimethylsulphamoyl, N,N -diethylsulphamoyl, N -methyl- N -ethylsulphamoyl or phenyl; and

R^{24} is selected from C_{1-6} alkyl, C_{1-6} alkanoyl, C_{1-6} alkylsulphonyl, C_{1-6} alkoxycarbonyl, carbamoyl, N -(C_{1-6} alkyl)carbamoyl, N,N -(C_{1-6} alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;

or a pharmaceutically acceptable salt thereof.

2. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in claim 1 wherein R¹ is C₁₋₆alkyl, C₁₋₆alkoxy and cyclopropyl.

5

3. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in either claim 1 or claim 2 wherein R² is hydrogen.

10 4. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-3 wherein X³ or X⁴ is =N-, X¹ and X² and the other of X³ and X⁴ are independently selected from =CR⁸-, =CR⁹- and =CR¹⁰-.

5. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-4 wherein R³ is hydrogen.

15

6. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-5 wherein R⁴ and R³⁴ are independently selected from hydrogen or C₁₋₆alkyl; wherein R⁴ and R³⁴ may be independently optionally substituted on carbon by one or more R¹²; wherein R¹² is selected from hydroxy.

20

7. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-6 wherein A is a direct bond.

25 8. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-7 wherein Ring C is phenyl, pyridyl or pyrimidinyl.

9. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-8 wherein R⁵ is selected from halo, C₁₋₆alkanoylamino, C₁₋₆alkylsulphonylamino or carbocyclyl-R³⁷-; wherein R³⁷ is -C(O)N(R³¹)-; wherein R³¹ is
30 hydrogen.

133

10. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-9 wherein n is 1 or 2; wherein the values of R⁵ may be the same or different.

5 11. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-10 wherein R⁸, R⁹ and R¹⁰ are independently selected from hydrogen, halo, nitro, cyano, amino, carboxy, carbamoyl, C₁₋₆alkyl, C₁₋₆alkanoyl, N-(C₁₋₆alkyl)amino or carbocyclyl-R²⁵; wherein R⁸, R⁹ and R¹⁰ independently of each other may be optionally substituted on carbon by one or more R¹⁸;

10 R¹⁸ is selected from hydroxy, amino, N-(C₁₋₆alkyl)amino, C₁₋₆alkanoylamino, C₁₋₆alkylsulphonylamino, carbocyclyl-R²⁷- or heterocyclyl-R²⁸-; wherein R¹⁸ may be optionally substituted on carbon by one or more R²⁰; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R²¹;


15 R²⁰ is selected from halo, amino, C₁₋₆alkyl, N,N-(C₁₋₆alkyl)₂amino, C₁₋₆alkylsulphonyl-N-(C₁₋₆alkyl)amino, carbocyclyl-R³⁵- or heterocyclyl-R³⁶-; wherein R²⁰ may be optionally substituted on carbon by one or more R²³;

R²¹ is selected from C₁₋₆alkylsulphonyl;

R²³ is dimethylamino or phenyl; and

20 R²⁷, R²⁸, R³⁵ and R³⁶ are independently selected from a direct bond, -C(O)N(R³¹)-, -NH=CH- or -SO₂N(R³²)-; wherein R³¹ and R³² are independently selected from hydrogen or C₁₋₆alkyl.

12. A compound of formula (I):



wherein:

125
134

R¹ is methyl, *t*-butyl, isopropoxy or cyclopropyl;

R² is hydrogen;

X³ or X⁴ is =N-, X¹ and X² and the other of X³ and X⁴ are independently selected from =CR⁸-, =CR⁹- and =CR¹⁰-;

5 R³ is hydrogen;

R⁴ and R³⁴ are independently selected from hydrogen, methyl or hydroxymethyl;

A is a direct bond;

Ring C is phenyl, pyrid-2-yl, pyrid-3-yl or pyrimidin-2-yl;

R⁵ is selected from fluoro, acetylamino, mesylamino or cyclopropylcarbonylamino;

10 n is 1 or 2; wherein the values of R⁵ may be the same or different;

R⁸, R⁹ and R¹⁰ are independently selected from hydrogen, fluoro, chloro, iodo, nitro, cyano, amino, carboxy, carbamoyl, formyl, methylamino, hydroxymethyl, acetylaminomethyl, (2-aminoacetyl)aminomethyl, (2-morpholinoacetyl)aminomethyl, (R)-2-oxopyrrolidin-5-yl-carbonylamino

15 (S)-2-oxopyrrolidin-5-yl-carbonylamino

(R,S)-2-oxopyrrolidin-5-yl-carbonylamino, isoxaxol-5-yl-carbonylamino, mesylaminomethyl, morpholinomethyl, benzoylamino

pyrid-3-yl-carbonylamino, 6-dimethylaminopyrid-3-yl-carbonylamino

6-morpholinopyrid-3-yl-carbonylamino, pyrid-4-yl-carbonylamino

20 5-methylisoxaxol-4-yl-carbonylamino, thien-2-yl-carbonylamino

4-dimethylaminobenzylcarbonylamino

2-(*N*-(isopropyl)-*N*-(mesyl)amino)acetylaminomethyl,

2-(*N*-(phenethyl)-*N*-(mesyl)amino)acetylaminomethyl,

1-mesylpiperidin-1-ylcarbonylamino, 2-(pyrid-3-yl)acetylaminomethyl,

25 tetrahydro-2*H*-thiopyran-4-yl-carbonylamino

2-(thien-2-yl)acetylcarbonylamino, 2-(thien-3-yl)acetylcarbonylamino

3-phenylpropionylaminomethyl, 2-(*N*-benzoyl-*N*-methylamino)acetylaminomethyl,

4-dimethylaminobenzoylamino, phenylsulphonylamino

2-amino-3-methylbutanoylamino, cyclopropylcarbonylamino


30 pyrrol-2-yl-carbonylamino, tetrahydrofuran-2-yl-carbonylamino

furan-2-yl-carbonylamino, cyclopropylsulphonylamino

(cyclopropylimino)methyl, methylaminomethyl, trifluoromesylaminomethyl, isopropyl, isopropylamino or methylamino;

or a pharmaceutically acceptable salt thereof.

13. A compound of formula (I):



selected from:

(S)-6-(5-cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino)-4-(methylamino)nicotinonitrile;

(S)-6-(5-cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(5-fluoropyridin-2-yl)ethylamino)nicotinonitrile;

(S)-5-fluoro-2-(1-(5-fluoropyridin-2-yl)ethylamino)-6-(5-isopropoxy-1H-pyrazol-3-ylamino)nicotinonitrile;

(S)-6-(5-cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino)-4-(isopropylamino)nicotinonitrile;

(S)-5-chloro-6-(5-cyclopropyl-1H-pyrazol-3-ylamino)-2-(1-(5-fluoropyridin-2-yl)ethylamino)nicotinonitrile;

6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-[[[(1S)-1-(3,5-difluoropyridin-2-yl)ethyl]amino]-5-fluoronicotinonitrile;

(S)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino)-6-(5-isopropoxy-1H-pyrazol-3-ylamino)nicotinonitrile;

(S)-6-(5-cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino)nicotinonitrile;

(R)-6-(5-cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)-2-hydroxyethylamino)nicotinonitrile; or


(R)-5-fluoro-2-(1-(4-fluorophenyl)-2-hydroxyethylamino)-6-(5-isopropoxy-1H-pyrazol-3-ylamino)nicotinonitrile;

132
136

or a pharmaceutically acceptable salt thereof.


14. A process for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof, as claimed in claim 1, which process comprises of:

5 *Process a)* reaction of a compound of formula (II):



(II)

wherein Pg is a nitrogen protecting group; with a compound of formula (III):




(III)

10

wherein L is a displaceable group;

Process b) for compounds of formula (I) wherein R⁴ is hydroxymethyl and R³⁴ is hydrogen; reaction of a compound of formula (II) with an epoxide of formula (IV):




(IV)

15


Process c) reacting a compound of formula (V):

132




with hydrazine;

Process d) reacting a compound of formula (VI):



5


wherein L is a displaceable group; with an amine of formula (VII):



10 Process e) reacting a compound of formula (VIII):


134
138

133



(VIII)


wherein L is a displaceable group; with an amine of formula (IX):



(IX)


5

Process f) reacting an amine of formula (X):



(X)

with a compound of formula (XI):



(XI)

wherein L is a displaceable group;

and thereafter if necessary:

i) converting a compound of the formula (I) into another compound of the formula (I);

10

145
139

- ii) removing any protecting groups;
- iii) forming a pharmaceutically acceptable salt.

15. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed
5 in any one of claims 1-13, for use as a medicament.

16. The use of a compound of formula (I), or a pharmaceutically acceptable salt thereof,
as claimed in any one of claims 1-13, in the manufacture of a medicament for use in the
inhibition of Trk activity.

10

17. The use of a compound of formula (I), or a pharmaceutically acceptable salt thereof,
as claimed in any one of claims 1-13, in the manufacture of a medicament for use in the
treatment or prophylaxis of cancer.

15 18. The use of a compound of formula (I), or a pharmaceutically acceptable salt thereof,
as claimed in any one of claims 1-13, in the manufacture of a medicament for use in the
production of an anti-proliferative effect.

19. A method of inhibiting Trk activity comprising administering to a host in need of such
20 treatment a therapeutically effective amount of a compound of formula (I), or a
pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-13.

20. A method for the treatment or prophylaxis of cancer comprising administering a
therapeutically effective amount of a compound of formula (I) or a pharmaceutically
25 acceptable salt thereof, as claimed in any one of claims 1-13.

21. A method of producing an anti-proliferative effect in a warm-blooded animal, such as
man, in need of such treatment which comprises administering to said animal an effective
amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as
30 claimed in any one of claims 1-13.

14/148

22. A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-13, together with at least one pharmaceutically acceptable carrier, diluent or excipient.

5 23. A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-13, together with at least one pharmaceutically acceptable carrier, diluent or excipient for use in the inhibition of Trk activity.

10 24. A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-13, together with at least one pharmaceutically acceptable carrier, diluent or excipient for use in the treatment or prophylaxis of cancer.

15 25. A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-13, together with at least one pharmaceutically acceptable carrier, diluent or excipient for use in the production of an anti-proliferative effect in a warm-blooded animal such as man.

20 26. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-13, for use in the inhibition of Trk activity.

27. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-13, for use in the treatment or prophylaxis of cancer.

25

28. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-13, for use in the production of an anti-proliferative effect.

29. The method or use according to claims 17, 20, 24 or 27 wherein said cancer is selected
10 from congenital fibrosarcoma, mesoblastic nephroma, mesothelioma, acute myeloblastic leukemia, acute lymphocytic leukemia, multiple myeloma, melanoma, oesophageal cancer, myeloma, hepatocellular, pancreatic, cervical cancer, Ewings sarcoma, neuroblastoma, Kaposi sarcoma, ovarian cancer, breast cancer including secretory breast cancer, colorectal

142
141

WO 2006/082392

PCT/GB2006/000334

136

cancer, prostate cancer including hormone refractory prostate cancer, bladder cancer, melanoma, lung cancer - non small cell lung cancer (NSCLC), and small cell lung cancer (SCLC), gastric cancer, head and neck cancer, renal cancer, lymphoma, thyroid cancer including papillary thyroid cancer, mesothelioma and leukaemia.

142

INTERNATIONAL SEARCH REPORT

PCT/GB2006/000334

A. CLASSIFICATION OF SUBJECT MATTER		
INV. C07D401/14 A61K31/4439	C07D413/14 A61P35/00	C07D401/12 C07D409/14 C07D405/14
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols) C07D A61K A61P		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, CHEM ABS Data, BEILSTEIN Data		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, Y	WO 2005/049033 A (ASTRAZENECA AB; ASTRAZENECA UK LIMITED; BLOCK, MICHAEL, HOWARD; HAN, Y) 2 June 2005 (2005-06-02) the whole document	1-29
P, Y	WO 2005/103010 A (ASTRAZENECA AB; ASTRAZENECA UK LIMITED; LYNE, PAUL; WANG, BIN; WANG, T) 3 November 2005 (2005-11-03) the whole document	1-29
X	WO 02/22601 A (VERTEX PHARMACEUTICALS INCORPORATED; KNEGTEL, RONALD; BEBBINGTON, DAVI) 21 March 2002 (2002-03-21) claims 1,24	1-29
☐ Further documents are listed in the continuation of Box C. ☒ See patent family annex.		
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family		
Date of the actual completion of the international search 26 April 2006		Date of mailing of the international search report 04/05/2006
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer Johnson, C

184
143

INTERNATIONAL SEARCH REPORT

International application No.
PCT/GB2006/000334

Box II Observations where certain claims were found unsearchable (Continuation of Item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 19-21, 29 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of Item 3 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

144

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/GB2006/000334

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2005049033	A	02-06-2005	NONE
WO 2005103010	A	03-11-2005	NONE
WO 0222601	A	21-03-2002	AT 294797 T 15-05-2005
		AU 9091201 A	26-03-2002
		AU 9091401 A	26-03-2002
		AU 9094401 A	26-03-2002
		AU 9101301 A	26-03-2002
		AU 9267001 A	26-03-2002
		AU 9455801 A	26-03-2002
		AU 9687101 A	26-03-2002
		AU 9687501 A	26-03-2002
		BR 0114088 A	17-06-2003
		CA 2422299 A1	21-03-2002
		CA 2422354 A1	21-03-2002
		CA 2422367 A1	21-03-2002
		CA 2422371 A1	21-03-2002
		CA 2422377 A1	21-03-2002
		CA 2422378 A1	21-03-2002
		CA 2422379 A1	21-03-2002
		CA 2422380 A1	21-03-2002
		CN 1469874 A	21-01-2004
		CN 1469875 A	21-01-2004
		CN 1473161 A	04-02-2004
		DE 60110616 D1	09-06-2005
		DE 60110616 T2	23-02-2006
		EP 1317447 A1	11-06-2003
		EP 1317444 A1	11-06-2003
		EP 1317448 A1	11-06-2003
		EP 1318997 A1	18-06-2003
		EP 1317449 A1	11-06-2003
		EP 1317450 A1	11-06-2003
		EP 1317452 A1	11-06-2003
		EP 1318814 A2	18-06-2003
		ES 2242771 T3	16-11-2005
		HK 1057890 A1	16-12-2005
		HU 0302172 A2	29-09-2003
		HU 0302173 A2	29-09-2003
		HU 0302411 A2	28-11-2003
		HU 0401819 A2	28-12-2004
		JP 2004509113 T	25-03-2004
		JP 2004509114 T	25-03-2004
		JP 2004525075 T	19-08-2004
		JP 2004512277 T	22-04-2004
		JP 2004509115 T	25-03-2004
		JP 2004509116 T	25-03-2004
		JP 2004509117 T	25-03-2004
		JP 2004509118 T	25-03-2004
		MX PA03002289 A	06-06-2003
		MX PA03002291 A	06-06-2003
		MX PA03002292 A	06-06-2003
		MX PA03002293 A	06-06-2003

(12) SOLICITUD INTERNACIONAL PUBLICADA SEGÚN EL TRATADO DE COOPERACIÓN INTERNACIONAL EN MATERIA DE PATENTES (PCT)

(19) Organización Mundial de Propiedad Intelectual
Oficina Internacional



(43) Fecha de Publicación Internacional
10 de agosto de 2006 (10.08.2006)

(10) Número de Publicación Internacional
PCT WO 2006/082392 A1

(51) Clasificación Internacional de Patentes:
C07D 401/14 (2006.01) C07D 405/14 (2006.01)
C07D 413/14 (2006.01) A61K 31/4439 (2006.01)
C07D 401/12 (2006.01) A61P 35/00 (2006.01),
C07D 409/14 (2006.01)

(21) No. Solicitud Internacional: PCT/GB2006/000334

(22) Fecha de Presentación Internacional:
1 de febrero de 2006 (01.02.2006)

(25) Idioma de Presentación: Inglés

(26) Idioma de Publicación: Inglés

(30) Datos relativos a la Prioridad:
60/650,053 4 de febrero de 2005 (04.02.2005) US
60/653,329 16 de febrero de 2005 (16.02.2005) US
60/721,633 29 de septiembre de 2005 (29.09.2005) US

(71) Solicitante (AE, AG, AL, AM, AT, AU, AZ, BA, BB, BE, BF, BG, BJ, BR, BW, BY, BZ, CA, CF, CG, CH, CI, CM, CN, CO, CR, CU, CY, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, FR, GA, GB, GD, GE, GH, GM, GN, GQ, GR, GW, HR, HU, ID, IE, IL, IN, IS, IT, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MC, MD, MK, ML, MN, MR, MW, MX, MZ, NA, NE, NG, NI, NL, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, SM, SN, SY, SZ, TD, TG, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW únicamente): ASTRAZENECA AB [SE/SE]; S-SE-151 85 Södertälje (SE).

(71) Solicitante (para MG únicamente): ASTRAZENECA UK LIMITED [GB/GB]; 15 Stanhope Gate, London, Greater London W1K 1LN (GB).

(72) Inventores, e

(75) Inventores/Solicitantes (para US únicamente): DAVIES, Audrey [US/US]; AstraZeneca R & D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451 (US). LAMB, Michelle [US/US]; AstraZeneca R & D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451 (US). LYNE, Paul [IE/US]; AstraZeneca R & D

Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451 (US). MOHR, Peter [US/US]; Array BioPharma Inc, 3200 Walnut Street, Boulder, Colorado 80301 (US). WANG, Bin [CN/US]; Array BioPharma Inc, 3200 Walnut Street, Boulder, Colorado 80301 (US). WANG, Tao [CN/US]; AstraZeneca R & D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451 (US). YU, Dingwei [CN/US]; AstraZeneca R & D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451 (US).

(74) Agente: GLOBAL INTELLECTUAL PROPERTY; Astrazeneca AB, SE-151 85 Södertälje (SE).

(81) Países designados (a menos que se indique lo contrario para cada clase de protección disponible): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Países designados (a menos que se indique lo contrario para cada clase de protección disponible): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasiática (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), Europea (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Publicado:

— con informe internacional de búsqueda

Para códigos de dos letras y otras abreviaturas, remítase a las "Notas Guía sobre Códigos y Abreviaturas" que aparece al comienzo de cada edición regular del Boletín Oficial PCT.

(54) Título: DERIVADOS DE PIRAZOLILAMINOPIRIDINA ÚTILES COMO INHIBIDORES DE CINASA



(57) Extracto: Esta invención se refiere a compuestos novedosos que tienen la Fórmula (I), a sus composiciones farmacéuticas y a sus métodos de uso. Estos compuestos novedosos ofrecen un tratamiento para el cáncer.

WO 2006/082392 A1